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CHAPTER 1
GENERAL INTRODUCTION AND 
SCOPE OF THIS THESIS
Sreenivasa C. Ramaiahgari, Bob van de Water, Joost van Delft and Leo S. Price
Part of this chapter is accepted as a book chapter in 
Toxicogenomics-based cellular models - 





Driven by the emergence of new diseases, increased drug resistance and an unmet 
need for therapies for existing diseases, there is an ever-increasing demand for new 
medicines. The remarkable advances in science and technology have supported the 
discovery of new chemical entities but the pharmaceutical industry is struggling to 
translate this into approved drugs for the clinic. Considering the enormous invest-
ments associated with the development of a new drug, attrition at later stages of 
drug development or after release into the market is a major concern for pharmaceu-
tical companies, not to mention patients. Toxicity is the major reason for drug attrition 
with 40% of new chemical entities failing after pre-clinical safety studies in animals 
and 89% before they enter clinical trails [1], with hepatotoxicity and cardiotoxicity 
being the main reasons followed by nephrotoxicity, neurotoxicity and gastro-intes-
tinal toxicity [2]. It is therefore important to efficiently screen new chemical entities 
for their adverse effects, excluding toxic drugs at an earlier stage, and selecting the 
most promising drug candidates for further development. 
  Predicting safety of a chemical entity at the preclinical stage has remained 
a major challenge. Recent years have seen an increase in attrition rates - even after 
rigorous testing in both in vitro and in vivo test models. This is partly due to poor 
prediction of human-specific responses in these models. The drug metabolism of an-
imals differs from those of humans and may not accurately predict a human specific 
stress response. For example nifedipine, a calcium channel blocker, is metabolized 
by CYP3A4 in humans but not in rats [3] [4]. Human derived cell lines might offer an 
advantage in drug screening at the pre-clinical stage; currently primary human he-
patocytes are considered as the gold standard [5] for toxicity testing but they too lose 
liver cell properties within hours after in vitro culture and show a high donor specific 
variability in gene expression [6, 7]. In addition to primary cells, immortalized cell 
lines and hepatocarcinoma cell lines can be used.  These cells have either under-
gone mutations or lost a majority of liver specific functions under non-physiological 
culture conditions. The unnaturally high rate of proliferation of these cell lines also 
compromises their suitability for testing. Therefore there is a lack of in vitro models 
that can stably maintain human liver specific functions. To address this, development 
of a physiologically relevant human organotypic in vitro model is essential for safety 
assessment. In such models hepatocytes should remain differentiated and acquire 
many of the growth and metabolism characteristics of functional liver, thereby offer-
ing a promising tool to improve in vitro testing by both reducing and complementing 
pre-clinical animal testing. 
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Drug discovery and development
Drug discovery and development is a precarious process taking up to 12-16 years 
with costs exceeding $1.8 Billion and increasing every year [8, 9]. The process of 
drug development is mainly divided into the discovery phase, clinical development 
phase and approval phases. In the early discovery phase once a druggable target is 
selected for a disease compounds are screened with a battery of in vitro and in vivo 
tests to identify hits [10]. Later, the identified hits or lead compounds go through a 
series of tests to characterize the pharmacokinetic and toxicological properties of the 
drug. Successful lead candidates are further optimized and rigorously tested in both 
in vitro and in vivo models before they are tested in humans. Accurate screening of 
safe druggable targets plays a key role in the success of the drug.
 After a thorough investigation at the discovery phase, drug candidates are 
selected for human clinical trials by filing an application with regulatory agencies. 
Both EMEA and FDA have a similar evaluation process with preclinical testing fol-
lowed by a clinical development phase [11]. On approval, phase I clinical studies are 
conducted, in which the compound is tested in about 20 to 80 volunteers looking 
mainly at pharmacokinetics and pharmacodynamics of the drug to evaluate a safe 
dosing range. In phase II, effectiveness of the drug is analyzed in about 100 to 300 
patients with a disease condition that is intended for treatment and studying any side 
effects caused by the drug.  After a positive evaluation the drug candidate is ready 
for phase III testing on a large number of patients (100 – 3000) to further evaluate 
safety and efficacy of the drug candidate [12]. Different populations are analyzed at 
this stage to find dosage, drug reactions, and drug-drug interactions [12]. After suc-
cessful clinical trials and approval by regulatory authorities the drug is released into 
the market.
 Even after this conscientious drug development process there are several 
drug withdrawals from the market due to adverse drug reactions. When we look from 
the early discovery phase 40% of the drugs are withdrawn due to toxicity after ani-
mal testing [1]. Between 1997-2005, forty-five of the approved drugs had black box 
warnings with 10 related to hepatotoxicity and 16 drugs were withdrawn out of which 
5 (31%) were due to hepatotoxicity [13, 14]. In another survey on post-marketed 
drug withdrawals between 1998 to 2008 liver toxicity was the major reason for drug 
withdrawal [2]. After liver toxicity renal injury is the second most leading cause of 
drug attrition [15]. 25% of the marketed drugs with potential nephrotoxicity warnings 
lead to acute kidney injury increasing mortality and morbidity in patients [15, 16]. 
Development of advanced alternative methods to identify the liver and kidney organ 
toxicities may therefore aid in decreasing drug attrition.
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The liver: a major organ for drug metabolism and a main target for drug-in-
duced toxicity. 
The liver is the major organ involved in drug metabolism and disposition. Liver pa-
renchymal cells (hepatocytes) carry out this function and possess the majority of 
the enzymes involved in metabolism, which are housed in smooth endoplasmic re-
ticulum. Of all cell types in the body, hepatocytes have the most extensive network 
of smooth endoplasmic reticulum. The expression of the xenobiotic metabolizing 
enzymes is a coordinately regulated and controlled mechanism. Drug metabolism 
by Phase I enzymes involves catalysis of the drug either by oxidation, reduction 
and hydrolysis steps leading a water-soluble or toxic reactive metabolites, which are 
further, modified by phase II enzymes for excretion. Phase II enzymes are mainly 
involved in conjugation steps, where a charged group is added to make a reactive 
metabolite less toxic to hepatocytes either by glucuronidation, sulphation, acetyl-
ation, methylation. Phase I and II steps render drugs into less toxic water soluble 
molecules that could be excreted through various routes, either blood, bile or renal 
elimination. 
 Approximately 70% of drugs are eliminated by CYP450 metabolism [17]. 
CYP450 metabolism can also lead to toxic reactive metabolites, which can cause 
hepatocellular necrosis [18]. These enzymes can also convert certain chemicals to 
carcinogenic metabolites; electrophilic metabolites produced by the CYP450 en-
zymes may bind to nucleophilic cellular components such as DNA leading to muta-
tions and cancer in humans [19]. Some drugs have the ability to induce or reduce 
the expression levels of CYP450 enzymes, which can be detrimental to patients who 
are on multiple medications, as the co-administered drug may change the pharma-
cokinetics of a second drug leading to adverse drug reactions [20, 21]. It is estimated 
that out of two million serious adverse drug reactions that occur per year in United 
States, 26% of them are caused due to such drug-drug interactions, [17, 22] empha-
sizing a need for creating a complete safety profile of all the drugs. Positive evalua-
tion of hepatotoxic drugs may decrease the incidence of liver toxicity and therefore 
drug attrition and huge costs involved with it. 
Figure 1. Process of metabolism and excretion of 200 drugs prescribed in 2002 (A) and CYP450 en-




Renal drug clearance and toxicity 
After the liver, the kidneys play a major role in the clearance of drugs [17]. The 
primary functions of the kidney are filtration, secretion, reabsorption of body fluids, 
but importantly, excretion of drugs and drug metabolites. When the filtrates or drug 
metabolites reach the nephron, the functional unit of the kidney, they are highly con-
centrated to up to 100–fold in the tubular regions of the nephron [23, 24], making 
the kidney vulnerable to toxic injury leading to acute renal failure or loss of kidney 
function. In a study of patients admitted to intensive care due to kidney failure, 19% 
were caused by drug-induced toxicity [23, 25]. 
 Proximal tubular epithelial cells in the nephron have the highest level of 
transporters compared to any other segment in the nephron playing a major role in 
reabsorption [26, 27]. These are the first cells that are exposed to the glomerular 
filtrate containing high levels of toxins, which makes them susceptible to toxic injury 
causing mitochondrial dysfunction, increased oxidative stress and decreased excre-
tion leading to kidney injury [24, 28, 29]. Upon injury by a nephrotoxic agent proximal 
tubule cells die either by apoptosis or necrosis [30]. Nephrotoxic drugs have either 
a direct toxic effect on various segments of the nephron or they induce inflammation 
of the renal interstitium leading to acute renal failure. Many antibiotics, chemothera-
peutics and immunosuppressant’s induce direct injury to the tubules [31]. The intact 
tight junction complex, which is essential for proper reabsorption, may also be dis-
rupted causing a leaky epithelium ultimately leading to proximal tubular disruption 
[31, 32].
Renal Inflammation in nephrotoxicity
Several nephrotoxic compounds induce an inflammatory response, which can ag-
gravate renal injury. At the early stages of injury morphological and functional chang-
es in tubular epithelium and vascular endothelial cells are observed [33]. This leads 
to infiltration of leukocytes to the injured site where renal tubular epithelial cells pro-
duce inflammatory cytokines TNFα, IL-6, IL-1β and TGF-β [34, 35] which induce an 
inflammatory cascade and can enhance cytotoxicity. 
 Nephrotoxic drugs such as cisplatin can increase the expression of various 
pro-inflammatory cytokines and chemokines, with TNFα being identified as a key 
factor in enhancing the inflammatory response. Inhibition of cisplatin-induced TNFα 
production led to downregulation of other cytokines and decreased renal injury [36-
38]. Several mechanisms have been proposed for cisplatin-induced TNFα produc-
tion, involving ERK and p38 MAPK mediated activation, [37, 39] imbalance in NF-
κB and JNK/c-Jun signaling [40]. Therefore, inflammation plays a major role in the 
pathophysiology of kidney injury, which needs to be thoroughly investigated during 
early phases of drug discovery. Nephrotoxicity is mainly detected at late stages of 
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drug development with only 2% of attrition at preclinical testing and 19% during clini-
cal trials [41]. Besides the current conventional end points, use of advanced screen-
ing methods such as live cell imaging for early apoptotic events [42] might help in 
identifying safe compounds thereby decreasing attrition rates due to nephrotoxicity.
Pre-clinical safety testing: where do we stand?
With a high incidence of drug-induced organ toxicity it is very important to make an 
accurate estimation of pharmacokinetic and pharmacodynamics properties of a new 
chemical entity during pre-clinical assessment. Currently various in vivo and in vitro 
studies are performed to validate the safety of chemical entities and their targeted 
use for a human disease, mainly relying on animal models for long-term effects of 
the drug. But only 50% of the chemicals that caused hepatotoxicity in clinical devel-
opmental phases had concordance with toxicity in animal models [43]. This may be 
attributed to species difference, interbred lab animals, disease state vs. healthy ani-
mals, genetic and environmental difference that exist in human population [14]. This 
emphasizes a need for efficient models that could accurately predict the safety pro-
file of the compounds. Human cell based models offer several advantages in terms 
of relevance to humans and increased throughput compared to animal models. Cur-
rent standard in vitro models used for screening assays include hepatocytes for liver 
toxicity, renal proximal tubule epithelial cells for nephrotoxicity, vascular endothelial 
cells for vascular toxicity, neuronal and glial cells for neurotoxicity, cardiomyocytes 
for cardiotoxicity, skeletal myocytes for rhabdomyolysis [44]. 
Sensitivity Specificity
DNA synthesis 10 92
Protein synthesis 4 97
Glutathione depletion 19 85
Superoxide induction 1 97
Caspase-3 induction 5 95
Membrane integrity 2 99
Cell viability 10 92
Cell viability or GSH or DNA synthesis 25 83
Regulatory animal toxicity tests 52 N/A
Table 1. Percentage predictivity of in vitro toxicity assays and regulatory animal studies for 611 com-
pounds with hepatotoxicity warnings as described by Xu et al in [14].
However, in vitro models fail to preserve organ specific functions in an artificial envi-
ronment and are not reliable for making accurate predictions. For example, in vitro 
testing on hepatic cell lines measuring various indicators of cell stress and toxicity 
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did not improve predictivity compared to animal studies alone [14, 45]. All the in vi-
tro tests combined together had only half the sensitivity to that of regulatory animal 
testing (as shown in table 1, sensitivity and specificity of 611 hepatotoxic compounds 
tested [14]).
The main focus of this thesis work is to explore improved in vitro models and meth-
ods for organ toxicity, with a principal focus on in vitro liver toxicity, which will be 
discussed in detail.
Predicting drug induced liver injury (DILI) at preclinical stages
There are several possible reasons for poor prediction of human toxicity in pre-clini-
cal studies. The current methods used to assess toxicity at the preclinical level were 
introduced in 1970’s and have not kept pace with technological developments [46]. 
Furthermore, test models may not give a toxic response due to loss of organ specific 
cell functionality or there is a difference in the mechanism of drug metabolism be-
tween humans and the cells/tissues of the model. The implementation of improved 
toxicological approaches and exploring the mechanistic toxicity on human-relevant 
test models may improve the early safety prediction.
 Preclinical hepatotoxicity assessment is done in a tiered approach. In the 
tier 1 studies normal animal models (rodent and non-rodent) are exposed with mul-
tiple doses and durations of the drug at much higher levels than those used in clin-
ical studies to estimate the ‘dose-limiting toxicity’ or no effect level (NOEL) and no 
adverse effect level (NOAEL) [47]. Various parameters are measured to evaluate 
toxicity and identify the safety level of the drug that could be administered in the clin-
ical phases. If hepatotoxicity was found to be the limiting factor, then various in vitro 
screening assays, including covalent binding assays are considered to indicate spe-
cific toxicity issues and their potential severity [48, 49]. Though the main reason for 
poor prediction lies with a lack of physiological relevance of the models, human ge-
netics and other underlying disease conditions might lead to idiosyncratic reactions, 
which are hard to identify at the pre-clinical and clinical phases. Of 28 compounds 
developed by Rhone-Poulenc Rorer (now a subsidiary of Sanofi-Aventis) between 
1988 and 1994, 10 of them showed signs of liver toxicity in animal models; 7 of these 
compounds were tested in humans of which only 1 compound showed human liver 
toxicity [50]. There are many other studies, which show a lack of correlation with ani-
mal toxicity [51]. In this respect, human cell based models with a stable liver specific 
function could make an important contribution to predicting drug safety. 
in vitro cell models for studying hepatotoxicity
Precision cut liver slices (PCLS): Tissue slices contain all the cell types and tis-
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sue microenvironment [52], which may enable them to respond better to a chemical 
stimulus. Precision cut human liver slices have shown to retain drug metabolism 
enzymes [53-55] and they have been used for various drug metabolism and toxic-
ity studies [56, 57]. Microarray transcriptomic studies on rat PCLS showed similar 
mechanistic gene expression profile as in vivo liver tissue [58]. Recently, proteomic 
analysis after compound exposure on mouse, rat and human PCLS was shown to 
demonstrate in vivo like responses [59]. Though the model is unique in its composi-
tion and similarity to in vivo liver responses, a rapid decline in liver specific functions 
[54] is a limitation for chronic drug exposure studies. Recent advances in slicing and 
cryo-preservation techniques were shown to maintain the viability of liver slices [52], 
which may help to overcome laborious extraction procedures for test samples and 
low-throughput.  
Primary hepatocytes (PHH): Primary hepatocytes isolated from human or animal 
tissue largely retain liver specific enzymes and are widely used for evaluating drug 
metabolism. Freshly isolated primary human hepatocytes are considered the ‘gold 
standard’ for in vitro drug assessment [5, 60]. Isolation of primary human hepato-
cytes is a complex process, which can lead to poor retention of liver enzyme activity 
[61]. Recent advances in cryopreservation techniques have helped to maintain the 
differentiated status of primary hepatocytes without any major loss of functions due 
to cryoinjury [62, 63]. But once cultured in vitro, primary hepatocytes rapidly lose 
their liver specific functions [5, 64]. Sandwich culturing of primary hepatocytes (be-
tween layers of collagen gel) has been shown to improve stability of expression of 
metabolic enzymes and support formation of bile canaliculi [65-68]. Although human 
primary hepatocytes are most promising for in vitro assessment in terms of physio-
logical relevance, the limited availability of human donors, donor specific variability 
and cost have made this impractical for routine assessment [6, 61]. Primary hepato-
cytes from rat and mouse were also investigated and similar limitations were ob-
served. Compared to rat hepatocytes, mouse hepatocytes are better in maintaining 
liver specific functions and discriminating carcinogens from non-carcinogens in a 
toxicogenomics study [69-71]. 
Immortalized cell lines: Cell immortalization either due to mutations in growth reg-
ulating genes or certain gene insertions provide a valuable and limitless source of 
material for studying the biological responses of the organs. Due to their unlimited 
growth, ease of availability and use they are convenient for high-throughput screen-
ing assays without large variation between experiments. Among the various immor-
talized cell lines available, Fa2N4 and HepG2 are ‘first alternatives’ after primary 
human hepatocytes [72] and the recently introduced HepaRG is a promising addition 
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with their high levels of metabolic enzymes [73].
Fa2N4: Fa2N-4 cells are derived from primary human hepatocytes and immortalized 
with SV40 large T-antigen [60, 74, 75]. These cells were shown to posses various 
CYP450 enzymes and transporters [75] but at the same time they lack certain xe-
nobiotic nuclear receptors like CAR and important drug transporters classes like 
OATPs [60, 76] which limits their use for assessing hepatotoxicity. 
HepaRG: HepaRG cell line is derived from female carcinoma patient.  It is a bi-po-
tent progenitor cell line, which differentiates into biliary and hepatocyte-like cells in 
the presence of DMSO [77-79]. Once differentiated in the presence of DMSO, Hep-
aRG cells express high levels of metabolic enzymes, transporters and xenobiotic nu-
clear receptors [73, 80]. The culture of HepaRG cells in high concentration of DMSO 
in the medium has seen certain drawbacks such as increased cell death and LDH 
and AST enzymes levels [81]. Earlier observations in primary hepatocytes and our 
observations with HepG2 cells have shown that concentrations of DMSO at 0.1% or 
above can induce phase 1 and 2 enzyme expression [5, 6, 82]. Therefore high levels 
of DMSO might give an inappropriate estimation of enzyme induction. It was also 
observed that prototypical inducers of CYP3A4 like rifampin and phenobarbital did 
not induce CYP3A4 induction in HepaRG cells [73, 80]. Though promising with high 
levels of drug detoxifying enzymes, the media formulation and proprietary status of 
these cells may complicate their use for routine toxicological assessments. 
HepG2 cells: HepG2 is a well-differentiated hepato-carcinoma cell line. HepG2 cells 
are best characterized and are widely used for various toxicological and pharmaco-
logical studies [83-87]. They express various liver-specific enzymes and drug me-
tabolizing enzymes [88]. HepG2 cells express functionally active p53 protein, which 
can activate the DNA damage response and induce apoptosis, making it a desirable 
model for toxicity studies, especially genotoxic studies [60, 89]. These cells also 
show the presence of active nuclear transcription factor E2-related factor-2 (Nrf2) 
system, which is essential for induction and the expression of various phase II drug 
metabolizing enzymes and transporters for detoxification [90].
 HepG2 cells are widely used in various high-throughput studies [86, 91-
95] including EPA’s ToxCast™ and Tox21™ programs for predicting and prioritizing 
chemicals [95-98]. The cells were also used in the pharmaceutical industry for lead 
identification [99]. A recent study combining a toxicogenomics approach and Ames 
test demonstrated that HepG2 cells could accurately predict in vivo genotoxicity 
[100]. In a high content screening approach these cells showed 93% sensitivity in 
identifying hepatotoxic compounds [86]. Comparative toxicogenomics analysis be-
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tween HepG2 and HepaRG showed that HepG2 cells are better in discriminating 
genotoxic compounds and non-genotoxic compounds than HepaRG [101]. Earlier 
studies also indicated that these cells had high sensitivity and specificity in identify-
ing genotoxic compounds [94, 102, 103].
 With several advantages in ease of use, availability and considerable biolog-
ical responses, HepG2 cells could be an ideal replacement for primary hepatocytes. 
However, the major concern with HepG2 cells and other hepatocyte cell lines is the 
lack of metabolic competence compared to primary hepatocytes [7, 14] [104]. This 
may be partly due to their hepatocarcinoma origin and oncogenic transformation, but 
also because they have been passaged extensively, resulting in drift from the origi-
nal hepatocyte genetic profile. Furthermore, the absence of an in vivo like environ-
ment in a tissue culture dish results in a dedifferentiated phenotype with inevitable 
loss of function. A high proliferation rate associated with immortalized cells is a major 
limitation in identifying compounds that inhibit cell growth and induce apoptosis.
3D cell culture
In vivo, hepatocytes are highly polarized with distinct basal-lateral sinusoids and api-
cal canalicular domains [105] which are essential for proper functioning of the liver. 
This highly polarized morphology is lost when cells are cultured under non-phys-
iological conditions [106]. Hepatocytes cultured in a 3D environment using biore-
actors [107, 108], hanging drop methods [109], collagen sandwich cultures [110], 
micro-space cultures [111], micro-patterned systems [112], microfluidic perfusion 
systems [113, 114], collagen and Matrigel cultures [115, 116] and other synthetic bio-
materials [68, 117] have shown to re-acquire tissue specific properties and possess 
many hallmarks of in vivo epithelial cells. 
 Besides an increased physiological relevance, 3D models could also sup-
port long-term culture of the micro-tissues [108, 118, 119], representing a new dimen-
sion in in vitro toxicity assessment for repeated drug exposure studies.  Maintaining 
robust tissue-like properties and balancing this with a high-throughput methodolo-
gy is a big challenge. Some of the current 3D platforms cannot offer flexibility for 
high-throughput toxicity studies. A preferred choice for high-throughput screening 
assays would be to grow micro-tissues in a 384 or 1536 well formats. Bioreactors or 
microfluidic devices might emulate a tissue-like environment with respect to gaseous 
exchange and flow of nutrients but the throughput may be challenging with these 
models requiring complex equipment. High content imaging is increasingly used for 
toxicological screening assays [86]. Such imaging based approaches are technically 
challenging to apply to 3D culture systems.  Although these challenges will inevitably 
be resolved as the technology develops, the use of biochemical end-points for 3D 
cultures are more feasible for routine high-throughput assays. 
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HepG2 cells in 3D culture
HepG2 cells show a spheroid morphology when cultured in micro-space cultures 
[111], bioreactors [107], peptide gels [68] and Matrigel [119] with distinctive charac-
teristics of polarized epithelial hepatocytes. The gene expression of metabolic en-
zymes is also higher in HepG2 spheroids cultured on micro-space cultures [111] or 
ECM gels, in contrast to low levels with conventional 2D cultures. Increased expres-
sion of CYP450 enzymes might offer a great improvement to safety assessment 
studies and studying drug-drug interactions where the activation of a xenobiotic re-
sponse by one (not necessarily toxic) compound may increase the metabolism of 
a second compound into toxic intermediates [120]. The absence or impairment of 
CYP450 enzymes most likely accounts for the failure to identify some hepatotoxic 
compounds in vitro.
 Some functional activities of polarized hepatocytes were also recapitulated 
in 3D cell culture models. The formation of bile canaliculi is an important feature that 
was shown in HepG2 cells cultured on peptide hydrogels [68] and even more prom-
inently with Matrigel cultures in our lab as described in chapter 2. The restoration of 
excretory function is likely due to the improved morphological differentiation of the 
hepatocytes, in particular, the establishment of apical-basal polarity - but also the re-
stored expression of transporters and other components of the excretory machinery. 
Many drugs disrupt excretion pathways, for example rifampicin inhibits activity of 
OATP1B3, a transporter essential for bile acid flow [121]. HepG2 3D culture models 
may therefore allow the evaluation of the effects of new chemical entities on trans-
porter function at the in vitro screening stage.
 Earlier reports have shown that HepG2 cells have higher gene expression 
associated with cell cycle regulation, DNA, RNA nucleotide metabolism, transcrip-
tion, transport and signal transduction and lower transcription levels associated with 
cell death, lipid metabolism and xenobiotic metabolism. In this thesis, we demon-
strate that in HepG2 spheroids, genes associated with cell cycle were strongly 
downregulated and most of the xenobiotic metabolism pathways and stress signal-
ing pathways such as the Nrf2 system were highly upregulated. HepG2 cells were 
also known to be inherently lacking in important nuclear xenobiotic receptors, [122, 
123] but were re-expressed in the differentiated HepG2 spheroids as described in 
chapter 2 of this thesis. 
 An improved metabolic competence in 3D HepG2 spheroids and a func-
tional similarity to in vivo hepatocytes in a micro plate setup would be promising 
for high-throughput toxicity screening assays. The ability to maintain a functionally 
stable phenotype for an extended period is an important feature that would allow the 
study of chronic drug exposure. A thorough investigation on low-dose, long-term ef-
fects on the gene expression, metabolite formation and morphological perturbations 
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will provide more insight into the mechanisms of toxicity, and should be taken into 
consideration when validating and evaluating the potential of 3D cell culture systems 
as surrogates to human liver tissue or a replacement for animal models. Modern 
sensitive approaches such as toxicogenomics to identify the mechanistic information 
and high content screening (HCS) to identify subtle morphological and physiological 
changes that occur before cell death on 3D organotypic models will provide further 
detailed insight into the mechanisms of toxicity and will help identify biomarkers of 
liver injury.
Toxicogenomics approaches in DILI
The availability of complete genome sequences led to the successful evolution of 
functional genomics which helped to discern biological responses at a whole new 
level. Toxicogenomics, a combination of transcriptomic, proteomic and metabolomic 
analysis with conventional toxicology investigates the effects of compounds on over-
all changes giving comprehensive mechanistic information on mode of action of a 
toxic response. 
 Transcriptomics analysis with microarray technology allow us to identify tens 
of thousands of genes that change upon xenobiotic exposure, allowing us to quick-
ly interpret genes and stress signaling pathways associated with chemical toxicity. 
Also, recent advances in proteomic technologies either by two-dimensional gel elec-
trophoresis 2-DE and gel-free LC-MS techniques are available for high-throughput 
protein analysis [124, 125]. Many toxicogenomic studies have been conducted to 
assess hepatotoxicity in rodent species, especially in rats, as it is a preferred choice 
due to ease of manipulation and breeding characteristics [126-132]. These studies 
have demonstrated that specific liver pathologies can be predicted by toxicogenomic 
approaches [133-137].  
 A repository of toxicogenomics data is available in public databases such as 
Gene Expression Omnibus (GEO) [138], Array Express [139], Comparative Toxicog-
enomics Database (CTD) [140] or EDGE [141, 142], Chemical Effects in Biological 
Systems (CEBS) [129]. Additionally, the InnoMed PredTox consortium developed 
large-scale toxicogenomics databases, aimed at assessing the value of toxicog-
enomics by combining the results with conventional readouts [143]. TG-GATES (Ge-
nomics Assisted Toxicity Evaluation System) has a database of in vivo and in vitro 
gene expression profiles of liver and kidney upon exposure to 150 chemicals, mainly 
including drugs that are currently used for patients [144]. These databases will help 
us to perform a comparative analysis of prototypical compounds in various models.
 Availability of large ‘omics’ data sets requires complex analysis algorithms 
to interpret the biological response. Availability of open source bioinformatics tools, 
like Bioconductor are helpful for data normalization of transcriptomics data. Several 
22
Chapter 1
commercial applications like ingenuity pathway analysis (IPA ®), Metacore™ (and 
other tools as discussed in [145]) are valuable for interpreting complex genomic 
data. These programs are built on a knowledge base developed from scientific liter-
ature databases on genes, proteins and chemicals providing relationships between 
changes in the gene expression to biological pathways. 
 Toxicogenomics aims to discern biological responses upon toxic insult and 
develop biomarkers that could predict a toxic outcome. The discovery of biomarker 
signatures will not only help in accurate prediction of toxicity, but also greatly reduces 
the use of animals for toxicity studies or may even replace animal testing if an in vitro 
model out-performs animal test models. A thorough comparative investigation of in 
vitro models with their in vivo counter parts may weigh the similarities between them. 
Kienhuis et al compared rat hepatocytes and rat in vivo gene expression profiles, 
which showed only a very minor overlap between the models, although the overlap 
increased with modification of the cell culture medium [146]. Additional improvement 
in the cell culture conditions - either media or using 3D cell culture models might 
further improve the predictive power of in vitro assays. In vitro toxicogenomics stud-
ies using human cell lines might be valuable to predict human specific responses; a 
number of studies from human derived hepatocytes - either primary or cell lines - are 
currently available [101, 147-151] and are promising. Our observations of gene ex-
pression profiles with diclofenac exposed in vitro 3D HepG2 cells showed a similar 
pathway profile to that of in vivo models. A number of stress signaling pathways that 
are not activated in 2D HepG2 cells were seen in 3D HepG2 cells which were in 
common with human liver slices exposed to diclofenac.
High-content screening for studying drug induced organ toxicity
High content imaging is a valuable methodology, which has the capacity to identify 
sensitive biological changes that are otherwise impossible with end point cytotoxicity 
assays. It will allow us to visualize dynamics of stress induced biological perturba-
tions inside a cell in real time. Recent technical advances in fully automated micros-
copy stations and image data analysis methodologies have further improved the 
power to HCS for high-throughput screening assays.  
 Availability of various cell-permeable fluorescent molecular probes allowed 
us to study the kinetics of stress responses in real time. Automated measurements 
of live-cell apoptosis using Annexin-V, which binds to phosphotidyl-serine during ear-
ly events of apoptosis is an efficient way to measure the kinetics of apoptosis upon 
compound exposure [152]. HCS has an advantage that multiple parameters can be 
measured. In a study to identify DILI compounds, primary human hepatocytes were 
challenged with 300 compounds measuring mitochondrial damage, oxidative stress 
and intracellular glutathione levels [153]. This analysis had a true-positive rate of 50-
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60% and very low false-positive rate of 0-5%. In another study using HepG2 cells, 
four parameters were used; these measured intracellular calcium (Fluo-4AM), DNA 
content (Hoechst), mitochondrial membrane potential (TMRM) and plasma mem-
brane permeability (TOTO3) and were compared with 7 conventional readouts that 
are used to assess toxicity. The high-content image analysis showed much higher 
sensitivity of 93% and specificity of 98 % compared to 25% and 90% of conventional 
assay readouts [86].  
 The application of toxicogenomics and high content screening in drug safety 
testing on human relevant in vitro models, may increase the predictive power of in 
vitro toxicity screening assays and provide sufficient functional data to reduce the 
reliance on animal models. The near in vivo properties of 3D cultures, their ease of 
use, low cost and availability suggest that these models offer great promise and are 
likely to play a significant part in animal-free toxicity testing in the future.
Aim and outline of this thesis:
Currently there is a dearth of in vitro models that could preserve the functional prop-
erties of a tissue for an extended period and offer compatibility to high-throughput 
screening assays. The key aim of this thesis is to develop an organotypic in vitro 
model for toxicity studies that can be used in pre-clinical drug safety testing and the 
in vitro study of liver biology. To this end we have developed a robust in vitro model, 
which show many hallmarks of in vivo hepatocytes, is applied in a 384-micro-well 
format and is compatible with standard medium- and high-throughput lab infrastruc-
ture for routine drug screening. 
Chapter 2 describes the development and validation of a 3D cell culture methodol-
ogy, which enables HepG2 cells to reacquire lost functional hepatocytes properties. 
The cells differentiated and formed spheroids. Spheroids were analyzed for their 
polarized morphology, expression of functional differentiation markers, presence of 
functional activities of hepatocytes and their sensitivity to identify hepatotoxic com-
pounds. 
Chapter 3 further characterizes the 3D HepG2 spheroid model and compares them 
to other in vitro liver models by analyzing gene transcription. Microarray analysis 
gene expression data was acquired during the differentiation process of HepG2 cells 
in 3D culture. Biologically significant pathways that are altered in differentiated 3D 
HepG2 cells compared to conventional 2D cultured HepG2 cells were thoroughly 
investigated. A detailed comparison of gene expression profiles was made between 
3D HepG2 spheroids and other hepatocyte models (PHH and HepaRG) to human 
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liver. Common pathways between human liver and 3D HepG2 spheroids were high-
lighted. 
Chapter 4 describes a comparative transcriptomic study between various in vitro 
and in vivo models in response to hepatotoxicant exposure. Gene expression pro-
files from in vitro HepG2 spheroids, primary human hepatocytes, primary rat and 
mouse hepatocytes, human liver slices and in vivo rat and mouse models exposed 
with diclofenac were compared. Various stress-signaling pathways that are activated 
upon diclofenac exposure were analyzed. 
Chapter 5 describes a novel live-cell HCS assay for measuring nephrotoxicity. Tox-
icity caused by nephrotoxic compounds was analyzed in real time on proximal tubu-
lar kidney cells. The role of inflammation in conferring sensitivity to nephrotoxicants 
was investigated using the pro-inflammatory cytokine TNFα. 
Chapter 6 provides a summary and general discussion of the findings and implica-
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Immortalized hepatocyte cell lines show only a weak resemblance to primary he-
patocytes in terms of gene expression and function, limiting their value in predicting 
drug induced liver injury. Furthermore, primary hepatocytes cultured on two-dimen-
sional (2D) tissue culture plastic surface rapidly de-differentiate losing their hepato-
cyte functions and metabolic competence. We have developed a three-dimensional 
(3D) in vitro model using extracellular matrix-based hydrogel for long-term culture of 
the human hepatoma cell line HepG2. HepG2 cells cultured in this model stop pro-
liferating, self organize and differentiate to form multiple polarized spheroids. These 
spheroids re-acquire lost hepatocyte functions such as storage of glycogen, trans-
port of bile salts and the formation of structures resembling bile canaliculi. HepG2 
spheroids also show increased expression of albumin, urea, xenobiotic transcription 
factors, phase I and II drug metabolism enzymes and transporters. Consistent with 
this, cytochrome P450–mediated metabolism is significantly higher in HepG2 spher-
oids compared to monolayer cultures. This highly differentiated phenotype can be 
maintained in 384 well microtiter plates for at least 28 days. Toxicity assessment 
studies with this model showed an increased sensitivity in identifying hepatotoxic 
compounds with repeated dosing regimens. This simple and robust high through-
put-compatible methodology may have potential for use in toxicity screening as-
says and mechanistic studies and may represent an alternative to animal models for 
studying drug induced liver injury.
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INTRODUCTION
Drug induced liver injury (DILI) has been a major cause of attrition during drug de-
velopment [1]. The lack of accurate prediction with animal models and the increas-
ing legislative pressure in implementing 3R’s strategy demands an urgent need for 
robust in vitro models in safety assessment. In vitro human cell models offer many 
advantages compared to animal models. However, cells cultured in vitro on tissue 
culture plastic (2D), fail to develop normal tissue architecture, resulting in a poor 
level of differentiation and loss of tissue-specific functions, limiting their use as alter-
natives to animal models.
 The liver is the principal site for drug metabolism. Liver parenchymal cells 
or hepatocytes contain the majority of the enzymes required for drug metabolism. 
Currently human primary hepatocytes are considered as the gold standard for drug 
metabolism and toxicity studies [2], but the limited availability of human liver sam-
ples, short life span, inter-donor differences and cost represent a significant limita-
tion for in vitro screening assays [3]. With their unlimited life span, immortalized cell 
lines - in particular HepG2 cells - are commonly used as an alternative to primary 
cells [4]. However, in conventional 2D cultures, HepG2 cells express low levels of 
cytochrome P450 (CYP450) enzymes [5] and the xenobiotic receptors that regulate 
the expression of drug metabolic enzymes [6, 7]. Since the activity and inducibility of 
CYP450 enzymes is an important determinant of the pharmacokinetics and toxicity 
of drugs, poor expression of these and other metabolic enzymes in hepatocyte cell 
lines is thought to be a key factor in the poor prediction of toxicity in humans. 
 Hepatocytes are polarized epithelial cells with distinct apical and basolat-
eral domains [8, 9]. The lateral domains of the adjacent hepatocytes form micro-
villi-lined bile canaliculi, which collect bile secreted from the hepatocytes [8]. This 
polarized morphology is lost when cells are restricted to hard plastic surface. Various 
3D hepatocyte models have shown a significant improvement in maintaining the 
morphological and functional characteristics of liver tissue [10-15]. However, these 
models often require specialized equipment, are costly and/or not compatible with 
high volume screening.  Here we describe a robust high throughput-compatible 3D 
in vitro model using HepG2 cells. HepG2 cells cultured in this model form polarized 
spheroids with functional bile canaliculi and strongly increased expression of albu-
min, genes encoding phase I and II drug metabolism enzymes, drug transporters 
and xenobiotic receptors that mediate induction of CYP450 enzymes. This highly 
differentiated phenotype can be maintained for more than 28 days in a microtiter 
plate allowing repeated or sub-chronic drug exposures. A 6-day repeated treatment 
on 3D HepG2 spheroids showed increased sensitivity in determining cytotoxicity of 




Therefore, this 3D HepG2 cell culture model represents a novel, relatively low cost 
method that is promising for routine high-throughput drug safety assessment con-
taining many features reminiscent of metabolically competent human hepatocytes.
Cell line 
Human Hepatoma HepG2 cell line was obtained from American type tissue culture 
(ATCC, Wesel, Germany), cultured in Dulbecco’s modified Eagles medium (DMEM) 
supplemented with 10% (v/v) fetal bovine serum (Invitrogen, Lot.no. 41F3161K), 25 
U/mL penicillin, and 25 μg/mL streptomycin (PSA, Invitrogen).
3D cell culture
3D cell culture reagent, Matrigel (Cat.no: 354230; Lot: A6263, 24859, 2306532, 
2104930), was obtained from BD Biosciences (Erembodegem, Belgium) and was 
used to culture liver spheroids. Batches of matrigel vary in the total protein con-
centration; a stock concentration of 5 mg/ml was prepared and used for culturing 
spheroids. A CyBi-Selma semi-automatic pipettor was used for liquid handling and 
dispensing. Cells were incubated at 37°C degrees with 5% CO2 and culture medium 
was refreshed every 2-3 days. 1000 cells (384 well plate) and 5000 cells (96 well 
plate) for 3D culture were used for optimal spheroid size. Samples for LC-MS Metab-
olite analysis, RNA extractions for qPCR, IHC analysis and toxicity assays were per-
formed in 96-well plates.  The remaining analyses were performed in 384 well plates.
Reagents and antibodies 
Anti-human albumin (A80-229F, polyclonal), was from Bethyl laboratories Inc (Texas, 
USA), anti-β1-integrin antibody (MAB1981, monoclonal), was from Millipore (Am-
sterdam, Netherlands), anti-β-Catenin antibody (610153, monoclonal) and anti-Ez-
rin antibody (610602, monoclonal) was from BD transduction laboratories (Breda, 
Netherlands), anti-MRP2 (M2III-6) (AB3373, monoclonal) and anti-Ki-67 (AB15580, 
polyclonal) antibodies were obtained from Abcam (Cambridge, UK). Goat anti-mouse 
Alexa-488 (A11001) and anti-rabbit Alexa-488 (A11008) were from Molecular Probes 
(Breda, Netherlands). Hoechst 33258 from Sigma (Zwijndrecht, Netherlands) (2 μg/
ml) was used to visualize the nuclei of fixed cells and Hoechst 33342 (200 ng/mL) 
from Fisher Scientific (Leiden, The Netherlands) for live cells.  Rhodamine phalloidin 
was obtained from Sigma (Zwijndrecht, Netherlands).
Albumin and urea measurements
Albumin in cell culture supernatant was measured using human albumin ELISA kit 
from abcam (ab108788) according to the manufacturer’s protocol. Samples were 
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collected after 72 hours of initial cell seeding from 2D cultures. Changing the culture 
media every 2-3 days was essential for optimal spheroid growth in 3D cultures and 
so a 72-hour cumulative albumin secretion was measured at day 3, 7, 14, 21 and 28. 
Cell number was estimated at each time point using ATPlite reagent (PerkinElmer) 
and the data normalized to 6x104 cells. Urea was measured using a colorimetric 
assay kit from BioVision (California, USA). Cultures were briefly washed with PBS 
and homogenized with urea assay buffer and analyzed according to manufacturers 
protocol.
Histological and immunohistochemical analysis
HepG2 cell spheroid suspension was collected in PBS and spun at 1000 rpm for 5 
minutes. The pellet was fixed in 10% buffered formalin and embedded in paraffin. 
3 µm tissue sections were prepared and stained with haematoxylin and eosin, PAS 
(Periodic acid-Schiff’s reaction) and PAS after treatment with diastase to remove 
glycogen. Human liver tissue was provided by Bronovo Hospital, The Netherlands, 
in accordance with the hospital’s code of conduct regarding use of patient-derived 
material. Immunohistochemical detection of cytokeratin 7 and 8 (CAM5.2, 1:20, BD 
Biosciences, Ref. 345779) and bile canaliculi (polyclonal CEA, 1:200, DAKO, Ref. 
A0115) was performed using an automated immunostainer (Benchmark ULTRA, 
Roche Diagnostics).
RNA extraction and Real time PCR analysis
Total RNA was extracted using Trizol reagent (Invitrogen) followed by clean up with 
RNeasy mini kit (Qiagen). 500 ng of RNA was used for cDNA synthesis using Revert 
aid First strand cDNA synthesis kit (Thermo Scientific) according to the manufactur-
er’s instructions. Real time PCR was performed using SYBR green master mix (Ap-
plied Biosystems). mRNA levels of target genes were normalized to housekeeping 
gene, GAPDH. The list of primer sequences is shown in supplementary table S3.
Determination of CYP450 enzyme metabolic activity 
2D and 3D cultures were incubated with a mixture of probe substrates, including: 
diclofenac (CYP2C9, 50 μM), midazolam (CYP3A4, 10 μM), bufuralol (CYP2D6, 20 
μM) and chlorzoxazone (CYP2E1, 100 μM).  Cell culture supernatants were collect-
ed at 0-, 4-, 24- and 48-h post exposure and stored at -80 degrees. LC-MS analysis 
of metabolites was performed at Pharmacelsus GmbH (Saarbrucken, Germany). 
Detailed methodology used is described in supplementary data S4. Diclofenac and 
chlorzoxazone were obtained from Sigma-Aldrich (Zwijndrecht, Netherlands). Bu-
furalol HCL was from Corning Gentest (Amsterdam, Netherlands), midazolam was 
from Actavis (Hafnarfirdi, Iceland).
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Determination of glucuronidation and sulfation activity
2D and 3D cells were incubated with 500 μM diclofenac and 1 mM acetaminophen 
to study glucuronidation and sulfation activity. A detailed protocol is in the supple-
mentary data S6.
Analysis of hepatobiliary transport in HepG2 cells
Cholyl-lysyl-fluorescein, CLF (BD Biosciences) a synthetic fluorescent bile acid an-
alogue with similar biological activity as cholyl glycine was used to determine the 
hepatobiliary transport activity. 2D and 3D HepG2 cells were rinsed with 1x Hanks 
balanced salt solution (Invitrogen, Breda, Netherlands) and incubated with 2 μM 
CLF in HBSS for 45 minutes similar to the protocol used for primary rat hepatocytes 
[16]. After the incubation period the cells were washed 3 times with HBSS and im-
aged live by confocal microscopy (Nikon TiE2000, Nikon). A series of images were 
collected across the Z-plane of the spheroid and a maximum intensity projection 
image was generated using the image processing software package, Image J.  
Assessment of drug-induced toxicity 
2D and 3D HepG2 cells were cultured for 24 hours and 21 days respectively prior 
to compound exposure. Bosentan was obtained from Sequoia Research Products 
(Pangbourne, UK), all the other compounds were obtained from Sigma-Aldrich (Zwi-
jndrecht, Netherlands). The concentrations of the compounds and solvents used are 
as shown in the supplementary data S7. A maximum concentration of up to 100X 
Cmax or above was tested (a reference scaling factor as used in earlier studies with 
primary hepatocytes [17, 18]). Compounds that are not toxic at 100X Cmax and 
that are soluble in culture media were tested up to 100 mM (acetaminophen, isoni-
azid and valproic acid). Cell death was estimated as percentage of viable cells after 
compound exposure compared to its vehicle control. ATP-lite luminescence assay 
kit (PerkinElmer) was used to measure cell viability. Measurements were recorded 
24-hours after drug exposure. Additionally a repeated drug exposure was performed 
on 3D cell cultures, by adding the compound every 24 hours for 6 days (at day 22, 
23, 24, 25, 26, 27 of spheroid culture) and measuring cell viability on 7th day (day 
28 of spheroid culture).
Statistical analysis
Data expressed is either representative of 3 independent experiments (mean ± stan-
dard deviation (± S.D.) or mean of 3 independent experiments (± S.D.). Graphs were 
plotted using Graphpad Prism 4 (Graphpad software, San Diego, CA, USA).
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RESULTS
HepG2 cell proliferation and differentiation in 3D cultures
5000 or 1000 cells in suspension were added on top of a pre-cast gel in 96 or 
384-well microplates, respectively. Maintaining this cell number was critical for op-
timal spheroid size (~100 μm). After seeding, cells settled, adhered to the gel and 
self-aggregate to form cell clusters (87+/- 16 clusters per well in a 384 microplate) 
(Supplementary Figure S1). These gradually formed well-defined spheroids over a 
period of 21 days. The average diameter of the spheroids at day 28 was 118 ± 5 μm 
(supplem-ementary Figure S1), which is sufficient for oxygen diffusion, as spher-
oids above 200 μm are known to become hypoxic at the core [19] [20]. To examine 
the effect of 3D culture on cell proliferation, HepG2 cells were immunostained with 
antibodies against the proliferation marker Ki-67. The majority of HepG2 cells in 2D 
Figure 1. Spheroid development in 3D culture. Phase contrast images of HepG2 cells cultured in Matrigel 
(A) scale bar 100 μm. Immunostaining of HepG2 cells for the proliferation marker, Ki-67, counterstained 
with Hoechst 33358 for nuclei (Blue) (B). Scale bar – 50 μm.  Ki-67 protein level assessed by Western 




culture were positive for Ki-67 (Fig. 1B). However, in 3D cultures, there was a sharp 
decline in Ki-67 positive cells between day 7 and 14, and positive cells were barely 
present after 21 days. This was confirmed by analyzing the protein and mRNA tran-
script levels of Ki-67 (Fig. 1C and D). Together, these data demonstrate that HepG2 
cells transform from a highly proliferative state in monolayer culture to non-prolifer-
ating spheroids after a period in 3D culture. 
HepG2 cells form functionally differentiated spheroids in 3D culture
Primary hepatocytes cultured as monolayers lose tissue-specific polarity and func-
tion and eventually die [21]. Differentiated HepG2 spheroids acquire a uniform size, 
which remains stable after 21 days. Larger spheroids can show signs of necrosis in 
the center due to hypoxia [20]. H&E staining of HepG2 spheroids show organized 
nuclei and cytoplasm and did not show signs of necrosis although the formation 
of large and multiple cavities was occasionally observed  (Fig. 2B). Since the pro-
liferation of HepG2 cells in 3D culture ceased, we anticipated a probable repro-
gramming into a more differentiated liver cell phenotype. Positive immunostaining 
for cytokeratins 7 and 8 at cell-cell junctions in HepG2 spheroids indicate that the 
cells of the spheroid retain epithelial characteristics (Fig. 2B). To further study the 
differentiation of the cells in the spheroid we examined the expression of apico-basal 
surface epithelial markers by immunofluorescent staining. An intense staining of the 
basal membrane marker, β1 integrin, was seen at the margins of the spheroid where 
cells contact the extracellular matrix. β-catenin, which is associated with E-cadherin 
at sites of cell-cell contacts, was localized at lateral junctions. Together, the local-
ization of these two markers indicates that the cells at the periphery of the spher-
oid establish basal-lateral polarity (Fig. 2A). Finally, we determined the formation of 
bile canaliculi-like structures by examining the localization of the canalicular marker 
glycoprotein-1 [22]. HepG2 spheroids showed enhanced punctate staining for this 
marker between some cells with a similar pattern of immunohistochemical staining 
to that of human liver (Fig. 2B). We substantiated this with additional immunofluo-
rescent stainings for MRP2 and ezrin (Fig. 2A) that are typically associated in actin 
rich regions of the bile canaliculi [23, 24]. The localization of these markers was also 
observed in distinct punctae, which are suggestive of rudimentary canaliculi. 
 We also investigated the metabolic differentiation by evaluating the glyco-
gen storage capacity, a typical function of liver hepatocytes. 3D spheroids showed 
the presence of intracellular glycogen as determined by periodic acid-Schiff (PAS) 
staining. As a control, spheroids were also treated with diastase to digest the glyco-
gen, which resulted in decreased intracellular PAS staining confirming the presence 
of glycogen in 3D HepG2 spheroids (Fig. 2B).
 Cell polarity and ECM signaling have been shown to promote liver-specific 
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Figure 2. 3D HepG2 spheroids show increased expression of markers of differentiated and polarized he-
patocytes. Immunofluorescence staining of 3D HepG2 spheroids with epithelial cell markers β1-integrin, 
β-catenin, MRP2, ezrin and albumin counterstained with Rhodamine-phalloidin for F-actin and Hoechst 
33358 for nuclei (A), scale bars - 50 μm. Histological examination of human liver and HepG2 spheroids 
(B) scale bars - 100 μm. Albumin production in 2D and 3D HepG2 cells in 72 hours (C) data normalized 
to 6X104 cells (n=2).
functions such as albumin secretion and metabolic enzyme expression [25]. Immu-
nostaining of HepG2 spheroids showed the presence of albumin (Fig 2A).  Consis-
tently, mRNA expression levels of albumin were 10± 4 fold higher in differentiated 
3D HepG2 cultures compared to 2D cultures (Fig. 3B). Albumin protein level was 
approximately 16 μg/mL at day 21 and day 28 (Fig. 2C). Urea production was also 
found to be higher in spheroids (Supplementary S2). Taken together, these data 




Figure 3. Real-time PCR analysis of liver-specific markers and metabolic enzymes in 2D and 3D culture. 
Fold-change gene expression levels of 3D spheroids at day 3 (d3), day 7 (d7), day 14 (d14), day 21 
(d21) and day 28 (d28) compared to 3-day cultured 2D HepG2 cells (2D) (A). Data are representative of 
4 individual experiments. Real time PCR analysis of Albumin (B); and nuclear receptors AhR, CAR and 
PXR in 3D cell cultures (C) compared to 2D cultures. Data normalized to GAPDH, representative of 3 
independent experiments.
Metabolic competence is enhanced in 3D-cultured HepG2 spheroids
Low levels of drug metabolism enzymes in HepG2 cells contribute to mis-classifi-
cation of chemical entities that form toxic metabolites [5]. Real time PCR analysis 
showed higher expression of various phase I and II metabolizing enzymes and drug 
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transporters in 3D HepG2 spheroids compared to 2D cultures (Fig. 3A). mRNA tran-
script levels of phase I xenobiotic metabolic enzymes CYP3A4, CYP1A2, CYP2E1, 
CYP2C9, CYP2C19, CYP4F3 and CYP2D6 were systematically analyzed over a 
period of 28 days of spheroid development. Expression levels increased, with a ten-
dency to stabilize after day 14, which coincided with reduced cell proliferation and 
expression of differentiation markers (Fig. 2). Similarly, the mRNA levels of several 
phase II xenobiotic metabolizing enzymes UGT1A1, UGT1A6, UGT1A3, UGT2B4, 
SULT2A1 also increased during 3D culture. Phase III enzyme drug transporters also 
play a major role in the formation of metabolites and in drug detoxification. The ex-
pression levels of OAT2 and OAT7, which represent major transporters of various 
clinically relevant drug classes [26, 27], were highly increased in spheroids com-
pared to 2D culture.
 To evaluate whether increased mRNA levels of metabolic enzymes correlat-
ed with an increased functional metabolism, we compared the ability of 2D and 3D 
cultured HepG2 cells to metabolize CYP450 specific substrates. Rate of formation 
of 4’-hydroxydiclofenac catalyzed by CYP2C9 was profoundly higher in 3D spheroid 
cultures and this metabolite was not seen in 2D cultured HepG2 cells (Fig. 4). Day 
21 and day 28 spheroid cultures had similar metabolic activity which further sub-
stantiates a stable differentiated phenotype after 21-days in 3D culture. Similarly, 
1’-hydroxymidazolam, a metabolite of the major CYP450 enzyme, CYP3A4, was 
approximately 15, 30 and 40 nM at T= 4, 24 and 48, whereas in 2D cells the metab-
olite reached a maximum of 6 nM at 48 hours. 1’-hydroxybufuralol, a metabolite of 
bufuralol mediated by CYP2D6, was significantly higher in 3D spheroid cultures (10 
nM (4h), 30 nM (24h) and 60 nM (48h) respectively), compared to 2D cultures (3 nM 
(4h), 10 nM (24h) and 20 nM (48h)). 6’-hydroxychlorzoxazone formation, which is 
mediated by CYP2E1, was seen in 2D HepG2 cultures but no profound metabolism 
was observed in 3D spheroids for the concentration used (Fig 4). This was unexpect-
ed, since CYP2E1 mRNA was approximately 20-fold higher in 3D compared to 2D 
cultures. Further investigation is required to determine whether the metabolite is not 
generated or whether the compound has an affinity to bind to the hydrogel in our 3D 
model.
 Additionally, phase I enzyme activity was assessed by studying the me-
tabolism of testosterone. Testosterone undergoes oxidative metabolism by various 
CYP450 enzymes, forming several metabolites [28]. The formation of metabolites in-
creased in HepG2 spheroids compared to 2D culture. These include a major metab-
olite, androstenedione (Supplementary S5) consistent with previous observations 
[29]. In addition, a small quantity of 6β-hydroxy-testosterone was observed which 
was significantly increased in spheroids and 1β-hydroxy-testosterone which was de-
tected only in 3D cell cultures but below the detection threshold level in 2D HepG2 
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Figure 4. Comparison of Phase I en-
zyme activity in 2D and 3D culture. 
CYP450 enzyme activity as mea-
sured by rate of formation of OH-di-
clofenac (CYP2C9), OH-midazolam 
(CYP3A4), OH-bufuralol (CYP2D6), 
OH-chlorzoxazone (CYP2E1). Data 
is represented as mean of three in-
dependent experiments ± SD; (n=3), 
minimum detection level for Di-
clofenac is 2 nM and Chlorzoxazone 
is 25 nM. 
Figure 5. Comparison of Phase II 
enzyme activity in 2D and 3D cul-
ture. Rate of formation of acyl glu-
curonides from diclofenac and sulfa-
tion activity of acetaminophen in 2D 
HepG2 cells and 3D day 28 spheroid 
cultures. Data is representative of 
two independent experiments.
cell cultures (Supplementary S5 D&E). An unidentified hydroxy-metabolite was also 
observed only in 3D HepG2 cell cultures, although the level was too low for detailed 
quantification (data not shown).
 Phase II metabolism was investigated using diclofenac (glucuronidation) 
and acetaminophen (sulfation) as probe substrates. The rate of diclofenac glucuro-
nidation was significantly upregulated in 3D HepG2 cultures. The data shown in Fig. 
5 was based on the sum of four different acyl glucuronides as described previously 
[30]. In contrast, there was only a limited difference in acetaminophen sulfation be-
tween 2D and 3D cultures (Fig. 5), which was consistent with the expression level of 
of SULT1A1 mRNA (Fig. 3A), which is involved in sulfation of acetaminophen. The 
same trends for phase II metabolism (glucuronidation and sulfation) were obtained 
when 7-hydroxy coumarin was used as substrate (data not shown).
 Together, these data indicate that the differentiation of HepG2 cell spheroids 
is associated with an increased expression of numerous phase I, II and III enzymes 
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Figure 6. Functional analysis of bile 
acid transport in 3D HepG2 spheroids. 
Cholyl-lysyl-fluorescein (CLF) accumu-
lation in 2D and 3D HepG2 cells (A) 
scale bars - 100 μm. mRNA transcript 
level of OATP1B3 in 3D compared to 
2D culture (B). mRNA transcript level 
of OATP1B3 in 3D cell cultures after ri-
fampin treatment (C); data normalized 
to GAPDH, representative of three in-
dependent experiments.
that critically determine ADME of xenobiotics. This functionally correlates with an 
increased xenobiotic metabolic competence. 
Basal level expression of xenobiotic nuclear receptors in HepG2 cells
Various compounds induce ADME related genes by receptor-mediated mechanisms, 
resulting in drug-drug interactions that affect the pharmacokinetic and pharmacody-
namic properties of a second administered drug [31]. We therefore examined the 
basal expression level of nuclear receptors AhR, CAR and PXR by real time PCR. 
These were found to be expressed 7.7-, 12.7-, and 1.9- fold higher respectively in 
HepG2 spheroids compared to 2D HepG2 cultures (Fig. 3C), suggesting that our 
spheroid system may be more responsive to the inducers of these receptors.
Functional bile canaliculi are formed in HepG2 spheroids
Bile salts are transported by hepatocytes into the bile canaliculi. Perturbation of this 
process is often associated with drug-induced liver injury. To evaluate bile transport, 
we used a synthetic bile acid analogue, cholyl-lysyl-fluorescein (CLF). CLF accumu-
lated in canaliculi structures of 3D HepG2 spheroids, suggesting that these indeed 
represent rudimentary canaliculi (Fig. 6A). In contrast, there was no detectable ac-
cumulation of CLF in 2D HepG2 cultures. Uptake of CLF into hepatocytes in human 
liver is mediated by transporter OATP1B3 [32] and excreted into canaliculi via trans-
porters including MRP2 [32]. Immuno-staining of MRP2 on HepG2 spheroids clearly 
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Figure 7. Drug induced cytotoxicity in 2D and 3D HepG2 cells. ATP content of 2D HepG2 (filled circle), 3D 
HepG2 (filled square) after 24 hour drug exposure and 3D HepG2 6-day repeated drug exposure (filled 
triangle) to non-hepatotoxic compounds, ATP-lite assay was performed to measure the cell viability and 
assess cytotoxicity. Data is mean of 3 independent experiments (±SD).
shows its presence in the apical regions (Fig. 2A). The mRNA level of OATP1B3 
was found to be 95–fold higher in HepG2 spheroids compared HepG2 monolayer 
cultures (Fig. 6B). Inhibition of OATP1B3 with rifampin [25, 33] inhibited the transport 
of CLF into the bile canalicular regions (Fig. 6A). Consistent with this, mRNA level of 
OATP1B3 was also significantly downregulated after 24-hour treatment with rifampin 
(Fig. 6C). These results suggest that HepG2 spheroids are able to take up bile salts 
and actively transport them into canalicular structures via known drug transporters.
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Assessment of drug-induced toxicity 
In addition to impaired drug metabolism, the scope for chronic drug exposure is 
restricted in monolayer cultures due to the high rate of proliferation. We evaluated 
whether our HepG2 spheroid model could overcome these limitations by determin-
ing the cytotoxicity of several hepatotoxicants that require bio-activation and typically 
demonstrate liver injury after repeated dosing. Four compounds that were non-hep-
atotoxic in previous studies (aspirin, dexamethasone, fluoxetine and dextrometho-
rphan) [17, 18] were similarly not toxic in 2D and 3D HepG2 cell cultures. In contrast, 
sensitivity to most hepatotoxic compounds was considerably increased with repeat-
ed drug exposures in 3D spheroids (Fig. 7). The TC50 of trovafloxacin mesylate, a 
drug withdrawn from the market, was near to the peak human plasma concentration 
(Cmax = 4.078 μM; TC50 after repeated dose in 3D is 5.6 μM), whereas in 2D, this 
compound was not toxic up to 100X Cmax. For most other hepatotoxic compounds, 
the TC50 was less than or close to 100X Cmax (see supplementary table S7). In 
conclusion, our 3D spheroid system can report cytotoxicity of known hepatotoxi-
cants, where 2D HepG2 model systems often fail.
DISCUSSION
One of the major drawbacks with current drug safety evaluation studies is the failure 
of in vitro test models to adequately reflect hepatotoxic responses in humans. Here 
we present an ECM hydrogel–based 3D cell culture model using HepG2 cells for 
hepatotoxic studies. This system involves the re-programming of otherwise dediffer-
entiated HepG2 cells to acquire critical lost functions of in vivo hepatocytes including 
formation of bile canaliculi-like structures, bile acid transport, improved drug metab-
olism, transporter activity and sensitivity to hepatotoxicants. The compatibility with 
standard assay plates and automation equipment makes this approach suitable for 
high-throughput toxicity screening.
 HepG2 spheroids in this model differentiate and show many phenotypic 
characteristics of hepatocytes in vivo, such as reduced proliferation, localization of 
apical and basal-lateral markers and markers for canaliculi. Reduced proliferation 
may be a result of contact inhibition of growth driven by increased cell-cell interac-
tions. Formation of bile canaliculi was reported earlier in sandwich cultured human 
and primary rat hepatocytes cultures [21, 34, 35]. Bile-canalicular structures were 
also observed in hanging drop cultures of HepG2 cells [36, 37]. Recently a 3D pep-
tide nanofiber matrix was also shown to induce a spheroid phenotype and bile can-
aliculi formation with HepG2 cells, although these spheroids comprised fewer cells 
and did not result in up-regulation of metabolizing enzymes [38]. In contrast, we 
found that micro-environmental cues drive both structural organization of canaliculi 
and the expression and function of drug metabolizing enzymes and transporters. 
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The accumulation of the CLF in HepG2 spheroids resembled accumulation in prima-
ry rat hepatocytes cultured on a micro-patterned 3D-collagen gel [16]. Importantly, 
a pronounced increase in OATP1B3 expression was observed in HepG2 spheroids 
compared to 2D culture. Inhibition of OATP1B3 by rifampin inhibited CLF accumula-
tion in spheroids, indicating the central role of OATP1B3 in bile acid transport in our 
system. OATP1B3 plays an important role in hepatic uptake of drugs and various 
endogenous substrates [39]. Current EMA and FDA guidelines require new chemi-
cal entities to be tested for their effects on OATP1B3 (EMA 21 June 2012; FDA Feb 
2012) therefore, this HepG2 spheroid model may be suitable for evaluating effects 
on OATP1B3 activity and bile salt transport.
 Induction of CYP450 enzymes is a complex phenomenon mediated by acti-
vation of nuclear receptors and gene transcription. It was reported that the low levels 
of CYP450 enzymes in HepG2 cells is due to the absence of nuclear receptors that 
regulate their induction [6, 7]. In HepG2 spheroid cultures, the basal levels of nu-
clear receptors aryl hydrocarbon receptor (AhR), constitutive androstane receptor 
(CAR) and pregnane X receptor (PXR) were higher compared to monolayer culture. 
CAR and PXR are regarded as master regulators in drug metabolism [40, 41]. The 
increased expression of xenobiotic receptors in the spheroid model may make it 
suitable to study drug-drug interactions mediated by CYP450 enzymes.
 Many compounds induce toxicity due to their reactive intermediates [31]. 
We observed increased functional activity of several important CYP450 enzymes, 
such as CYP3A4, 2C9 and 2D6 which are involved in metabolism of approximately 
80% of marketed drugs [42].  This increased metabolic competence may improve 
the predictive power of 3D cytotoxic assays. Current in vitro models have limitations 
for repeated drug exposures studies, which may often be required to accurately re-
flect drug metabolism in humans. Repeat exposures of HepG2 spheroids resulted in 
increased sensitivity to DILI compounds compared to a 24 h cytotoxic assessment. 
Out of 8 hepatotoxic compounds tested, six showed increased sensitivity to repeated 
drug exposures in 3D cultures. The TC50 of acetaminophen, which is metabolized 
by CYP2E1 and CYP1A2 was 9.4 mM in 3D repeated exposures, (which is below 
its 100X Cmax, a scaling factor that represented a reasonable cut-off to differentiate 
toxic drugs in a study using primary human hepatocytes [17]), whereas for single 
exposure in 2D cultures, the TC50 was approximately 24 mM. The increased sensi-
tivity with repeated exposures might indicate a mechanistic toxic response over time 
with DILI compounds. Bosentan, which is metabolized by CYP2C9 and CYP3A4, is 
known to impair bile acid transport leading to liver toxicity [43]. The TC50 of bosen-
tan in repeat dosing was 400 μM. Although many fold higher than the Cmax (Cmax: 
1 μM) no toxicity was observed in 24 h exposures of 2D and 3D cultures. Valproic 
acid undergoes biotransformation via glucuronidation and CYP2C9, 2A6, 2B6 [44, 
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45] and liver toxicity is characterized by microvesicular steatosis [46]. The TC50 of 
valproic acid in 3D repeated exposures was 4 mM, whereas in 2D culture it was ~22 
mM. Further development and validation of the 3D spheroid assay may enable its 
use for prediction of cholestasis and steatosis.
 3D spheroids were also sensitive in identifying toxicity induced by the with-
drawn drugs, troglitazone and trovafloxacin mesylate. Troglitazone, which is mainly 
metabolized by CYP3A4, is toxic in our model with a TC50 of 100 μM (15X Cmax). 
Trovafloxacin mesylate had a TC50 of 5.6 μM, which was close to the human ther-
apeutic Cmax  (~4 μM) whereas single exposures were not toxic below 100 μM, 
demonstrating the significant effect of repeated exposure on sensitivity. Trovafloxa-
cin is primarily metabolized in liver by phase II metabolism (glucuronidation 13.2%, 
N-acetylation 10.4% and N-sulphoconjugation 4.1% [47]. The increased sensitivity 
in 3D compared to 2D may be due to the enhanced phase II activity in HepG2 
spheroids. Immune mediators, such as TNFα play an important role in sensitization 
to trovafloxacin-induced hepatotoxicity [48] under conditions of inflammatory stress. 
Further studies are needed to establish whether the increased sensitivity of HepG2 
spheroids involves autocrine signaling by immune mediators or whether the mech-
anism of toxicity in vitro differs from the mechanism of toxicity in vivo.  Interestingly, 
troglitazone was not toxic in HepaRG spheroids [13], whereas toxicity was donor 
dependent for troglitazone and valproic acid in human primary hepatocytes [18], 
highlighting the differential sensitivities of different in vitro models. 
 In summary, our findings suggest that the culture of HepG2 cells as spher-
oids on extracellular matrix-rich hydrogels improves their overall suitability for safety 
assessment studies. Further validation of this model with a large set of compounds 
is required to assess its potential use in preclinical safety studies. Development of 
this model by incorporating co-cultures with other hepatic cells (Kupffer cells, stel-
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SUPPLEMENTARY DATA
Supplementary S1. Schematic representation of 
3D HepG2 spheroid culture. (A) Matrigel was added 
to the plates using the Cybi-Selma semiautomatic 
pipettor. A 96-well mother plate was prepared by 
manually pipetting Matrigel into the wells. Plates 
were then incubated for 30-45 min at 37°C for gela-
tion before adding the required number of cells. (B) 
Number and area of spheroids after 28-days in 3D 
cell cultures.
Supplementary S2. Urea produc-
tion in 2D and 3D HepG2 cells. 
Data normalized to 6X104 cells. 
Data is representative of 2 inde-
pendent experiments.
Supplementary S5. Biotransformation of testosterone in 2D and 3D HepG2 cultures. Extracted ion chro-
matogram of androstenedione (m/z 287,20) in a 72hr 3D sample (A). Time curves of androstenedione for-
mation after exposure of 2D/3D cell cultures (B). Data is representative of two independent experiments. 
Extracted ion chromatogram of hydroxylated testosterone (m/z 305, 19) in a 72hr 3D sample (C), Time 
curves of 1-β and 6β-hydroxy testosterone formation (D and E) after exposure. Quantification is based on 
UV, and corrected for background. Data is representative of two independent experiments.
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     Supplementary S3. Primer sequences used for real-time PCR analysis.
[1] Kikuchi R, McCown M, Olson P, Tateno C, Morikawa Y, Katoh Y, et al. Effect of hepatitis C virus infec-
tion on the mRNA expression of drug transporters and cytochrome p450 enzymes in chimeric mice with 
humanized liver. Drug metabolism and disposition: the biological fate of chemicals 2010;38:1954-1961.
[2] Westerink WMa, Schoonen WGEJ. Cytochrome P450 enzyme levels in HepG2 cells and cryopre-
served primary human hepatocytes and their induction in HepG2 cells. Toxicology in vitro : an internation-
al journal published in association with BIBRA 2007;21:1581-1591.
[3] Westerink WM, Schoonen WG. Phase II enzyme levels in HepG2 cells and cryopreserved primary 
human hepatocytes and their induction in HepG2 cells. Toxicol In Vitro 2007;21:1592-1602.
Supplementary S4. Protocol used to analyse phase I metabolites at Pharmacelsus 
GmBH.
Compound exposure: 
Substrate mix was exposed to 2D and 3D cells in 96-well plates. Spheroids stop 
proliferating after day 14 and they have equal cell number between 21-day and 28-
days as determined using ATPlite assay. Same amount of cells (20x103 cells/well) 
were seeded to 2D plates and after 24 hours substrate mix was added to the cells 
and samples were collected at 0, 4, 24 and 48 h from a pool of 8 wells of 96-well 
plate at each time point and the data indicates nmol of metabolite formed/ 1.6x105 
cells initial cell density. Samples were stored at -80 degrees and shipped on dry ice 
to Pharmacelsus GmBH for further analysis as explained below.
Sample preparation:
Cell culture supernatants were precipitated with the twofold volume of acetonitrile 
supplemented with the internal standard (1 µM griseofulvin), vigorously shaken (10 
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min) and centrifuged (5,000xg). 
LC-MS conditions:
The HPLC system consisted of U-HPLC pump and an auto sampler (both by Thermo 
Fisher Scientific, Dreieich, Germany). Mass spectrometry was performed on a Q-Ex-
active mass spectrometer (Orbitrap technology, Thermo Fisher Scientific) equipped 
with a heated electrospray interface (Thermo Fisher Scientific) and connected to a 
PC running the standard software Xcalibur 2.2. The HPLC pump flow rate was set to 
600 µl/min and the compounds were separated on a Gemini C6-phenyl 3 µm, 50x2.0 
mm analytical column (Phenomenex, Aschaffenburg, Germany) with corresponding 
precolumn. Analytes were separated by gradient elution with acetonitrile as organic 
phase (A) and 10 mM ammonium acetate as aqueous phase (B) (% A (t (min), 0(0-
0.1)-97(0.4-1.7)-0(1.8–3.0). The mass resolution of the Orbitrap was set to 17,500. 
Further analyser settings were as follows: max. trap injection time 120 ms, sheath 
gas 40, aux gas 10, sweep gas 2, capillary voltage 4 kV, capillary temperature 350°C, 
H-ESI heater temperature 350°C. Full MS selected ion monitoring (SIM) analysis 
was applied using fast scan-to-scan polarity switching to analyse all metabolites in a 
single sample run. Target ions for SIM analysis ([M+H]+ or [M-H]-, respectively) were 
m/z 278.1751 (1-hydroxybufuralol), m/z 342.0804 (1’-hydroxymidazolam) and m/z 
353.0786 (griseofulvin, internal standard) in the positive mode and m/z 183.9796 
(6-hydroxychlorzoxazone) and m/z 310.0033 (4’-hydroxydiclofenac) in the negative 
mode. Retention times were 1.07 min (1-hydroxybufuralol), 1.20 min (1’-hydroxymid-
azolam), 1.10 min (6-hydroxychlorzoxazone), 1.13 min (4’-hydroxydiclofenac) and 
1.23 min (griseofulvin).
Calibration standards and quantification:
The stock solutions of each metabolite were prepared in acetonitrile/water (1:1, v/v), 
except for 6-hydroxychlorzoxazone was prepared in acetonitrile and methanol, re-
spectively. A cocktail working solution was prepared containing all metabolites at a 
concentration of 250 µM. Calibration samples were generated in cell culture medium 
to achieve the final concentrations of 5000, 2400, 1200, 400, 100, 25, 6.25, 2.08, 
1.04, and 0.52 nM for each metabolite. Calibration curves for each metabolite were 
represented by the plots of the peak-area ratio (metabolite/internal standard) versus 
the nominal concentration of the metabolite in cell culture medium. The line of best fit 
was generated using quadratic regression and weighing as appropriate. Metabolite 
concentrations in experimental samples were calculated from the resulting area ratio 
and the regression equation of the calibration curve.
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Supplementary S6. Protocol used to analyze testosterone metabolism and phase II 
metabolism (Glucuronidation and sulphation).
Qualitative and quantitative analysis of phase I (Testosterone) and Phase II 
(Diclofenac glucuronidation and Paracetamol Sulfation).
The total number of cells/well in 3D cell culture was measured by ATP-lite assay and 
an equal number of cells were seeded in 2D culture. 2D and 3D HepG2 cells were 
incubated with testosterone (500 μM), paracetamol (1mM) and diclofenac (500 μM). 
Incubations were terminated at 0, 4, 24, 48 and 72 hours by adding perchloric acid 
(1% v/v) final concentration in case of testosterone, perchloric acid (1%V/V) in 50% 
v/v acetonitrile for paracetamol and  ice cold methanol (50% v/v) for diclofenac.
 The samples were centrifuged at 14,000 rpm for 15 minutes. Supernatants 
were stored at -80°C until analysis. The analytical method used for diclofenac was 
described previously (1). For paracetamol the same method was used, with the only 
difference using of a Luna C18 reversed-phase column (150 mm x 4.6mm, 5 μm 
i.d.) (Phenomenex, Torrance, CA). For testosterone the analysis of metabolites was 
done using a Shimadzu Prominence HPLC system equipped with a Luna C18 re-
versed-phase column (150 mm x 4.6mm, 5 μm i.d.) (Phenomenex, Torrance, CA) 
and a SPD-2A UV/VIS detector (Shimadzu, Kyoto, Japan). The mobile phase for 
both HPLC and LC-MS/MS analysis (flow rate 0.5 mL/min) consisted of a gradient 
constructed of 0.1% formic acid in water (solution A) and 0.1% formic acid in meth-
anol (solution B). Testosterone and its metabolites were eluted using an isocratic 
elution at 50% B for 1 min after sample loading, followed by a linear gradient from 
50 to 99% B from 1 to 19 minutes. The final gradient composition was maintained 
for 1 minute, after which the column was re-equilibrated with the initial gradient com-
position. Metabolites were quantified by integration of analytes detected at 254 nm. 
Retention times of analytes were: 6β-hydroxy testosterone at 12.8 min, 1β-hydroxy 
testosterone at 13.5 min, androstenedione at 16.8 min, testosterone at 18 min.
 To identify metabolites by LC-MS, the final time points were pooled and ex-
tracted with 3 volumes of dichloromethane. The combined fractions were evaporated 
to dryness under a stream of nitrogen and reconstituted in 200μL 50% methanol. An 
Agilent 1200 Series Rapid resolution LC system was connected to a hybrid quadru-
pole-time-of-flight (Q-TOF) Agilent 6520 mass spectrometer (Agilent Technologies, 
Waldbronn, Germany), equipped with an electrospray ionization (ESI) source oper-
ating in the positive mode. The MS ion source parameters were set with a capillary 
voltage of 3500 V; nitrogen was used as the desolvation (12L/min) and nebulizing 
gas (pressure 60 psig) at a constant gas temperature of 350°C. Nitrogen was used 
as a collision gas with collision energy of 25 V. MS spectra were acquired using au-
tomated full scan MS/MS analysis over m/z range of 50−1000 using a scan rate of 
1.003 spectra/s. Metabolite identification was established by comparison with refer-
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ence compounds. Androstenedione was obtained from Sigma Aldrich (Zwijndrecht, 
the Netherlands). Hydroxy metabolites of testosterone were identified by compari-
son with metabolites formed by recombinant CYP3A4 (2).
1. Dragovic S. Boerma JS, Vermeulen NP, Commandeur JN Effect of human glutathi-
one S-transferases on glutathione-dependent inactivation of cytochrome P450-de-
pendent reactive intermediates of diclofenac .Chem Res Toxicol 2013;26:1632-41
2. Krauser JA, Voehler M, Tseng LH, Schefer AB, Godejohann M, Guengerich FP. 
Testosterone 1 beta-hydroxylation by human cytochrome P450 3A4. Eur J Biochem 
2004;271:3962-3969.
Supplementary S7. List of compounds used for toxicity assessment.
Compound Solvent cMax (μM) 100XCmax (μM) C o n c e n t r a t i o n 
range tested (μM)
TC50 (μM)
1 Aspirin DMSO 5.526 552.6 4.64 to 1000 N/A
2 Dexamethasone DMSO 0.224 22.4 2.15 to 464 N/A
3 Fluoxetine DMSO 0.049 4.9 0.0215 to 4.64 N/A
4 Dextromethorphan HBr DMSO 0.028 2.8 0.010 to 2.15 N/A
5 Isoniazid Culture media 76.6 7660 464 to 100000 ~14000
6 Troglitazone DMSO 6.387 638.7 1 to 215 ~100
7 Acetaminophen Culture media 139 13900 464 to 100000 ~9400
8 Nimesulide DMSO 6.5 650 10 to 2150 ~1000
9 Bosentan DMSO 1 100 4.64 to 1000 ~400 
10 Trovafloxacin mesylate DMSO 4.078 407.8 1 to 215 ~5.6 
11 Diclofenac DMSO 8.023 802.3 10 to 2150 ~530
12 Valproic acid Culture media 30.086 3008.6 464 to 100000 ~4000
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Hepatocytes rapidly de-differentiate when isolated from their natural tissue envi-
ronment. Three dimensional cell cultures provide physical and chemical cues that 
improve and preserve the differentiated status of hepatocytes for extended peri-
ods. Our recent findings have shown that HepG2 cells differentiate in 3D matrix 
hydrogels, more closely recapitulating the polarized morphology and functions of in 
vivo hepatocytes compared to conventional monolayer cultures. Here we report the 
findings from whole genome expression analysis of 2D and 3D HepG2 cell models 
and also a comparative analysis of these models together with other hepatocyte 
models including HepaRG and primary human hepatocytes. With increasing dura-
tion in 3D culture up to 28 days, HepG2 cells showed coordinated regulation of 
various signaling pathways associated with cellular differentiation, development, and 
metabolism  reminiscent  of  in vivo  hepatocytes.  Pathway  analysis  was  used  to 
identify canonical pathways that are differentially changed in HepG2 spheroids in 3D 
culture  during  differentiation.  Comparative  pathway  analysis  of  various  in vitro 
models  with  human  liver  highlighted  the  similarities  and  differences  that  are 
inherently associated with specific cell lines. PCA analysis of genes associated with 
some important biological pathways such as cell cycle regulation and xenobiotic me-
tabolism showed a different expression profile of HepG2 cells in 3D culture than 2D 
and a similarity with human liver and primary human hepatocytes and/or HepaRG 
cells. In conclusion, the gene expression of 3D HepG2 spheroids was significantly 
different from 2D cultures; some important physiological pathways that are absent 
in monolayer cultures were induced in 3D HepG2 cultures and showed similarity to 
primary hepatocytes and human liver. Though the expression profile is not similar to 
current ‘gold standard’ primary human hepatocytes, the presence of active xenobiot-
ic metabolism pathways, anti-oxidant response pathways and pathways involved in 
maintaining normal physiology of liver and possibility for a long term culture makes 
our 3D HepG2 model a powerful tool to detect and understand the mechanisms of 
drug-induced toxicity.
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INTRODUCTION
Various test models are used for assessing toxicity of new chemical entities, mostly, 
relying on animal models for short and long-term effects of compounds. With the 
potential risks in species-specific variation in toxic response with animal studies, 
human cell models are a preferred choice. But it is a major challenge to maintain the 
differentiated status of human cells in an in vitro culture condition. In the absence 
of a physiological niche, cells rapidly lose their tissue specific properties leading to 
poor biological responses and a failure to predict the toxicity of the compounds in 
humans. Different hepatocyte cell lines have been evaluated for their competence 
in drug screening assays, but an approved cell model that is efficient in accurately 
predicting the toxic effects of chemicals is still lacking. Currently, human primary he-
patocyte cell lines are considered as gold standards for safety assessment studies 
but these cells rapidly lose their differentiated status in two-dimensional (2D) mono-
layer cultures [1].
 Cells can be cultured as three-dimensional (3D) tissues using extra cellu-
lar matrix hydrogels including collagen, matrigel, peptide nanofiber gels and using 
hanging drop methods, all of which have shown an improvement in hepatocyte func-
tion. Although primary hepatocytes cultured as two-dimensional (2D) monolayer cul-
tures or on a single layer of collagen rapidly lose liver tissue properties, sandwich 
culturing was shown to improve the maintenance of specialized functions [1]. The 
limited availability of human primary cells, donor-specific variability and cost, drives 
a demand for the models that use cell lines that are functionally stable and metabol-
ically  competent.  HepaRG,  a  cell  line  derived  from  a  hepatocarcinoma patient 
[2] are ‘bi-potent’ progenitor cells which, when cultured in the presence of DMSO dif-
ferentiate into biliary and hepatocyte like cells and have drug-metabolizing enzymes 
similar to primary human hepatocytes [2-4]. However, culture of HepaRG cells in 
DMSO lead to a 3-4 fold increase in LDH and AST release, reduction in prolifera-
tion and decreased hepatic functions [5], which may adversely affect assessment 
of chemical-induced cytotoxicity. Nonetheless, the drug metabolism enzymes and 
metabolic capacity were found to be similar to or higher than PHH in HepaRG cells 
[6, 7].
 The other widely used cell line for hepatotoxic studies is HepG2. These cells 
are also of carcinoma origin but have low levels of cytochrome P450 enzymes com-
pared to primary human hepatocytes [8, 9]. Despite their carcinoma origin, these 
cells have functionally  active  p53  and  an  active  Nrf2  system,  which  is  an  ad-
vantage  for cytotoxic studies [10, 11]. A high content screening assay using HepG2 
cells, measuring calcium levels, mitochondrial membrane potential, DNA content and 




pounds [12]. A comparative toxicogenomics profiling of HepaRG and HepG2 for their 
ability to discriminate genotoxic and non-genotoxic compounds showed that HepG2 
could better predict chemical carcinogens [13]. However, the low-levels of CYP450 
enzymes and nuclear xenobiotic receptors [14, 15] have been a major drawback for 
their use in drug safety testing. Our previous studies showed that HepG2 cells cul-
tured in 3D form differentiated polarized spheroids that re-acquire many of the prop-
erties of hepatocytes in vivo [16]. These specialized functions could be maintained 
for at least 28 days in 3D culture allowing long-term assessment of toxic effects. 
Functions such as bile acid transport, glycogen storage were present in 3D HepG2 
spheroids and levels of phase I, II and III enzymes were also higher increasing its 
metabolic competency and the capacity to identify hepatotoxic compounds.
 In the present study we analyzed the gene expression profiles of HepG2 
cells at different stages of spheroid development and differentiation in 3D culture, 
comparing these with two-dimensional monolayer HepG2 culture, HepaRG, primary 
human hepatocytes (PHH) and human liver. We observed that HepG2 spheroids 
showed upregulation of genes associated with hepatocyte development, differentia-
tion and metabolism, which stabilized after 21 days in 3D culture. Ingenuity Pathway 
Analysis (IPA) was used to examine changes in the core signaling pathways upon 
culture in 3D and to compare these with other hepatocyte models. Many functional 
pathways associated with in vivo hepatocytes were significantly enriched in HepG2 
spheroids. Cell cycle regulation, xenobiotic metabolism pathways such as PXR/
RXR, complement system, bile-acid biosynthesis and coagulation system were sig-
nificantly upregulated and showed a close similarity to the human liver expression 
compared to other hepatocyte cells. Overall, the gene expression analysis of 3D 
spheroids showed robust improvement in the physiological and metabolic profile 
of HepG2 cells, indicating that this model may represent a powerful in vitro tool for 
studying liver biology.
Cell line and 3D cell culturing
Human  hepatoma  HepG2  cell  line  was obtained from American type tissue culture 
(ATCC, Wesel, Germany), cultured in Dulbecco’s modified Eagles medium (DMEM) 
supplemented with 10% (v/v) fetal bovine serum (Invitrogen, The Netherlands), 25 
U/mL penicillin, and 25 µg/mL streptomycin (PSA, Invitrogen). The cells were cul-
tured at 37°C with 5% CO2. Matrigel (Erembodegem,BD Biosciences) was used to 
culture 3D spheroids as previously described [16].
RNA isolation and microarray analysis of 2D and 3D HepG2 cells
RNA was extracted from 3 day cultured 2D HepG2 cells and 3D HepG2 cells cul-
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tured at day 3, 7 14, 21 and 28. Total RNA was extracted from 2D/3D cultured cells 
using Trizol reagent (Invitrogen) followed by clean up using RNeasy mini kit (Qiagen, 
Hilden, Germany). RNA integrity quality and integrity was determined using the Ag-
ilent bioanalyser (Agilent Technologies Inc, Santa Clara, USA). Biotinylated cRNA 
was prepared using the Affymetrix 3’ IVT-Express Labeling Kit (Affymetrix, Santa 
Clara, USA) and hybridization steps were performed by Service XS B.V (Leiden, The 
Netherlands) on Affymetrix HT Human Genome U133 plus PM plate. Array plates 
were scanned using the Affymetrix GeneTitan scanner. BRB Array Tools software 
(developed by Dr. Richard Simon and BRB-ArrayTools Development Team) was 
used to normalize the .cel data using the Robust Multichip Average (RMA) method. 
Differentially expressed genes (p-value < 0.001) between the various experimental 
conditions were identified with an ANOVA test followed by calculation of the false 
discovery  rate  according  to  Benjamini  and  Hochber  [17].  Classification  of  the 
selected  genes  according  to  their  biological  and  toxicological  functions  was 
performed using the Ingenuity Pathway Analysis IPA® software (Ingenuity Systems, 
Redwood,  USA).  Heatmap  representations  and  hierarchical  clustering  (using 
Pearson correlation) were performed using the Multi Experiment Viewer software 
[18].
 
Re-annotation, normalization, and data filtering for comparative gene expres-
sion profiling
To compare basal gene expression data from 2D and 3D HepG2 cells with other 
cell models, different data sources were combined. Raw data files from untreated 
HepaRG and HepG2 cells were obtained from the department of Toxicogenomics, 
Maastricht University [13, 19]. Primary cryopreserved human hepatocyte data was 
downloaded from TG-GATEs [20]; 16 microarrays of untreated conditions were ran-
domly selected from this database. Post-mortem liver data was obtained through 
GEO, accession numbers GSE13471 and GSE3526 respectively. Raw data files 
were loaded into R version 2.15.2 for Windows (64-bit) [21], re-annotated to Entrez 
Gene using Brainarray’s custom CDF version 15.1.0 [22]. The R-packages used 
was obtained from BioConductor version 2.11 [23] Since the combined data set  was 
originating  from  the  Affymetrix  Human  Genome  U133  Plus  2.0  and Affymetrix 
HT Human Genome U133 plus PM (GeneTitan) platforms, normalization was  per-
formed  in  a  multi-step  procedure.  Data  from  different  chip  types  were merged 
based on 18909 overlapping Entrez Gene ID’s, followed by scaling of the GeneTitan 
data and quantile normalization on the merged set.
Principal component analysis
Principal Component Analysis (PCA) was applied to identify data patterns and to 
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highlight data similarity and differences between the treated and untreated cell lines 
at different time points. Therefore, the normalized  intensities  of  the  combined  data 
sets  were  uploaded  into  the  PCA module of ArrayTrack [24]. PCA analysis was 
performed on whole genome expression and filtered gene sets of hepatocyte-specif-
ic canonical pathways. PCA data were visualized using Tibco Silver Spotfire (Paulo 
Alto, CA, USA).
Ingenuity Pathway analysis
To better understand the biological processes and canonical pathways that changed 
significantly and to make a comparative overview of gene expression profiles in the 
different cell models, differentially expressed genes (DEG’s) with a p value <0.001 
were uploaded onto ingenuity pathway analysis (Ingenuity® systems, www.ingenu-
ity.com).
RESULTS
Gene expression profile of HepG2 cells in 3D culture correlates with differen-
tiation of hepatocytes
When HepG2 cells are cultured in an extracellular matrix (ECM) protein-rich hydro-
gel that simulates a tissue microenvironment, cells form spheroids and exhibit many 
features of hepatocytes in vivo [16]. A significant change in the gene expression was 
observed during the 3D culture period with a gradual increase in DEG’s (P<0.001, 
Fold change>1.5) until day 14. Thereafter, the change in gene expression follows a 
downward trend with a steady gene expression between day 21 and 28 (Fig. 1A). 
Spheroid development in the 3D culture seems to recapitulate ontogeny of a devel-
oping liver. Genes that are associated with the fetal liver CYP3A7, CYP1A1 [25, 26] 
are highly expressed in the initial culture period until 7 days and their expression was 
reduced later during the culture (Fig. 2C). Similarly genes that are expressed by adult 
liver such as Flavin containing monooxygenase 5 (FMO5), haptoglobin (HP) [27, 28] 
were induced after 7-days in 3D culture and highly expressed from 14–days (Fig. 
2C). The terminal hepatocyte differentiation marker glucose-6-phosphate (G6PC) 
was 150-fold higher after 14 days and 230-fold at both 21 and 28 day cultures, in-
dicating that the differentiation process stabilizes between day  14  and  21  days. 
Differentiated  liver  marker  genes  albumin,  transferrin, fibronectin, aldolase-b, 
apolipoprotein, IGF2, fibrinogen beta-chain and fibrinogen gamma chain, which pre-
vious studies showed were either absent in HepG2 cells or weakly expressed (Yu 
et al. 2001) were increased in HepG2 spheroid cultures (Fig.1B). Recently, human 
iPSC-LB were shown to form vascularized and functional human liver [29] with up-
regulation of a set of 83-genes that are involved in liver development. Almost all of 
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these genes were also serially upregulated in the HepG2 spheroid cultures (Fig. 2B). 
Hepatocyte specific gene expression is controlled by liver-enriched  transcriptional 
factors  belonging  to  HNF,  C/EBP  family  members, which act synergistically to 
maintain tissue functions [30]. The transcript levels of HNF4α, C/EBPβ were also 
increased with time in HepG2 spheroids (Supplementary data S1). Taken together, 
these results indicate that HepG2 cells display a trend toward liver-like differentiation 
when cultured as 3D spheroids.
Figure 1. Gene expression changes in differentiated HepG2 spheroids. Differentially expressed genes 
which are significantly changed (p<0.001 and FC >1.5 fold) in time during 3D culture (A) Green represents 
number of genes downregulated / Red represents the upregulated genes. PCA plot showing the distri-
bution of genes in 2D HepG2 cells and at different times in 3D culture where HepG2 cells differentiate 
into a spheroid (B). Phase contrast images of HepG2 cells in 3D culture with time (C) scale bars 100 µm.
Drug detoxifying enzyme gene expression coordinately increases with (spher-
oid) differentiation
One of the major limitations of HepG2 cells in drug screening assays is their low level 
of cytochrome P450 enzymes, phase II conjugating enzymes and drug transport-
ers. Furthermore, the key transcription factors that regulate the drug metabolizing 
enzymes are also poorly expressed in HepG2 cultures [31]. Xenobiotic metabolism 
involves various phase I and phase II drug metabolism as well as phase III me-
diated excretion processes. Expression of these drug-metabolizing enzymes and 
transporters is higher in differentiated HepG2 spheroids compared to 2D monolayer 
cultured HepG2 cells. Xenobiotic CYP450 enzymes CYP 2C18, 3A5, 7A1, 4F2 and 
others (Fig. 2A) were upregulated upon 3D culturing. Also other CYP450 enzymes 
mainly involved in sterol and fatty acid metabolism, including CYP 7A1, 8B1, 17A1, 
19A1, 51A1, 2J2, 4B1, 4F12, had a significantly higher expression in 3D HepG2 
spheroids. Phase II enzymes, which are involved in glutathione, glucuronidation and 
sulfation conjugation reactions were also upregulated in HepG2 spheroids. Gluta-
thione- S- transferases GSTA1, K1, M3, M4 and sulfotransferases SULT2A1, 1C2, 
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1E1; UDP-glucoronosyltransferases UGT1A1, 1A6, 1A7, 1A8, 1A9,1A10, 2A3, 2B4, 
2B28 were significantly upregulated in 3D HepG2 spheroids (Fig. 2A). Besides these, 
alcohol dehydrogenases and aldehyde dehydrogenases showed an increased ex-
pression with time in 3D culture.
Figure  2. Expression of genes associated with differentiated  hepatocytes in 3D culture. Heat map show-
ing fold change gene expression changes in Phase I, II and III drug metabolism enzymes (A). Fold change 
expression of genes involved in differentiation and development of the liver (B) in HepG2 spheroids com-
pared to 2D monolayer cultures, data is average (4 experiments) fold change compared to 2D HepG2 
gene expression. Fold change gene expression  of  individual  genes  corresponding   to  xenobiotic 
metabolism, differentiation markers, fetal and adult liver markers over time in 3D culture (C).
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Liver-specific functions are enriched in 3D HepG2 spheroids
Besides the metabolic competence it is important for an in vitro system to emu-
late liver specific functions in order to accurately predict a human stress response. 
Ingenuity Pathway Analysis was used to identify the canonical pathways that are 
significantly enriched in differentiated HepG2 spheroids compared to HepG2 cells 
grown as monolayer cultures. The principal upregulated pathways included many 
xenobiotic metabolism pathways (FXR/RXR, LXR/RXR, PXR/RXR activation) and 
hepatocyte specific pathways related to liver physiology (coagulation system, com-
plement system, extrinisic prothrombin activation, bile acid biosynthesis) and many 
pathways related to functional hepatocytes are significantly upregulated (Fig. 3A). 
The principal downregulated pathways mostly belonged to cell cycle regulation with 
canonical pathway ‘cell cycle control of chromosomal replication’ being most strong-
ly downregulated pathway with 80% of downregulated genes (Fig 3B). This indicates 
that HepG2 spheroids are functionally and metabolically differentiated at the path-
way level. 
Figure 3.  Canonical pathways that are significantly induced in HepG2 cells  cultured as spheroids.  Sig-
nificantly enriched pathways in day 28  differentiated HepG2 spheroids compared to 2D cultured HepG2 
cells from Ingenuity Pathway Analysis (IPA), upregulated pathways (A), downregulated pathways (B).
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Pathway analysis of in vitro cellular 
models compared to human liver
It is anticipated that in vitro cultured he-
patocytes derived from liver tissue exhibit 
a different expression profile to intact liv-
er. Ingenuity Pathway Analysis was used 
to examine the similarities and overall 
changes in the expression profiles of in vi-
tro cellular models compared to human liv-
er. HepG2 cells in 2D culture from 2 differ-
ent sources showed a close association, 
but there was also a difference in several 
molecular pathways, highlighting the ef-
fects of source and culture conditions of 
the HepG2 cells as observed in earlier 
studies [32]. A close similarity in regulation 
of molecular pathway was observed be-
tween HepaRG and cryopreserved PHH. 
3D HepG2 gene expression was different 
from monolayer cultured HepG2 cells and 
an association with PHH and HepaRG 
was observed in hierarchical clustering 
(Fig. 4). A detailed heat  map  showing  the 
changes  in  individual  molecular  canon-
ical  pathways compared to human liver is 
in supplementary figure S3.
 Pathways that are differentially 
regulated or that are similar to human liv-
er, specific to a cell type are listed in Sup-
plementary data S4. Canonical pathways 
related to cytokine signaling, MAPK sig-
naling, xenobiotic receptor signaling were 
similar in PHH and human liver. In Hep-
aRG cells apoptosis signaling, hepatocyte 
functional pathways such as coagulation 
system, gluconeogenesis, cell cycle reg-
ulation etc. are some of the hepatocyte 
specific canonical pathways that are not 
differentially regulated compared to hu-
Figure  4. Heat map  showing regulation  of  ca-
nonical  pathways across hepatocyte models in 
comparison to human liver. Scale is – log  (p-val-
ue); -log  (pvalue)  1.3 (p=0.05) represent path-
ways that are significantly different from human 
liver. 2D HepG2 LU/2D HepG2 UM: Two sourc-
es of HepG2 cells from Leiden University (LU); 
Maastricht University (UM).
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man liver expression. Pathways related to protein biosynthesis, cytokine signaling, 
aryl hydrocarbon signaling in xenobiotic metabolism were some of the pathways that 
were unaltered in HepG2 monolayer cultures compared to human liver. Cell cycle 
regulation, coagulation system, complement system, PXR/RXR, FXR/RXR xenobi-
otic signaling, epithelial adherens junction signaling etc. were similar in 3D HepG2 
cells and human liver.
 To further understand the relationship between different liver models, import-
ant functional  pathways  of  hepatocytes  were  selected  and  their  distribution  was 
Figure  5.  PCA  of  physiologically  relevant  molecular  pathways.  PCA  of  selected  pathways related 
to   hepatocyte   function   and   differentiation,   cell   cycle   regulation,   xenobiotic metabolism,   bile 
acid   biosynthesis,   complement   system,   liver   proliferation   and   liver metabolism, in 2D/ 3D HepG2 
cells, primary human hepatocytes, HepaRG and human liver.
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Hepatocytes extracted from fresh liver tissue are considered as ‘gold standards’ for 
assessing liver toxicity, but their rapid deterioration in culture and high variability is 
a major limitation for their reliability in drug screening assays. In the wake of high-
drug attrition rates due to liver injury, there is a significant interest in developing a 
robust model that can predict hepatotoxicity in humans. We previously showed that 
3D HepG2 spheroids show many of the morphological and functional properties of 
human liver [16]. In this study we made a detailed investigation of the transcriptomic 
profile  of  HepG2  spheroids  comparing  these  with  those  of  HepG2  monolayer 
cultures, primary human hepatocytes, HepaRG cell line and human liver tissue
 Our findings suggest that the differentiation of HepG2 cells in 3D culture 
recapitulate many of the early ontogenetic events of a developing liver. After 21 days 
in 3D culture, HepG2 spheroids showed a steady state gene expression profile, after 
which there was no significant change in the gene expression up to day 28. Genes 
expressed by human fetal liver (CYP3A7, CYP1A1) were highly expressed during 
the first 7 days in 3D culture whereas genes associated with differentiated adult liver 
(Flavin containing mono-oxygenase 5 and haptoglobin) were expressed after day 7 
[27, 33].
 Under optimal conditions hepatocyte cell lines also have the capacity to gen-
erate well-differentiated functional hepatocytes and also may have the capacity to 
form a liver tissue. Similarly iPSC co-cultures in 3D ECM matrigel allowed the for-
mation of liver buds, and upon transplantation into immuno-deficient mice developed 
vasculature resembling adult liver, [29] opening new avenues to develop organs for 
DISCUSSION
analyzed using PCA. Pathways related to liver proliferation, liver metabolism, bile 
acid biosynthesis, complement system, xenobiotic metabolism and cell cycle reg-
ulation were analyzed by plotting the normalized log2 intensities of the genes from 
the groups on PCA (Fig. 5). As observed in IPA analysis, 3D HepG2 cells showed 
close  similarity  with  human  liver  expression  for  cell  cycle  pathway, supporting 
the previous observations that the proliferation is ceased in HepG2 spheroids [16]. 
The expression of cell cycle regulation genes were closely associated in HepaRG 
and 3D HepG2 spheroids. For  other  pathways  3D  HepG2  spheroid  expression 
was different from 2D HepG2 cells with a trend moving towards human liver. Primary 
human hepatocytes and HepaRG had a close association both at whole genome 
level and for selected pathways in this study. Bile acid biosynthesis and complement 
system pathways in 3D HepG2 spheroids showed a close similarity to human liver 
than other models, as observed in ingenuity pathway analysis. Together, this data 
suggests that HepG2 cells in 3D culture transformed into differentiated hepatocytes 
acquiring various specialized functions of a liver tissue.
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liver transplantation. In these experiments a set of 83 genes that were serially up-
regulated in liver development were analyzed in iPSC’s. Interestingly, almost all of 
these genes were also up regulated in 3D HepG2 spheroids over time, suggestive of 
a similar differentiation process in our hydrogel cultures.
 Differentiation of HepG2 in 3D spheroids also led to induction of various 
drug-metabolizing enzymes that are typically poorly expressed in 2D HepG2 cell 
cultures. Phase I enzymes belonging to CYP3A CYP2C, CYP1A, CYP2D families 
are major enzymes involved in metabolism of 90% of prescribed drugs [34-36]. Most 
of the members belonging to these families are upregulated in differentiated HepG2 
spheroids. Also various enzymes belonging to phase II drug metabolism and trans-
porters were also highly expressed in HepG2 spheroids compared to its native ori-
gin. The increased expression was observed after 14 days in 3D culture and a sta-
ble expression remained up to 28 days, thus providing a window for studying more 
chronic/repeated dose effects of novel drugs or other chemical entities.
 The higher expression of drug metabolic enzymes does not imply that a 
cellular model is sufficiently robust to detect a toxic stress response. Though, the 
presence of Phase I, II and drug metabolizing enzymes is promising for making an 
accurate estimation of toxicity, stress signaling pathways need various other co-reg-
ulatory genes in order to show an actual biological response.  Ingenuity pathway 
analysis (IPA) on differentiated 3D HepG2 spheroids showed significantly enriched 
xenobiotic metabolism pathways. The top upregulated pathway in the list was ‘acute 
response singling pathway’ which is required for a proper inflammatory response. 
Other xenobiotic signaling pathways PXR/RXR, PPARα/RXR, FXR/RXR, LXR/RXR, 
were also significantly enriched during 3D spheroid culture, suggesting that 3D 
HepG2 spheroids might be more sensitive for a xenobiotic response. PXR together 
with RXR plays an important role in drug metabolism, most importantly they activate 
the CY3A4 gene, which is involved in the metabolism of 50% of current drugs. Upon 
activation PXR/RXR induces the expression of various phase II and drug metabo-
lizing enzymes [37, 38]. It also plays a major role in regulating bile acid synthesis, 
gluconeogenesis and lipid  metabolism [39,  40].  PPARα  is  also  an important target 
for various pharmacological agents and play a major role in xenobiotic metabolism 
[41]. FXR/RXR and LXR/RXR pathways are also involved in regulating  both  en-
dogenous  and  xenobiotic  responses  [39,  42],  suggesting  3D HepG2 spheroids 
might be more responsive to xenobiotics and would serve as a useful model to help 
investigate the mechanisms of toxicity.
 Principal component analysis on whole genome gene expression profiles 
of different hepatocyte models was in agreement with previous studies for PHH and 
HepaRG [4, 6]. A close similarity of HepaRG gene expression profile with cryopre-
served PHH suggest that HepaRG may offer a suitable alternative to PHH in toxicity 
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assays. This still needs to be investigated, but until now there were no large scale 
toxicity screens comparing these two models. However, in a comparative toxicog-
enomics analysis both HepG2 and HepaRG cells performed similar compared to 
PHH [43] and in another transcriptomic study, HepG2 cells performed better in iden-
tifying genotoxic compounds than HepaRG  cells  [13].  The  gene  expression  pro-
file  of  3D  HepG2  spheroids  was different  from  2D  HepG2  cells  and  was not 
closely  associated  with  any  other models at  the global gene expression level, but 
showed a close similarity with human liver for important xenobiotic metabolism path-
ways such as PXR/RXR. Furthermore, the reduced expression of cell cycle genes 
and the absence of cell cycle, which might represent a physiologically relevant tissue 
level toxicity assessment and therefore may be advantageous in studying mecha-
nistic toxic responses. Further toxicogenomics studies on HepG2 spheroids would 
validate their xenobiotic response and similarity to higher models, which may be 
more similar to an in vivo response.
 In this study we did not make a direct comparison of drug metabolizing en-
zymes in various models due to the source of transcriptomic data from primary hu-
man hepatocytes and HepaRG. These data sets were from 0.5% DMSO treated 
controls from  another  study.  Though  DMSO  will  not  have  an  effect  on  overall 
gene expression, it is known that DMSO induces expression of various phase I, II 
xenobiotic metabolizing enzymes and transporters, which therefore might overesti-
mate the comparison with untreated 2D and 3D HepG2 cells. Instead a comparative 
pathway analysis was performed across different models to understand the similarity 
and association of different data sets.
 In conclusion, HepG2 spheroids in 3D culture showed transcriptional fea-
tures recapitulating liver development and differentiation. Phase I, II drug metabolic 
enzymes  and  drug  transporters  are  highly  upregulated  in  spheroid  cultures. 
Canonical pathways of functional hepatocytes are highly enriched and had a close 
similarity to human liver. With a higher complexity and amenability to high-through-
put assays, 3D HepG2 spheroid model could prove to be promising tool for future 
drug discovery and development research.
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SUPPLEMENTARY DATA
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Supplementary S3. Heat map of molecular canonical pathways in various in vitro models compared to 
human liver gene expression. Scale is – log  (p-value); -log  (pvalue)  1.3 (p=0.05) represent pathways 






















































































































































































































































































































































































































SYSTEMIC COMPARISON OF DICLOFENAC INDUCED 
GENE EXPRESSION CHANGES IN DIVERSE IN VITRO 
AND IN VIVO MODELS AND SPECIES
Sreenivasa C. Ramaiahgari1, Steven Wink1, Mackenzie Hadi3, 
John Meerman1, Mirjam Luijten2, Geny Groothuis3, 
Bob van de Water1 and Leo S. Price1
1Division of Toxicology, Leiden Academic Centre for Drug Research, 
Leiden University, Leiden, The Netherlands.
2Laboratory for Health Protection Research, 
National Institute for Public Health and the Environment, 
Bilthoven, The Netherlands.
3Division of Pharmacokinetics, Toxicology and Targeting, 






Drug-induced liver injury (DILI) is a major clinical concern. Various models are pro-
posed to investigate DILI, but a gold-standard model that could predict human DILI 
is still lacking. A systematic comparison of in vitro/in vivo models would help to char-
acterize the responses associated with the drug-induced hepatotoxicity and iden-
tify better model(s) that could closely predict human DILI. Here we performed a 
comparative transcriptomic analysis using ex-vivo human precision cut liver slices 
(PCLS), in vitro primary human hepatocytes, mouse hepatocytes, rat hepatocytes, 
the human hepatoma cell line HepG2, cultured in 2D monolayer or 3D spheroids, 
and in vivo rat and mouse livers. All models were exposed to the drug diclofenac, 
which causes idiosyncratic DILI. To dissect the canonical cellular stress responses 
upon diclofenac treatment in the different models we used Ingenuity pathway anal-
ysis, where human PCLS with its heterogeneous cell population representing intact 
liver tissue was used as a reference for all other models. Protein ubiquitination, 
Nrf2-associated oxidative stress and xenobiotic metabolism pathways were found 
to be significantly altered upon diclofenac treatment. Genes involved in liver diseas-
es including cholestasis and steatosis were significantly upregulated providing an 
early evidence for long-term effects of diclofenac treatment. HepG2 cells in 3D cul-
ture were more responsive and showed a significant upregulation of stress signaling 
pathways and genes related to diclofenac induced liver diseases with a similarity to 
human PCLS. Compared to mouse, rat gene expression profiles were more similar 
to human gene expression. In conclusion, transcriptomic analysis will allow us to 
identify various drug-induced cellular stress responses. Functionally and phenotyp-
ically stable HepG2 spheroids could serve as a better alternative model to identify 
human relevant biomarkers of DILI.
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INTRODUCTION
Adverse drug reactions are a major concern for the safe use of drugs. These reac-
tions are undetected during early clinical trials in small groups of patients and are 
often idiosyncratic in nature [1]. With the first pass effect and its central role in drug 
metabolism, the liver is prone to adverse drug reactions leading to drug induced liver 
injury (DILI) or causing liver diseases after chronic treatment. DILI has been the ma-
jor reason for pre- and post-marketed attrition of drugs [2]. There is an urgent need 
for improved methods and models that could reflect drug metabolism in a human 
system and ultimately predict DILI risk during early preclinical drug development.
 Animal models are the primary source for toxicity studies, as they are the 
only available laboratory models with the complexity approaching that of humans. 
But several studies have shown that the toxicity assessment using animal models 
and its translation to human toxicological responses is quite poor [3]. In order to 
predict human DILI, human cell-based models possessing tissue specific charac-
teristics are preferred. Current in vitro models are not feasible for long-term culture 
giving us no choice but to rely on animal models for studying repeated drug expo-
sure effects. Ex-vivo models such as precision cut liver slices (PCLS) can represent 
an intact functional liver with heterogeneous cell population [4], which could respond 
similar to in vivo liver tissue [5]. But, major disadvantages of liver slices are a rapid 
decline of its functional properties ex vivo [6] and the low throughput limiting its value 
in repeated dose-effect studies. Primary human hepatocytes are considered as gold 
standards for compound screening assays [7]. But they also show a rapid decline of 
liver function and due to its high variability between donors; even replicate samples 
of a single transcriptomic study can differ [8]. In this respect, immortalized cell lines 
might provide an advantage in maintaining a stable gene expression and models 
using HepG2 and HepaRG have been studied for their efficiency in toxicogenomics 
[9, 10]. Recent developments in in vitro cell culture methodologies have helped to 
maintain the differentiated phenotype of cells for extended periods [11-14]. Systems 
such as bioreactors, micropatterning and ECM gels for 3D growth have been pro-
posed that provide a physiological niche to various primary and immortal cell lines. 
Due to the ease of use and availability of HepG2 cells and the ability to maintain a 
highly differentiated spheroid phenotype with improved metabolic competence in 3D 
cultures [14], HepG2 spheroids could be an optimal choice for the evaluation of DILI. 
Drug-induced cytotoxicity is typically identified by simple cell death measurements in 
in vitro models. For accurate human translation it is important to determine whether 
the molecular initiation events and the subsequent cell state changes that trigger 
cytotoxicity are translatable from simple in vitro models to humans.
84
Chapter 4
Genome-wide microarray analysis allows the detailed evaluation of altered gene ex-
pression upon toxic insults, thereby representing the altered cell status after drug-in-
duced cellular perturbations. Likewise, such a transcriptomics analysis is highly 
suited to identify the cellular stress responses that underlie DILI-related cytotoxicity 
as well as the comparison of such stress responses between models. A wealth of 
toxicogenomics data from human, mouse, rat, canine in vitro and in vivo liver models 
has helped to identify promising biomarkers for liver injury [15]. These toxicogenom-
ics data are available in the public domain Gene Expression Omnibus (GEO) [16], 
Array Express [17], Comparative Toxicogenomics Database (CTD) [18], EDGE [19, 
20], Chemical Effects in Biological Systems (CEBS) [21], TG-GATES (Genomics 
Assisted Toxicity Evaluation System). TG-GATES has a database of in vivo and in 
vitro gene expression profiles of liver and kidney upon exposure to 150 chemicals, 
mainly drugs that are currently used for patients [22]. These databases can be used 
as a reference for comparing the gene expression profiles in different models upon 
exposure to toxicants relevant for DILI.  
 In the present study we compared the gene expression profiles of human 
PCLS, primary human hepatocytes, HepG2 cells, mouse primary hepatocytes, 
mouse liver, rat primary hepatocytes and rat liver treated with a widely used non-ste-
roidal anti-inflammatory drug diclofenac. Diclofenac is one of the most frequent 
causes of adverse drug injury to the liver, with 180 confirmed cases reported by FDA 
during the initial marketing period [23]. Several possible mechanisms of diclofenac 
induced liver injury have been proposed which involve formation of reactive metab-
olites, mitochondrial injury, ROS formation as well as interference with the immune 
system signaling, but the molecular mechanism leading to the liver damage is large-
ly unknown [24-26].
 Using Ingenuity pathway analysis, molecular pathways that were altered 
upon diclofenac exposure in human PCLS, rat and mouse in vivo, human, rat and 
mouse cultured primary hepatocytes, and human hepatoma cell line HepG2 cultured 
in 2D monolayer or 3D spheroids were compared and a similarity of gene expression 
profiles at the pathway level was analyzed across species. Since fresh PCLS most 
closely represented in vivo human liver tissue, it was used as a standard reference 
for the other models. Genes associated with diclofenac-induced chronic liver injury 
were found to be significantly activated in human PCLS. Several xenobiotic me-
tabolism and stress-induced pathways were significantly enriched highlighting their 
potential role in diclofenac induced liver injury. HepG2 spheroid cultures were more 
responsive than 2D HepG2 cultures and showed a high similarity to PCLS. Ingenuity 
classified toxicity-related pathways of HepG2 spheroids were very similar to PCLS. 
85
Systemic comparison of diclofenac induced gene expression changes
MATERIALS AND METHODS
Cell culture and diclofenac exposure
HepG2 cells: HepG2 cell line was obtained from American type tissue culture (ATCC, 
Wesel, Germany), cultured in Dulbecco’s modified Eagles medium (DMEM) supple-
mented with 10% (v/v) fetal bovine serum, (Invitrogen, The Netherlands), 25 U/mL 
penicillin and 25 μg/mL streptomycin (PSA, Invitrogen) and used for culture. 3D 
cultures were prepared as described earlier [14]. 500 μM Diclofenac (Sigma Aldrich, 
Zwijndrecht, The Netherlands) was incubated for 24 hours before RNA extraction. 
HepG2 cells in 2D culture were incubated with 500 μM diclofenac for 14 hours be-
fore RNA extraction. Human PCLS: Human PCLS were prepared and incubated with 
diclofenac as described earlier [27] Mouse liver and hepatocytes: Mouse hepato-
cytes were obtained as described earlier [28] and exposed with 500 μM diclofenac. 
Rat liver and hepatocytes: Rat liver and hepatocyte data was obtained from pub-
lic transcriptomics data base, Toxicogenomics Project-Genomics Assisted Toxicity 
Evaluation system’ (TG-GATEs). Rat in vitro hepatocytes were treated with 400 μM 
diclofenac for 24 h. Rat in vivo data single exposure with 100 mg/kg for 24 hours 
and for repeat exposures 100mg/kg daily dose via gavage until day 29 were used 
for analysis. Primary human hepatocytes: data set from primary human hepatocytes 
exposed with 400 μM diclofenac for 24 h obtained from public transcriptomics data 
base, Toxicogenomics Project-Genomics Assisted Toxicity Evaluation system’ (TG-
GATEs) was used for analysis.
RNA extraction for microarrays
Total RNA was extracted from 3D cultured HepG2 cells using Tri reagent  (Sigma) 
followed by clean up using RNeasy® mini kit (Qiagen, Venlo, The Netherlands). 
Purity and concentration of the RNA were analyzed using NanoDrop ND-1000 spec-
trophotometer (Nanodrop technologies, Wilmington, DE, USA). RNA quality and in-
tegrity was further determined using the Agilent bioanalyser (Agilent Technologies 
Inc, Santa Clara, CA, USA). Biotinylated cRNA was prepared using the Affymetrix 3’ 
IVT-Express Labeling Kit (Affymetrix, Santa clara, CA, USA) and hybridization steps 
were performed by Service XS B.V (Leiden, The Netherlands) on Affymetrix HT Hu-
man Genome U133 plus PM plate. Array plates were scanned using the Affymetrix 
GeneTitan scanner.
Microarray analysis
Probe annotation was performed using the hthgu133pluspmhsentrezg.db package 
version 17.1.0 and Probe mapping was performed with hthgu133pluspmhsentrezg-
cdf file downloaded from NuGO (http://nmg-r.bioinformatics.nl/NuGO_R.html).
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Probe-wise background correction, between-array (within same datasets) normal-
ization and probe set summaries calculation was performed using the RMA function 
of the Affy package (Affy package, version 1.38.1) [29, 30]. The normalized data 
were statistically analyzed for differential gene expression using a linear model [31, 
32] with coefficients for each experimental group using the Limma package (Limma 
package, version 1.22.0; [30]). A contrast analysis was applied to compare each ex-
posure with the corresponding vehicle control. For hypothesis testing the moderated 
t-statistics by empirical Bayes moderation was used followed by an implementation 
of the multiple testing correction of Benjamini and Hochberg.
 Array and normalization quality control was performed with the arrayQuali-
tyMetrics, a bioconductor package for quality assessment of microarray data [33]. All 
analysis was performed in the R statistical language environment (R development 
core team 2012).
Pathway analysis
Differentially expressed genes with P<0.05 (and FDR <0.05) were uploaded onto 
Ingenuity Pathway Analysis IPA® (Ingenuity® systems, Redwood, CA, USA). Genes 
that were </> 1.5 fold changed compared to vehicle control were selected for path-
way enrichment analysis. Activation of canonical pathways is predicted by calculat-
ing p-value using right-tailed Fisher Exact Test from the DEG’s and p-values less 
than 0.05 (-log=1.3) are said to be significantly activated. Heatmap and hierarchical 
clustering using Pearson correlation was performed using TM4: MultiExperiment 
Viewer program [34].
Table 1: Differentially expressed genes after diclofenac treatment in various in vitro and in vivo models. 
Selection was based on genes that are significant P<0.05, FDR<0.05.
Sl.no Test model DEG’s (up"˄") or (down"˅") 
r e g u l a t e d
Diclofenac Conc. Exposure time
1 Human liver slices 3737 (1690˄/2047˅)      500 μM 24 h
2 Primary human hepatocytes 4165 (2125˄/2040˅)      400 μM 24 h
3 HepG2 cells 3D 3183 (1523˄/1660˅)      500 μM 24 h
4 HepG2 cells 2D 4241 (2246˄/1995˅)      500 μM 14 h
5 Primary mouse hepatocytes 4012 (2073˄/1939˅)      500 μM 24 h
6 In vivo mouse liver 500 (192˄/308˅)      100 mg/kg 24 h
7 Primary rat hepatocytes 3421 (1973˄/1448˅)      400 μM 24 h
8 In vivo rat liver 2461 (1073˄/1388˅)      100 mg/kg 24 h
9 In vivo rat liver repeat ex-
posure
1141 (573˄ /568˅)      100 mg/kg 29 days
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RESULTS
Diclofenac induced differential gene expression in human and rodent models 
Differentially expressed genes (FDR & P<0.05) upon diclofenac treatment in various 
models are as shown in table 1. This included in almost all cases a 24-hour time point 
post exposure, except 2D HepG2 cultures (14-hour) and a chronic exposure in rat in 
vivo model (29-day); In vivo mouse and rat (repeated exposure) had the lowest num-
ber of DEGs of all models models (Fig 1A). Next, transcriptomic changes induced 
by diclofenac were compared across all models. 471 DEG’s were found to have an 
overlap in the human models (Fig 1B). IPA analysis demonstrated that these genes 
are functionally associated with signaling pathways including remodeling of epithe-
lial adherens junction, NRF2 mediated oxidative stress response and p53-signaling 
pathway. A complete list of pathways associated with these 471 genes is shown in 
Figure 1: Similarity of differentially expressed genes in various models. Differentially expressed genes in 
various in vitro/in vivo models (A). Venn diagrams of DEG’s from human derived cell lines (B); DEG’s with 
P<0.05 (and FDR P<0.05) were selected. 
supplementary figure S2. The overlap of DEGs in 2D/3D HepG2, hPCLS to primary 
hepatocyte models of human, mouse and rat was also analyzed: 214 genes were 
in common for 3D HepG2 spheroids; 242 for 2D HepG2 and 267 for human PCLS 
(Supplementary S2). Molecular pathways associated with these overlapping genes 
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Figure 2:  Altered canonical pathways upon diclofenac exposure. Heatmap showing significantly altered 
canonical pathways in human PCLS and their expression on other models from ingenuity pathway analy-
sis (A). Venn diagram comparing significantly altered pathways in human cell models (B), Mouse models 
compared to human PCLS and PHH (C), Rat models compared to human PCLS (D). Significance calcu-
lated based on the ratio of the genes that are associated with specific canonical pathway, -log (p-value) 
1.3 = P (0.05).
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are as shown in supplementary S4. A closer similarity in overlapping pathways was 
seen between 3D HepG2 spheroids and human PCLS than 2D HepG2 and hPCLS 
(Supplementary S4). In vivo mouse liver exposed to diclofenac for 24 hours showed 
only 500 genes that were significantly changed, yet almost half of them overlapped 
with the mouse primary hepatocytes (Supplementary S1). Similarly, almost 50% of 
the DEGs of the single dose treatment of rat in vivo overlapped with the DEGs of 
the primary rat hepatocytes; also repeated diclofenac exposures in rats gave more 
than 60% concordance with either rat liver in vivo or rat hepatocytes in vitro. Venn 
diagrams showing association of DEG’s between other models are in supplementa-
ry S1. Overall these data indicate that although there is quite a good concordance 
between all models, the highest concordance is reached within one species, either 
human, rat or mouse.
Differentially regulated canonical pathways upon diclofenac treatment
Although the overlap between the DEGs between species was relatively low, over-
all, DEGs could be part of similar cellular stress response pathways. Therefore, 
for all the models the molecular pathways that are associated with DEG’s from di-
clofenac exposure were analyzed using Ingenuity Pathway Analysis (IPA®). We 
ranked the pathways of the different models according to the significance levels 
in the human PCLS model (Fig 2A). This demonstrates quite a differential mod-
ulation of pathways in the different models. Significant activation of the Nrf2 ox-
idative stress pathway was seen in all the models, highlighting its prime role in 
diclofenac induced liver injury. A higher number of significantly activated canoni-
cal pathways are seen in mouse primary hepatocytes than mouse liver, which 
is due to less number of significant genes in mouse liver samples (Table 1). 
 Next we evaluated the overlap of the differentially modulated path-
ways in the different models. Nine pathways had an overlap in human mod-
els (Fig. 2B), which included some important stress pathways such as Nrf2 
oxidative stress response and p53 signaling. Only two pathways overlapped 
between mouse models, PHH and human PCLS: Nrf2 pathway and PXR/
RXR activation (Fig. 2A and C). Six pathways showed an overlap with rat mod-
els and human PCLS, which also included Nrf2 signaling (Fig. 2A and D). 
 The pathways that are activated are not necessarily determined by 
the same gene sets. Therefore, for the most common pathways we first ex-
tracted the genes that are significantly affected for the individual path-
ways for the human PCLS model, and then extracted the fold change val-
ues for all these individual genes from the other models. We focused on some 
of the top affected pathways that also contained sufficient DEGs (Fig. 3). 
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Figure 3: Individual genes associated with altered canonical pathways upon diclofenac treatment in hu-
man PCLS and their expression in other models. Fold change gene expression compared to vehicle 
controls.
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Nrf2 oxidative stress response was a major common pathway that was induced upon 
diclofenac exposure. Diclofenac metabolites may cause mitochondrial impairment, 
ROS generation and subsequent oxidative stress, which is proposed as a possible 
mechanism of diclofenac-induced liver injury [35-38]. Oxidative stress activates the 
Nrf2 pathway to adapt to a more pro-oxidant environment. Genes regulated by Nrf2, 
such as HO-1 (heame oxygenase 1), are important markers for oxidative stress [39] 
and upregulation of HO-1 has been observed after diclofenac treatment [35, 36]. 
Here, HO-1 gene expression was seen in in vivo rodent models, human PCLS, pri-
mary hepatocytes and 3D HepG2 spheroids (Fig 3), but not in HepG2 cells in 2D 
culture in agreement with earlier reports [35]. This could be due to poor metabolism 
of diclofenac in 2D HepG2 cultures, since HO-1 expression was seen in HepG2 cells 
with S9 mixture [36]. In contrast, HepG2 cells cultured in hydrogels as spheroids 
expressed HO-1 supporting an increased metabolic competence in these HepG2 
spheroids. Another Nrf2 target, DNAJB9, a HSP40 family protein, [40, 41] was in-
duced >2-fold in human PCLS, rat primary cells and liver and 3D HepG2 cells. The 
expression of DNAJB9 was lower or not seen (mouse liver and rat repeated expo-
sures) in other models (Fig 3). Interestingly, MafK expression was upregulated upon 
diclofenac exposure in all the models except mouse liver and rat chronic exposures 
where it was unchanged with diclofenac treatment (Fig 3). Nrf2/MafK heterodimer 
binds and activate anti-oxidant responsive elements (ARE), inducing the expression 
of phase II enzymes [42, 43]. It was also reported that over expression of MafK re-
sulted in negative regulation of ARE-dependent transcription [44, 45]. The positive 
and negative regulation of antioxidant responsive elements by Nrf2/MafK may play 
an important role in balancing the oxidative stress response upon toxicant exposure. 
 Next we evaluated the p53 signaling pathway in more detail. Cellular inju-
ry-induced mitochondrial dysfunction and subsequent generation of ROS was shown 
to be involved in upstream activation of p53 mediated apoptotic signaling [46]. p53 
plays a major role in DNA damage response, cell cycle regulation and apoptosis 
[47]. p53 signaling pathway is significantly altered upon diclofenac exposure in the 
all models studied, except mouse liver (Fig 2A). Downstream targets of p53 involved 
in cell cycle regulation and apoptosis showed a varied response in different models. 
GADD45a, is induced upon DNA damage and is involved in G2-M cell cycle arrest 
[48]. GADD45a is upregulated after diclofenac exposure in all the models except 
primary rat hepatocytes, 3D HepG2 and mouse liver (Fig 3A). Earlier studies have 
reported that diclofenac induces oxidative stress leading to DNA fragmentation and 
apoptotic cell death [49]. Activation of GADD45a may indicate induction of a DNA 
damage response upon diclofenac exposure in this study. Up regulation of p53 me-
diated apoptosis inducer, Bax, was seen only in mouse and rat primary hepatocytes 
(Fig 3A). MDM2, a negative regulator of p53 [50] was down-regulated in primary 
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human hepatocytes and rat repeated diclofenac exposures, but not differentially ex-
pressed in mouse models and is upregulated in other models. 
 PXR/RXR activation, PI3K/AKT signaling, protein ubiquitination pathway 
and remodeling of epithelial adherens junctions were all significantly altered upon 
diclofenac treatment. For these models the highest concordance for individual gene 
expression was observed amongst the human models. Overall these data indicate 
that, while in the different models diclofenac may activate similar pathways, overall 
the genes that are affected in these pathways is quite different. Most concordance 
is observed for species-specific changes. Regardless, some genes do overlap 
amongst all models, with the exception for mouse liver in vivo and rat repeated dose. 
Figure 4. Diclofenac induced gene expression changes associated with liver diseases. Significance cal-
culated based on the ratio of the genes that are associated with the onset or mechanism of liver disease 
manifestation, -log (p-value)1.3 = P 0.05 from Ingenuity Pathway Analysis.
Gene expression analysis identifies liver diseases associated with diclofenac 
treatment
Several cases have shown that long-term use of diclofenac lead to overt liver diseas-
es. We used our transcriptomics data from different models to relate gene expres-
sion to disease models. FDA reports show that cholestasis was an adverse effect 
in 8% of patients taking diclofenac in 180 reported cases [23]. Analysis of genes 
involved in manifestation of liver diseases showed a significant induction of genes 
associated with cholestatic liver injury in all the models except 2D HepG2 cultures 
(Fig 4). Genes involved in liver hyperplasia were also significantly present in human 
cell models and mouse hepatocytes. Liver steatosis was significantly activated in 
human PCLS, primary human hepatocytes, 2D HepG2 cells, mouse and in vivo rat 
models. In particular, mouse primary hepatocytes showed a significant activation of 
genes involved in steatotic injury, ~4 fold higher than the human PCLS. Steatosis 
is not reported with diclofenac treatment in clinical use. Genes associated with liver 
hyperbilirubinemia and inflammation were significantly induced in human PCLS and 
primary human hepatocytes. Clinical cases associated with inflammation leading to 
hepatitis and hyperbilirubinemia were reported earlier with diclofenac use [51, 52]. 
Our data suggest that transcriptomic analysis could provide early evidence to poten-
tial drug-induced liver diseases. 
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Toxicity pathways activated upon diclofenac exposure
Our initial IPA analysis involved all signaling pathways and networks, without a fo-
cus on pathways involved in toxicity. Therefore, as a final step we focused solely on 
pathways that are related to toxicity. 22 pathways that are listed in the IPA program 
that have a significant role in xenobiotic toxicity response were further analyzed (Fig. 
5A and B). Overall, mouse hepatocytes and rat in vivo single dose showed the stron-
gest toxicity pathway activation. Genes involved in mitochondrial dysfunction were 
significantly activated in human PCLS, 3D HepG2 spheroids and rat primary hepato-
cytes. Cell cycle pathways; G2/M and G2/S checkpoint were significantly activated 
in all human cell models and rat hepatocytes (Fig. 5A). NF-κB signaling was signifi-
cantly active in human PCLS and in vivo rat models. Other xenobiotic metabolism 
pathways FXR/RXR, TR/RXR, LXR/RXR were primarily activated in rodent models. 
Pathways involved in inflammatory signaling and acute phase response signaling 
were significantly activated in primary human hepatocytes, mouse hepatocytes and 
Figure 5. Toxicity pathways from ‘IPA Tox pathways’ and their induction upon diclofenac treatment. Ca-
nonical toxicity pathways in various models (A); Hierarchical clustering of toxicity pathways (B).
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rat models (Fig 5A).
 Next we performed unsupervised hierarchical clustering of toxicity pathways 
to determine which model was closest to human PCLS (Fig 5B). The 3D HepG2 
spheroid model was in closest proximity to PCLS with high similarity in the activation 
of mitochondrial dysfunction, PXR/RXR pathway, p53 signaling, hypoxia signaling, 
cell cycle: G2/M DNA damage checkpoint regulation and Nrf2 signaling. All primary 
hepatocyte models were also in close similarity in particular with respect to PXR/
RXR activation, AhR signaling, LXR/RXR activation, hepatic cholestasis. 
DISCUSSION
With several in vitro and in vivo models in practical use as surrogates to study human 
specific DILI, comparative gene expression profiling of these models will provide an 
improved insight into the molecular changes that occur upon xenobiotic exposure. 
This type of comparative analysis will also help in characterizing the value of differ-
ent in vitro/ in vivo models in predicting human specific responses associated with 
xenobiotic insult. In this study we used transcriptomics data to compare the effect 
of diclofenac treatment in human and rodent in vitro/in vivo models. Human PCLS 
showed a clear upregulation of molecular pathways that are associated with the 
pathogenicity of diclofenac induced liver injury. We anticipated a similar xenobiotic 
response in primary human hepatocytes (PHH). Although we observed a similar lev-
el of gene expression changes in PCLS and PHH, there were quite significant differ-
ences in the expression profile and even less similarities in the significantly affected 
cellular stress signaling pathways. Intriguingly, HepG2 cells cultured as spheroids 
showed diclofenac-induced activation of various stress signaling pathways compa-
rable to human PCLS models; this was not observed in HepG2 cells cultured as 2D 
monolayer cells. This is likely due to increased metabolic competence observed in 
differentiated HepG2 spheroid cultures [14]. Phase 1 metabolism enzymes CYP2C9, 
CYP3A4 and phase II UGT’s are involved in metabolism of diclofenac [37]; acyl 
glucuronides from glucuronosyl-transferse UGT2B7 and 4-hydroxy diclofenac from 
CYP2C9 are the major metabolites in diclofenac metabolism [53, 54]. These metab-
olites were previously shown to form in HepG2 spheroids exposed to diclofenac [14], 
suggesting a mechanistic response in HepG2 spheroids which is not seen in HepG2 
2D cultures where drug metabolism enzymes are poorly expressed [55]. 
 Diclofenac induces apoptosis by disrupting mitochondrial function and gen-
erating reactive oxygen species [24]. Genes that lead to mitochondrial dysfunction 
were seen only in human PCLS, 3D HepG2 spheroids and rat hepatocytes. Due to 
large inter-individual variability, primary human hepatocytes from 10 different cryo-
preserved donors were used for this transcriptomic study.  However, the genes as-
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sociated with mitochondrial dysfunction were not significantly activated in PHH, or in 
other primary hepatocytes or HepG2 cells in 2D culture. The differentiated HepG2 
spheroids responded similarly to PCLS and rats treated with diclofenac, suggesting 
an increased functional complexity that has developed during differentiation of cells 
in 3D culture. Mitochondrial dysfunction has been proposed to be one of the under-
lying causes of idiosyncrasy [56, 57]; failure to identify mitochondrial toxicity in some 
models is a caveat for predictive toxicogenomics assays.
 Nrf2-mediated oxidative stress response is a major signaling pathway that 
was reported in diclofenac hepatotoxicity and significantly activated in all the mod-
els in the current study. Earlier studies have shown that Heameoxyenase-1 (HO-1) 
in Nrf2 pathway is significantly induced upon diclofenac treatment [35]. Induction 
of HO-1 is seen in 3D HepG2 spheroids and other models compared in this study 
but not in 2D cultured HepG2 cells. FXR/RXR activation pathway was significantly 
activated upon diclofenac treatment in human (except 3D HepG2), rat and mouse 
models. FXR/RXR plays a role in bile acid regulation, lipid and glucose metabolism, 
[58] activation of drug metabolism enzymes [59] and protection against xenobiotic 
injury [60]. Activation of FXR/RXR pathway was also seen in diclofenac exposed rat 
livers in earlier studies [61] suggesting a role in diclofenac metabolism. 
 Genes and molecular events associated with diclofenac injury were highly 
enriched in DEG’s from PCLS. PCLS may be a better alternative in understanding 
the short-term responses induced by the drugs, but its dependency on availability 
of human liver samples, variability due to different genetic backgrounds of individual 
samples and rapid decline of its native liver physiology have to be addressed for 
its relevance in exploring long-term effects of the xenobiotics. Similarly PHH have 
several limitations as described earlier for its dependence in toxicological assays. 
Although important stress signaling pathways such as Nrf2 oxidative stress pathway, 
genes associated with liver diseases such as cholestasis and steatosis were activat-
ed in both PCLS and PHH there was a considerable difference in activated pathways 
between PCLS and PHH. 
 DEG’s in rat and mouse primary hepatocytes shared higher similarity to their 
in vivo counterparts than to human models. Mouse hepatocytes had similar enriched 
pathways as mouse in vivo, and in some aspects genes associated with liver dis-
eases were significantly higher in mouse hepatocytes, although this may be due to 
the low number of DEG’s in mouse in vivo treatments. DEG’s in rat had higher sim-
ilarity to humans than mouse, highlighting the increased capacity of rat compared 
to mouse in predicting human specific responses. Nonetheless, animal models are 
poor in predicting human responses and their current dependency is mainly due to 
lack of complex models that closely reflect complex human systems. Human derived 
immortalized hepatocytes with improved metabolic competence and polarized he-
96
Chapter 4
patocyte morphology such as 3D HepG2 spheroids used in this study gave similar 
responses as PCLS. 3D HepG2 spheroids showed upregulation of genes and path-
ways that are associated with the mechanism of diclofenac injury, which were not 
seen in same cells cultured in a 2D monolayer. The ability to sustain a stable pheno-
type for a longer period whilst maintaining their polarized morphology and increased 
metabolic competence is also ideal for studying repeated dose effects of drugs. 
 In the current investigation we have used transcriptomics data from in-house 
and publicly available sources. Moreover, the isolation procedures and culturing pro-
tocols have been different for all individual models. In addition, concentrations of 
diclofenac, mRNA isolation and Affymetrix hybridization procedures may have been 
slightly different. Despite these discrepancies we find quite strong overlap in vari-
ous pathways that are activated in the different models. Moreover, several individ-
ual genes that are modulated across different models and that represent individual 
pathway activation are likely ideal markers for cross species comparison and human 
translation. Future next generation sequencing approaches of similar comparative 
treatment samples across species and models will further limit the variability and 
likely identify additional candidate translational biomarkers for DILI. 
 In conclusion, this study provides an overview of transcriptional responses 
in various models upon diclofenac exposure and their commonality. The ability to 
predict long-term effects of diclofenac and its toxicity pathways at gene level further 
supports toxicogenomic approaches in predicting toxicity of new chemical entities. 
New improved in vitro models such as the HepG2 spheroid model used in this anal-
ysis would be valuable to consider in future toxicogenomic approaches.
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Ingenuity Canonical Pathways  -log(p-value)
Remodeling of Epithelial Adherens Junctions 3.66E+00
tRNA Charging 2.63E+00
14-3-3-mediated Signaling 2.61E+00
Epithelial Adherens Junction Signaling 2.49E+00
NRF2-mediated Oxidative Stress Response 2.32E+00
Bladder Cancer Signaling 2.26E+00
p53 Signaling 1.95E+00
Sertoli Cell-Sertoli Cell Junction Signaling 1.94E+00
Gap Junction Signaling 1.88E+00
Germ Cell-Sertoli Cell Junction Signaling 1.83E+00
Activation of IRF by Cytosolic Pattern Recognition Receptors 1.78E+00
TCA Cycle II (Eukaryotic) 1.78E+00
Cell Cycle: G1/S Checkpoint Regulation 1.70E+00
Neuregulin Signaling 1.70E+00
Breast Cancer Regulation by Stathmin1 1.69E+00
IL-17A Signaling in Gastric Cells 1.63E+00
Thio-molybdenum Cofactor Biosynthesis 1.60E+00
Glutamate Removal from Folates 1.60E+00
Lipoate Salvage and Modification 1.60E+00
L-cysteine Degradation II 1.60E+00
Asparagine Biosynthesis I 1.60E+00
Chronic Myeloid Leukemia Signaling 1.57E+00
HMGB1 Signaling 1.55E+00
Guanosine Nucleotides Degradation III 1.46E+00
Prolactin Signaling 1.46E+00
Assembly of RNA Polymerase III Complex 1.40E+00
Role of IL-17A in Psoriasis 1.40E+00
Urate Biosynthesis/Inosine 5’-phosphate Degradation 1.40E+00
PDGF Signaling 1.37E+00
Thrombopoietin Signaling 1.32E+00
Lipoate Biosynthesis and Incorporation II 1.31E+00
Sulfate Activation for Sulfonation 1.31E+00
Cysteine Biosynthesis/Homocysteine Degradation 1.31E+00
Supplementary S1. Molecular Pathways associated with 471 overlapping genes in human cell models 
(from Figure 1B); as calculated by Ingenuity Pathway Analysis.
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Supplementary S2. Venn diagrams of DEG’s upon diclofenac treatment in human, mouse and rat model 




Supplementary S3. Venn diagrams of significantly altered canonical pathways from human, mouse and 
rat DEG’s upon diclofenac exposure.
Molecular pathways that are common between 3D HepG2_PHH_PMH_PRH
Ingenuity Canonical Pathways  -log(p-value)
Cell Cycle: G1/S Checkpoint Regulation 4.01E+00
NRF2-mediated Oxidative Stress Response 3.59E+00
Tryptophan Degradation X (Mammalian, via Tryptamine) 3.09E+00
Putrescine Degradation III 3.09E+00
tRNA Charging 2.99E+00
Tyrosine Degradation I 2.87E+00
Dopamine Degradation 2.73E+00
Hepatic Fibrosis / Hepatic Stellate Cell Activation 2.24E+00
Noradrenaline and Adrenaline Degradation 2.20E+00
Complement System 2.20E+00
PXR/RXR Activation 2.18E+00
Supplementary S4. List of pathways that overlap between human in vitro models and primary hepato-
cytes of human, mouse and rat. (PHH- primary human hepatocytes; PMH - primary mouse hepatocytes; 
PRH - primary rat hepatocytes).
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Mevalonate Pathway I 2.07E+00
Histamine Degradation 2.07E+00
Choline Biosynthesis III 2.00E+00
Phenylalanine Degradation IV (Mammalian, via Side Chain) 1.94E+00
Colanic Acid Building Blocks Biosynthesis 1.94E+00
Asparagine Biosynthesis I 1.93E+00
Fatty Acid α-oxidation 1.88E+00
Oxidative Ethanol Degradation III 1.88E+00
RAN Signaling 1.83E+00
Superpathway of Geranylgeranyldiphosphate Biosynthesis I (via 
Mevalonate)
1.83E+00
Ethanol Degradation IV 1.77E+00
FXR/RXR Activation 1.76E+00
D-myo-inositol (1,4,5)-trisphosphate Degradation 1.73E+00
Aryl Hydrocarbon Receptor Signaling 1.68E+00
Serotonin Degradation 1.63E+00
Taurine Biosynthesis 1.63E+00
Glycine Biosynthesis I 1.63E+00
Antioxidant Action of Vitamin C 1.60E+00
Phospholipases 1.57E+00
Polyamine Regulation in Colon Cancer 1.56E+00
Tumoricidal Function of Hepatic Natural Killer Cells 1.49E+00
Superpathway of D-myo-inositol (1,4,5)-trisphosphate Metabolism 1.49E+00
Xenobiotic Metabolism Signaling 1.49E+00
Pancreatic Adenocarcinoma Signaling 1.43E+00
Superpathway of Cholesterol Biosynthesis 1.40E+00
Heme Degradation 1.33E+00
Phenylethylamine Degradation I 1.33E+00
Melatonin Degradation II 1.33E+00
Arginine Degradation I (Arginase Pathway) 1.33E+00
NAD Biosynthesis III 1.33E+00
L-cysteine Degradation I 1.33E+00
Ethanol Degradation II 1.31E+00
p38 MAPK Signaling 1.31E+00
Molecular pathways that are common between 2D HepG2_PHH_PMH_PRH
Ingenuity Canonical Pathways -log(p-value)
4-hydroxyproline Degradation I 3.76E+00
tRNA Charging 2.82E+00
Superpathway of Serine and Glycine Biosynthesis I 2.60E+00
Tumoricidal Function of Hepatic Natural Killer Cells 2.43E+00
Complement System 2.07E+00
NRF2-mediated Oxidative Stress Response 2.04E+00
Cell Cycle: G1/S Checkpoint Regulation 2.02E+00
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Hepatic Fibrosis / Hepatic Stellate Cell Activation 2.02E+00
Asparagine Biosynthesis I 1.88E+00
Tryptophan Degradation X (Mammalian, via Tryptamine) 1.74E+00
Putrescine Degradation III 1.74E+00
FXR/RXR Activation 1.60E+00
Lipoate Biosynthesis and Incorporation II 1.58E+00
Proline Degradation 1.58E+00
Taurine Biosynthesis 1.58E+00
Thiosulfate Disproportionation III (Rhodanese) 1.58E+00
Glycerol-3-phosphate Shuttle 1.58E+00




Induction of Apoptosis by HIV1 1.37E+00
Aldosterone Signaling in Epithelial Cells 1.31E+00
Molecular pathways that are common between human precision cut liver slices_PHH_PMH_PRH
  Ingenuity Canonical Pathways -log(p-value)
Putrescine Degradation III 4.16E+00
Polyamine Regulation in Colon Cancer 3.59E+00
PXR/RXR Activation 3.53E+00
Histamine Degradation 3.22E+00
NRF2-mediated Oxidative Stress Response 2.95E+00
Fatty Acid α-oxidation 2.92E+00
Oxidative Ethanol Degradation III 2.92E+00
Arginine Degradation I (Arginase Pathway) 2.91E+00
Tryptophan Degradation X (Mammalian, via Tryptamine) 2.83E+00
Ethanol Degradation IV 2.75E+00
Cell Cycle: G1/S Checkpoint Regulation 2.66E+00
Acute Phase Response Signaling 2.50E+00
Dopamine Degradation 2.48E+00
Hepatic Fibrosis / Hepatic Stellate Cell Activation 2.41E+00
Sucrose Degradation V (Mammalian) 2.38E+00
Tumoricidal Function of Hepatic Natural Killer Cells 2.31E+00
Retinoate Biosynthesis I 2.08E+00
LXR/RXR Activation 2.07E+00
Ethanol Degradation II 2.04E+00
Noradrenaline and Adrenaline Degradation 1.96E+00
Complement System 1.96E+00
Protein Ubiquitination Pathway 1.92E+00
Guanosine Nucleotides Degradation III 1.90E+00
Aryl Hydrocarbon Receptor Signaling 1.88E+00
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Acetyl-CoA Biosynthesis III (from Citrate) 1.84E+00
Asparagine Biosynthesis I 1.84E+00
ILK Signaling 1.78E+00
The Visual Cycle 1.71E+00
Small Cell Lung Cancer Signaling 1.71E+00
p38 MAPK Signaling 1.57E+00
Purine Nucleotides Degradation II (Aerobic) 1.56E+00
D-myo-inositol (1,4,5)-trisphosphate Degradation 1.56E+00
Lipoate Biosynthesis and Incorporation II 1.54E+00
Proline Degradation 1.54E+00
4-hydroxyproline Degradation I 1.54E+00
Atherosclerosis Signaling 1.51E+00
Xenobiotic Metabolism Signaling 1.47E+00





Methionine Salvage II (Mammalian) 1.37E+00
Phospholipases 1.34E+00
HMGB1 Signaling 1.33E+00
Superpathway of D-myo-inositol (1,4,5)-trisphosphate Metabolism 1.33E+00
Common elements in “2D HepG2” and “Human liver”:    
4-hydroxyproline Degradation I  
Cell Cycle: G1/S Checkpoint Regulation 
Lipoate Biosynthesis and Incorporation II 
Proline Degradation   
Apoptosis Signaling   
    
Common elements in “3D HepG2” and “Human liver”:    
Noradrenaline and Adrenaline Degradation 
PXR/RXR Activation   
Histamine Degradation  
Fatty Acid α-oxidation   
Oxidative Ethanol Degradation III  
Ethanol Degradation IV  
D-myo-inositol (1,4,5)-trisphosphate Degradation
Aryl Hydrocarbon Receptor Signaling 
Serotonin Degradation  
Phospholipases   
Polyamine Regulation in Colon Cancer 
Superpathway of D-myo-inositol (1,4,5)-trisphosphate Metabolism
Xenobiotic Metabolism Signaling  
Arginine Degradation I (Arginase Pathway) 
Ethanol Degradation II  
p38 MAPK Signaling   
Common elements in “3D HepG2”, “2D HepG2” and “Human PCLS”:
NRF2-mediated Oxidative Stress Response 
Tryptophan Degradation X (Mammalian, via Tryptamine)
Putrescine Degradation III  
Dopamine Degradation  
Hepatic Fibrosis / Hepatic Stellate Cell Activation
Complement System   
Asparagine Biosynthesis I  
FXR/RXR Activation
Tumoricidal Function of Hepatic Natural Killer cells




Supplementary S5. Genes associated with liver diseases from models systems in which the disease 
state is positively predicted from ingenuity pathway analysis.
Liver inflammation
Human liver slices 
ABCB4 ABCC2 ADIPOR2 APOB CAMLG CCL2 
CCL8 CD274 COL3A1 CXCL1 
CXCL10 CXCL2 CYP2E1 DDX5 FKBP1A GSTP1 
IFNAR1 IFNAR2 IL10 RBIL8 INSR MMP9 
MTOR NAGLU PEMT POR PPARA PPARG 
PPP3CA PPP3CBP PP3CC RASSF1 SOD2 THOP1 
TIMP1
Primary human hepatocytes 
ABCB4 ABCC2 ADIPOR2 AGTR1 APOB CAMLG 
CSF1 CXCL1 CXCL10 CXCL2 CYP2E1 EPO 
GSTP1 IL8 NR3C1 PDE3B POLA1 POLB 
POLD1 POR PPARA PPP3R1 RASSF1 
SLC10A1 SLCO1B1 SOD2 THOP1
3D HepG2  
ADIPOR2 ADK AGTR1 AMY2B CAMLG EPO 
IFNGR1 IL8 IMPDH2 NR3C1 PEMT POLA1 




A1BG ABCC2 ABCC3 ADAM17 ADAM9 ADH1C 
AKR1B10 AKR1D1 ALDOB ANXA2 APOA5 ARPC5 
ATF5 ATP1B3 AXIN1 C1S C7 CA2 
CASD1 CASP8 CDC25B CDK14 CDK5 CD-
KN1B CHUK CKS2 CP CSE1L CTNNB1 
CTSD CYP1A1 DGAT2 DPP3 DSE DYNLL1 
EIF2AK2 EIF4E ELMO1 EPHA2 ERBB3 FAIM 
FAM83D FCN3 FOS FRK FUCA1 GOLM1 
GOT1 GPAA1 H2AFY HABP2 HGS HNRNP-
DL HPD HSD17B6 HSP90AA1 HSP90AB1 HSPA8 
HTATIP2 IFNAR1 IFNAR2 IL8 ING4 ISG15 
JUN KAT5 KDR KIT KNG1 KRAS 
LBP MAPRE1 MDM2 MED30 MMP9 MTOR 
NFE2L2 NQO1 NUPR1 OSMR PDGFRB PDK4 
PFN1 PGK1 PHGDH PLAUR PNRC1 POLE4 
POR PPARG PPP1R3C PRDX1 PRDX3 PTEN 
PTGS2 RAD50 RASSF1 RASSF5 RB1 RDH16 
RELA RELB RIOK1 RNMT RPL4 RRM1 
S100A4 SERPINE1 SLC22A9 SLC35C1 SLC47A1 SL-
CO1B3 SPARC SRRT SULF2 TMX2 TOP2B 
TPI1 TRIM8 TUBB4B TXN TYMS USP9X 
VEGFA VPS37A VTN WBSCR22 YWHAG
Primary human hepatocytes 
A1BG AADAC ABCB1 ABCC2 ABCC3 ABCC6 
ADAM17 ADH1B AKR1B10 AKR1C1/AKR1C2 ALDOB 
ANXA1 ARID2 ARSE ASF1B ATP1B3 AURKA 
BAG2 BCL2L1 BSG C4BPA C9 CA2 
CA9 CAP2 CASD1 CCNB1 CCND1 CD44 
CDK5 CDK5RAP3 CDKN1A CENPH CKS2 COPG1 
CP CREB3L3 CRELD2 CSF1 CSPP1 CY-
P1A1 DGAT2 DLC1 DSE DYNLL1 E2F5 
ECT2 EIF1AX ELMO1 ENPP2 EPCAM EPHA2 
ERBB2 ERBB3 FAIM FAM83D FGL1 FOXQ1 
FUCA1 GC H2AFY HABP2 HAMP HGS 
HMGB1 HNRNPDL HPD HPX HSD17B6 HSPA5 
HSPA8 IL8 IPO7 ISG15 ITIH4 JUN 
KEAP1 LBP LRG1 MAP3K4 MAT2A MDM2 
MED30 MET MLF1IP MT2A MYO6 NCAPG 
NNMT NPC1 NR1H4 NUPR1 NUSAP1 ORC6 
PAQR4 PDK4 PGLYRP2 PHGDH PKM PLG 
POLD3 POLE POLE2 POLE3 POLE4 POR 
PPP1R3C PSEN1 RAD50 RASAL2 RASSF1 RB1 
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RDH16 RELA RIOK1 RNMT RRM1 RRM2 S100A4 SCP2 SERPINE1 SLC10A1 
SLC15A1 SLC22A1 SLCO1B1 SMO SMYD5 SOX4 SQLE SRRT SULF2 TACSTD2 
TBP TDO2 TFCP2 TM4SF1 TMX2 TOP2A TPX2 TRIM8 TUBB4B TYMP 
TYMS UBE2C UBE2T UCHL1 UGT1A6 VEGFA VTN WHSC1
3D HepG2
ABL1 ADAM17 AKR1D1 ANLN APOA5 ARPC5 ASRGL1 ATAD5 ATP1B3 AURKA 
AXIN2 BIRC5 CASD1 CASP2 CASP8 CCDC138 CCNB1 CDC25B CDK5 CDKN3 
CKS2 CSE1L CTNNB1 CYP1A1 DGAT2 DKK1 DSE E2F5 ECT2 EIF1AX 
ENPP2 EPHA2 ERBB3 FAM83D FOS GLUD1 GOT1 GSTT1 H2AFY HAMP 
HEATR6 HGS HPD IGFBP3 IL8 ISG15 JUN MAP3K4 MAVS MDM2 
MED30 MLF1IP MT2A NCAPG NPC1 NQO1 NUPR1 NUSAP1 ORC6 OSMR 
PGK1 PKM PLK4 POLE2 POLE4 POR PPARG RIOK1 RNMT RPL13A 
RRM1 RRM2 S100A4 SCP2 SERF2 SERPINE1 SLC2A1 SOAT2 SOCS1 SQSTM1 
SRRT STAT3 SULF2 TM4SF1 TOP2A TP53 TPI1 TPX2 TUBB4B TYMS 
UBE2C VEGFA VPS37A
2D HepG2
AADAC ABCB1 ABCC1 ABCC2 ABCC5 ABCC6 ADAM17 AKR1B10 AKR1C1/AKR1C2 
AKR1D1 APOA5 ARL2 ASF1B ASRGL1 ATAD5 ATF5 ATP1B3 AXIN2 B4GALT1 
BIRC5 BRAF C7 CASP2 CASP8 CCDC138 CCNB1 CDC25B CDK5 CDKN1B 
CDKN3 CRELD2 CSE1L CST3 CTNNB1 CTSD DGAT2 DKK1 DLC1 E2F5 
E2F8 EIF1AX EIF3H ENPP2 EPHA2 ERBB3 EXOSC4 FAIM FAM83D FER 
FGFR1 FOS FOXQ1 FRK GDPD1 GOT1 GPAA1 GSTT1 HAMP HEATR6 
HMGB1 HP HPD HPX HSPA5 IFT81 IGFBP3 IL8 ING4 ISG15 
JUN KCTD2 LETM1 LMCD1 LRG1 MAP3K4 MCRS1 MDM2 MED30 MMP2 
MYO6 N4BP2L2 NCAPG NFE2L2 NKD1 NPC1 NRAS NUPR1 ORC6 OSMR 
PAQR4 PFN1 PGK1 PIK3CA PIK3IP1 PKM PLK4 PNRC1 POLD3 POLE 
POLE2 POLG POR PPARG PPP1R3C PRPF6 RAD50 RASSF1 RIOK1 RNMT 
RRM1 RRM2 S100A4 SERPINA6 SERPINC1 SERPINE1 SLC2A1 SLC35C1 SMO SOAT2 
SOX4 SPARC SQSTM1 STAT3 TGFB1 TM4SF1 TOP2A TP53 TRIM8 TUBB4B 
TYMS UBE2C UBE2T USP9X VEGFA VPS37A
Liver Steatosis
Human liver slices 
ACACA ACOX1 ACOX2 ADIPOR2 APOB AR 
CAT CCL2 CYP2E1 FABP4 GNMT GSTP1 
NPHP3 PEMT PLIN2 PPARA PPARG PPARG-
C1A SOD2 UCP2
Primary human hepatocytes 
ACADL ACOX1 ACOX2 ADIPOR2 APOB CD44 
CYP2E1 CYP4A11 GSTP1 HMGCR MOGAT2 
MOGAT3 PDE3B PLIN2 PPARA PPARGC1A SOD2 
SPP1 SREBF1 
2D HepG2
ACOX2 CAT CPT1A DGAT1 FASN 
MOGAT3 PDE8A PEMT PLIN2 PPARA PPARG 
PPARGC1A TNFRSF1A UCP2
Liver Cholestasis
Human liver slices 
ABCB4 ABCB6 ABCB7 ABCC2 ABCC3 ABCG1 
ABCG2 ADH1C ADH4 AKR1C3 AKR1D1 BAAT 
CAT CYP27A1 CYP7B1 GPX2 IL8 LBP 
LIPA MGST2 NR0B2 RDH16 SCD 
SLC12A2 SLC25A13 SULT1A2 UGP2 UGT2B15  
Primary human hepatocytes 
ABCB4 ABCB6 ABCC2 ABCC3 ABCG2 ACSL1 
ADH4 ADH6 APOA1 ATP8B1 BAAT CY-
P27A1 HDLBP HMGCR HPX IL8 LBP 
LIPC MGST2 MGST3 NR0B2 NR1H4 PAH 
RDH16 SCD SCP2 SLC10A1 SLC22A1 SL-
C35B1 SLCO1B1 SREBF1 SULT1A1 SULT1A2 UGP2 
UGT2B15
3D HepG2
 ABCG2 ACSL1 ADH6 AKR1D1 BLVRA CYP7A1 
GK GPX2 HMGCR HNF1B IL8 LIPA 
MGST2 MTTP NR0B2 SCP2 SLC25A6 UGP2

CHAPTER 5
A SCREEN FOR APOPTOTIC SYNERGISM BETWEEN 
CLINICAL RELEVANT NEPHROTOXICANT AND THE 
CYTOKINE TNF-α
Giulia Benedetti1,*, Sreenivasa C. Ramaiahgari1,*, Bram Herpers1, Bob van de 
Water1, Leo S. Price1, Marjo de Graauw1
1Division of Toxicology, Leiden Academic Centre for Drug Research, Leiden Uni-
versity, Leiden, The Netherlands.
*contributed equally 




Nephrotoxicity remains one of the main reasons for post-market drug withdrawal. 
Tumour necrosis factor α (TNF-α) secretion has been shown to underlie the neph-
rotoxicity induced by some of these drugs. Yet, there is currently no reliable and 
sensitive in vitro assay available to screen for nephrotoxicants of which toxicity 
largely depends on TNF-α secretion. Therefore, we developed and applied a sensi-
tive fluorescence-based in vitro assay for TNF-α-mediated nephrotoxicity screening 
using mouse immortalized proximal tubular epithelial cells (IM-PTECs). Our assay 
allows rapid evaluation of TNF-α-mediated toxicant-induced apoptosis and necrosis 
using fixed endpoint and live cell measurements. To evaluate our assay, sixteen 
nephrotoxicants and two control non-nephrotoxicants were used. Out of the sixteen 
nephrotoxicants, eight induced cell death, of which five induced apoptosis as well 
as necrosis. Moreover, TNF-α significantly enhanced apoptotic cell death induced 
by cisplatin, cyclosporine A, tacrolimus and azidothymidine. These nephrotoxicants 
are known to induce inflammation in vivo which has been linked to an enhancement 
of nephrotoxicity for cisplatin, cyclosporine A and tacrolimus, confirming the func-
tionality of our assay. Overall, our assay allows rapid and sensitive measurement 
of apoptosis and necrosis induced by a combination of nephrotoxicants and inflam-
matory components such as TNF-α and can be used as an alternative assay for 
nephrotoxicity prediction in vitro.
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INTRODUCTION
Nephrotoxicity is a significant cause of post-market drug withdrawal. This is partly 
due to inadequate and non-sensitive pre-clinical tests to detect the nephrotoxic po-
tential of new drugs. Acute toxicity testing in animals is traditionally used to evalu-
ate the potential toxicity of new chemicals. However, the increase in the number of 
new chemicals tested and the lack of sensitivity of the traditional animal tests have 
prompted pharmaceutical companies to explore in vitro cell culture screening sys-
tems for toxicity prediction. Several in vitro screening systems using different cell 
lines, such as  primary cells, LLC-PK1 (swine), NRK-52E (rat), MDCK (canine), OK 
(opossum), HK-2 (human) and RPTEC/hTERT1 (human) have been developed to 
assess the nephrotoxic potential of compounds [1-10]. However, these assays do 
not take into account the factors contributing to the pathophysiology of nephrotox-
icant-induced acute renal failure (ARF) in patients such as mediators of inflamma-
tion. Moreover, mostly only one cytotoxicity parameter was taken into account and 
fixed time-points were used.  
 It is known that upon a nephrotoxic insult, the proximal tubule is considered 
the major target. Nephrotoxic injury of proximal tubular epithelial cells (PTECs) is 
characterized by mitochondrial dysfunction, adenosine triphosphate (ATP) deple-
tion, activation of stress signalling pathways, impaired solute and ion transport, loss 
of brush border morphology, loss of cell polarity and cytoskeletal disruption [11,12]. 
Loss of cell adhesion also correlates with loss of cell function, pro-apoptotic signal-
ling and cell death [13]. During nephrotoxicant-induced ARF, inflammation plays a 
major role. Several nephrotoxicants have been shown to induce an inflammatory 
response and attenuation of the inflammation can result in renal-protective effects 
[14-18]. It is believed that during nephrotoxicity, the initial insult by the nephrotoxi-
cant results in changes in vascular endothelial cells and/or in tubular epithelial cells 
leading to the generation of inflammatory mediators (cytokines and chemokines) by 
these cells. These inflammatory mediators induce migration and infiltration of leuko-
cytes into the injured kidneys and, importantly, aggravate the primary injury induced 
by the nephrotoxicant [19].
 One the main inflammatory mediators secreted by PTECs [20,21] as well as 
by the infiltrating immune cells [22] is the pro-inflammatory cytokine tumour necrosis 
factor α (TNF-α). TNF-α was shown to be up-regulated and directly involved in the 
pathophysiology of cisplatin- and acetaminophen-induced renal injury [23-25]. In ad-
dition, other nephrotoxicants were shown to up-regulate TNF-α levels in the kidneys, 
in serum or in macrophages, including adefovir [26], methotrexate [27], carmustine 
[28] and mitomycin C [29], but a functional role for TNF-α in the toxicity induced by 




two immunosuppressive drugs cyclosporine A and tacrolimus. Both cyclosporine A 
and tacrolimus were shown to inhibit TNF-α production in vitro in macrophages [30] 
and cultured PTECs [31] as well as in murine models [32,33].  However, studies 
performed on renal transplant recipients treated with cyclosporine A or tacrolimus 
showed that cyclosporine A did not affect TNF-α production by peripheral blood 
mononuclear cells [34] and tacrolimus increased TNF-α production by monocytes 
[35]. Despite these contradictory results in the effects of these immunosuppressive 
drugs on TNF-α production, both are known to induce inflammation after renal trans-
plantation [36-38]. 
 In addition to upregulation of TNF-α, some nephrotoxicants clearly inhibit 
TNF-α production. Gentamicin was shown to inhibit lipopolysaccharide (LPS)-in-
duced TNF-α production in human and mouse PTECs [39] even though it induced 
inflammation in vivo [40]. The antiviral azidothymidine reduced TNF-α levels in 
HIV-infected patients [41,42] and the analgesic diclofenac decreased mRNA levels 
of TNF-α in obese men [43]. 
 Given the importance of the immune system in nephrotoxicity we set-out to 
develop an alternative in vitro assay for prediction of TNF-α-mediated drug-induced 
nephrotoxicity. Using immortalized proximal tubular epithelial cells (IM-PTECs) we 
developed and characterized a fluorescence-based in vitro assay for nephrotoxicity 
screening, which allows apoptosis and necrosis measurements at both at a fixed 
time point as well as live over a 24-48 hour time-course in the presence of the 
cytokine TNF-α. IM-PTECs were exposed to 16 different nephrotoxicants and two 
control non-nephrotoxicants in the presence or absence of TNF-α. In total, 8 neph-
rotoxicants induced apoptosis of which cisplatin, cyclosporine A, tacrolimus and az-
idothymidine-induced cell death was enhanced by TNF-α. Overall, our cell model 
for inflammation-related nephrotoxicity combined with semi high-throughput fluores-
cence-based measurements allows rapid and sensitive measurement of cell death 
and can be used as an alternative assay for nephrotoxicity prediction in vitro.
Reagents
Cisplatin (Cis-PtCL2(NH3)2)) was provided by the pharmacy unit of University Hos-
pital in Leiden (The Netherlands). Adefovir was acquired from Shanghai PI chemicals 
(Shanghai, China). All the other nephrotoxic and non-nephrotoxic compounds were 
acquired from Sigma-Aldrich (Zwijndrecht, The Netherlands). Mouse recombinant 
TNF-α was acquired from R&D Systems (Abingdon, UK). AnnexinV-Alexa488 was 
made as previously described [44]. Propidium iodide was provided by Sigma-Aldrich. 
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Cell culture 
Mouse immortalized proximal tubular cells (IM-PTECs) [45] were cultured at 33°C 
in DMEM/F12 medium (Invitrogen, Breda, The Netherlands) with 10% fetal bovine 
serum (Invitrogen, Breda, The Netherlands), 5 μg/ml insulin and transferrin, 5 ng/ml 
sodium selenite (Roche, Almere, The Netherlands), 20 ng/ml triiodo-thyronine (Sig-
ma-Aldrich), 50 ng/ml hydrocortisone (Sigma-Aldrich), and 5 ng/ml prostaglandin E1 
(Sigma-Aldrich) with L-glutamine and antibiotics (both from Invitrogen) and mouse 
interferon-γ (IFN-γ) (1 ng/ml; R&D Systems) in 5% CO2 and 95% air between pas-
sage 3 and 20. Prior to each experiment, the cells were differentiated into proximal 
tubular cells by culturing them for 4 days in restrictive conditions (at 37°C in the ab-
sence of IFN-γ). The cells were then plated in 96-well plates and cultured for 2 more 
days. In total, IMPTECs were cultured in restrictive conditions for 6 days, allowing 
the disappearance of SV40 activity and completion of differentiation [45].
Exposure of the cells
Compound concentrations used in the study were based on previously published 
in vitro studies or were extrapolated from the plasma levels in patients. Compound 
stock solutions were prepared freshly in DMSO, water, NaCl or NaOH depending 
on the compounds. Stock solutions were diluted with complete medium to obtain 
100X the final testing concentration. The final concentration of DMSO was maximum 
0.1% IM-PTECs were exposed to 16 different nephrotoxic compounds and 2 control 
non-nephrotoxic compounds at two different concentrations in combination or not 
with TNF-α (8 ng/ml). Cisplatin was used as a positive control and the two non-neph-
rotoxic compounds valacyclovir and bisphenol A were used as negative controls. 
Proper vehicle controls were used (DMSO, water, NaCl or NaOH) according to the 
compounds. After 24 hours, the cells were re-exposed only to the compounds that 
are known to be administered in patients daily. The compound concentrations and 
exposure schedules are indicated in Table 1. 
Cell death measurement
Apoptosis and necrosis were measured simultaneously as described in Fig. 1. 
Apoptosis was measured using a live cell apoptosis assay previously described [44]. 
Briefly, binding of annexin V-Alexa488 conjugate to phosphatidyl serine present on 
the membranes of apoptotic cells was measured at 24 and 48 hours or was fol-
lowed over time by imaging the cells every hour after drug ±TNF-α exposure with BD 
Pathway 855 imager (Becton Dickinson, Erembodegem, Belgium). The total area of 
annexin V-Alexa488 fluorescence per image was quantified using Image Pro (Media 
Cybernetics, Bethesda, MD). Necrosis was measured by incubating the cells with 
propidium iodide followed by imaging at 24 and 48 hours with a BD Pathway 855 
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imager (Becton Dickinson, Erembodegem, Belgium). The number of cells stained 
by propidium iodide was quantified using Image Pro (Media Cybernetics, Bethesda, 
MD). 
Statistical procedures 
All data are expressed as mean ± standard error of the mean (S.E.M.). Statisti-
cal significance was determined by GraphPad Prism using an unpaired two-tailed 
t-test. The level of confidence is represented by p-values indicated in the figures. 
The apoptotic synergism between nephrotoxicant and TNF-α was quantified with the 
Chou-Talalay method [46] for the live cell death measurements. 
Compounds Concentrations Exposure times
Valacyclovir 300 µM 0 and 24 h
Bisphenol A 5 µM 0 and 24 h
Cyclosporine A 10 and 20 µM 0 and 24 h
Tacrolimus 10 and 20 µM 0 and 24 h
Cephaloridin 200 and 500 µM 0 and 24 h
Cephalothin 200 and 500 µM 0 and 24 h
Gentamicin 200 and 1000 µM 0 and 24 h
Neomycin 40 and 400 µM 0 and 24 h
Methotrexate 30 and 300 µM 0 h
Carmustine 100 and 300 µM 0 h
Mitomycin C 100 and 150 µM 0 h
Cisplatin 10 µM 0 h
Azidothymidine 200 and 400 µM 0 and 24 h
Adefovir 4 and 5 µM 0 and 24 h
Foscarnet 250 and 1000 µM 0 h
Phenacetin 30 and 100 µM 0 and 24 h
Acetaminophen 750 and 1000 µM 0 and 24 h
Diclofenac 500 and 1000 µM 0 and 24 h
Table 1. Compound concentrations and exposure schedules
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RESULTS
TNF-α enhanced the apoptotic response of renal cells exposed to cyclospo-
rine A, tacrolimus, cisplatin and azidothymidine
To identify nephrotoxic compounds of which nephrotoxicity was enhanced by the 
cytokine TNF-α we set-up a sensitive fluorescence-based in vitro assay for nephro-
toxicity screening using immortalized proximal tubular epithelial cells (IM-PTECs). To 
test the predictive value of this assay, we used a panel of nephrotoxicants, including 
2 immuno-suppressants, 4 antibiotics, 4 chemotherapeutics, 3 antivirals and 3 an-
algesics. None of the compounds significantly affected endogenous TNF-α secre-
tion as determined by ELISA (data not shown), indicating that endogenous TNF-α 
secretion did not influence the assessment of the tested compounds. To determine 
whether TNF-α potentiated an apoptotic response as has been observed in vivo 
for cisplatin [24,25], we exposed the IM-PTECS to the panel of nephrotoxicants in 
combination with exogenous TNF-α. Apoptosis was measured on BD Pathway 855 
imager using annexin V-alexa 488 at 24 and 48 hours. While no apoptosis was 
measured in the two control compounds valacyclovir and bisphenol A, 8 out of 16 
nephrotoxic compounds induced apoptosis at 24 or 48 hours after treatment. These 
compounds included the two immunosuppressants cyclosporine A and tacrolimus, 
the four chemotherapeutics methotrexate, carmustine, mitomycin C and cisplatin, 
the antiviral azidothymidine and the analgesic diclofenac (Fig. 2). None of the antibi-
otics resulted in detectable apoptosis at the high concentrations tested - even after 
48 hours exposure (Fig. 2). These findings were confirmed using a commercially 
available ATP-lite assay (data not shown). Of importance, the presence of serum 
in the exposure medium did not have an effect on drug-induced cell death as no 
significant difference was observed between cells exposed under low or high serum 
conditions, suggesting that drug-protein interactions were not an issue for the com-
pounds tested (data not shown).
 TNF-α enhanced the apoptotic response of 4 out of these 8 apoptosis-in-
ducing compounds (Fig. 2). These included cisplatin, the two immunosuppressants 
cyclosporine A and tacrolimus, as well as the antiviral azidothymidine at the highest 
concentration. Cyclosporine A-induced apoptosis was more strongly enhanced by 
TNF-α at 24 hours in comparison to the response to tacrolimus and azidothymidine 
at 48 hours. 
 Intriguingly, while cisplatin showed a strong synergy with TNF-α, none of the 
other DNA damaging nephrotoxicant mimicked this response, despite their pro-apop-
totic activities. In contrast, methotrexate showed the opposite effect with TNF-α at 
the highest concentration:  a significant decrease in apoptosis was observed when 
IM-PTECS were exposed to the compound in combination with TNF-α in comparison 
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Figure 1. Flowchart of the in vitro screen procedure. Following exposure of the IM-PTECs to the com-
pounds in the presence or not of TNF-α, the amount of apoptotic and necrotic cell death was determined 
in a fluorescent-based manner at 24 and 48 hours or followed over time. Apoptosis was measured with 
Annexin-V-Alexa488 conjugate, which binds the phosphatidyl serine that flips on the outer membrane 
in apoptotic cells, and necrosis was measured with propidium iodide, which binds to the nucleus only 
when the membrane of the cells is partly disrupted. The amount of apoptotic and necrotic cells was then 
quantified using ImagePro. 
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Figure 2. TNF-α enhanced the apoptotic response of renal cells exposed to cyclosporine A, tacrolimus, 
cisplatin and azidothymidine. IM-PTECs were exposed to two different concentrations of 16 different 
nephrotoxicants and two non-nephrotoxicants in combination or not of TNF-α (8 ng/ml) and apoptosis of 
the cells was measured at 24 and 48 hours. The compounds are grouped by pharmacological properties. 
The compounds inducing apoptosis are highlighted in bold and the compounds inducing synergistic apop-
tosis with TNF-α are highlighted in bold and are underlined. The data are represented as means of three 




to exposure to the compound alone (Fig. 2). 
TNF-α enhanced the necrotic response of renal cells exposed to cyclosporine 
A and cisplatin
In addition to apoptosis, necrosis was measured in our IM-PTECs after exposure to 
the 16 different nephrotoxicants and 2 control non-nephrotoxicants in the presence 
or absence of TNF-α. Five out of the 16 nephrotoxicants showed staining for the ne-
crosis maker propidium iodide. These compounds included the immunosuppressant 
cyclosporine A, the three chemotherapeutics carmustine, mitomycin C and cispla-
tin and the analgesic diclofenac (Fig. 3). The other three nephrotoxic compounds 
shown to induce apoptosis (Fig. 2) did not induce any necrosis - even after 48 hours 
(Fig. 3). As expected, the two negative controls also did not induce any necrotic 
response (Fig. 3).
 Out of the 5 compounds inducing necrosis, TNF-α enhanced the response 
of two: cyclosporine A and cisplatin (Fig. 3). Although apoptosis induced by these 
compounds could result in secondary necrosis, the strong necrotic response ob-
served after cyclosporine A treatment, suggests that the necrosis observed for this 
compound was not secondary necrosis. 
The TNF-α-mediated enhancement of apoptosis was confirmed with live apop-
tosis
To confirm the hits obtained in our primary compound screen, IM-PTECs were ex-
posed to the four synergistic apoptosis-inducing compounds cisplatin, cyclosporine 
A, tacrolimus, and azidothymidine. For all of these four compounds, the enhanced 
apoptotic response towards TNF-α addition was confirmed (Fig. 4A and Fig. 5). Us-
ing the Chou-Talalay statistical test for synergy we could confirm confirmed the syn-
ergistic effect of TNF-α with cisplatin (CI of 0.99) and cyclosporine A (CI of 0.74 for 
10µM and CI of 0.84 for 20µM).
 More importantly, while cyclosporine A and cisplatin exposure alone resulted 
in an increase in apoptosis, a significant increase in apoptosis after tacrolimus and 
azidothymidine exposure was only observed in combination with TNF-α, indicating 
a synergistic response for combined treatment of TNF-α with tacrolimus and azido-
thymidine. These data indicate that our assay could identify nephrotoxic compounds 
that would not have been identified by current assays that do not incorporate the 
immune component. 
 Finally, to obtain more detailed information on the time of onset of apoptosis 
for the four synergistic apoptosis-inducing compounds cyclosporine A, tacrolimus, 
azidothymidine and cisplatin, a real time fluorescence-based apoptosis assay was 
used as was developed previously in our laboratory [44]. IM-PTECs were exposed to 
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Figure 3. TNF-α enhanced the necrotic response of renal cells exposed to cyclosporine and cisplatin.
IM-PTECs were exposed to two different concentrations of 16 different nephrotoxicants and two non-neph-
rotoxicants in combination or not of TNF-α (8 ng/ml) and necrosis of the cells was measured at 24 and 48 
hours. The compounds are grouped by pharmacological properties. The compounds inducing necrosis 
are highlighted in bold and the compounds inducing synergistic necrosis with TNF-α are highlighted in 
bold and are underlined. The data are represented as means of three independent experiments ± S.E.M. 
* P ≤ 0.05, and # P ≤ 0 .05 compared to vehicle-treated cells.
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the four compounds in the presence or absence of TNF-α and the onset of apoptosis 
was followed over time. While cisplatin and cyclosporine A gave a strong TNF-α-me-
diated apoptotic response at 24 hours, as predicted, hardly any effect was observed 
after tacrolimus or azidothymidine treatment at 24 hours (Fig. 4B). Yet, TNF-α sig-
nificantly enhanced apoptosis of the IM-PTEC cells over a 24-48 hour time-course. 
Using this live apoptosis assay, we could clearly observe that TNF-α enhanced the 
onset of apoptosis induced by both cisplatin and cyclosporine A.
Figure 4. The synergistic apoptotic response of renal cells exposed to the four compounds in combination 
with TNF-α was confirmed with live apoptosis. IM-PTECs were exposed to two different concentrations of 
the 4 synergistic nephrotoxicants and the two non-nephrotoxicants in combination or not of TNF-α (8 ng/
ml) and apoptosis of the cells was measured at 24h and 48h (A) or was followed over time until 24 hours 
(B). The compounds inducing synergistic apoptosis with TNF-α are highlighted in bold and are underlined. 
The data are represented as means of three independent experiments ± S.E.M. * P ≤ 0.05, ** P ≤ 0.01 and 
# P ≤ 0 .05 compared to vehicle-treated cells.
DISCUSSION
Recent efforts have been made to develop new in vitro screening tests for the pre-
diction of nephrotoxicity of new chemicals. Although, these in vitro systems cannot 
reproduce the complex behaviour of animal cells in vivo, they allow toxicity testing 
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Figure 5. Annexin-V staining of apoptotic cells after exposure to the drugs synergizing with TNF-α. Annex-
in-V staining of the apoptotic cells was visualized by a BD Pathway 855 imager for IM-PTECS exposed to 
compounds in combination of not with TNF-α. Increased annexin-V stained cells was demonstrated for all 
4 compounds inducing a synergistic apoptosis of the cells with TNF-α. The images represented here were 
obtained with the highest concentration for each compound at 24 hours for cisplatin and cyclosporine A 
and 48 hours for tacrolimus and azidothymidine and are representative of three independent experiments.
in a high throughput manner and provide important predictive and mechanistic in-
formation. Yet, nephrotoxicity remains a critical cause of drug withdrawal. Here we 
set-out to extend beyond these current in vitro tests by incorporating one of the 
most important contributors of nephrotoxicity and main secreted pro-inflammatory 
cytokine TNF-α. To evaluate the predictive potential of our assay a small screen was 
performed using 16 different nephrotoxicants. Cell death induced by the compounds 
in the presence or absence of TNF-α was assessed by a semi-high throughput fluo-
rescence-based method. This innovative method allowed the measurement of both 
apoptosis and necrosis in real-time, which is a clear advantage over current com-
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mercially available assays. In total we identified 8 out of 16 compounds that induced 
cell death, of which 5 induced apoptosis as well as necrosis. Moreover, TNF-α sig-
nificantly enhanced the nephrotoxic response of cisplatin, cyclosporine A, tacrolimus 
and azidothymidine. 
 We recently examined the mechanisms underlying the synergistic response 
between cisplatin and TNF-α. This synergistic apoptotic response was due to inhi-
bition of the NF-κB pathway and consequently increased c-Jun N-terminal kinase 
(JNK) activation [47]. A similar mechanism may be involved in the response between 
TNF-α and the three other nephrotoxicants identified in our screen. Indeed, Du et al. 
showed that both cyclosporine A and tacrolimus inhibited TNF-α-induced NF-κB ac-
tivation in renal cells [48]. Moreover, cyclosporine A was shown to induce JNK acti-
vation in primary human PTECs [49] and tacrolimus induced JNK activation in Madin 
Darby canine kidney cells [50]. Thus far, it remains unknown whether the inhibition of 
NF-κB is directly associated with the changes in JNK activation as we observed for 
cisplatin and TNF-α co-exposure. Also, azidothymidine was reported to inhibit NF-
κB, but studies were performed in Epstein-Barr virus-positive Burkitt lymphoma lines 
[51]. Moreover, to the best of our knowledge, no studies showed that azidothymidine 
treatment results in activation of JNK. 
 In contrast to the aforementioned compounds, co-exposure of the chemo-
therapeutic methotrexate with TNF-α led to a reduction in methotrexate-induced 
apoptosis. Protective effects of TNF-α on methotrexate-induced apoptosis were pre-
viously observed in macrophages in vitro and was shown to be due to enhanced 
activation of the NF-κB pathway [52]. Whether TNF-α reduce methotrexate-induced 
apoptosis in IM-PTECs via enhanced activation of the NF-κB pathway has also yet 
to be determined. 
 Since cell death was used as a read-out for renal cell injury, 50% of the 
compounds could not be identified as a nephrotoxicant in our assay, despite the fact 
that all of the compounds used in our screen induce nephrotoxicity in the clinic. One 
explanation may be that despite being nephrotoxic, many of the compounds are not 
reported to induce cell death in vivo. Indeed, in contemporary pre-clinical assays it 
is difficult to identify compounds that are nephrotoxic but do not induce cell death 
[4,5,39,53]. Even so, the lack of acetaminophen- and phenacetin-induced cytotoxic-
ity in our assay could be explained by lack of bioactivation to reactive intermediates 
[5,54]. The lack of cell death response for neomycin and gentamicin is most likely 
due to the lack of the membrane binding site in the brush border and basolateral 
membrane [55] and for cephaloridine, cephalothin, and adefovir could be due to low 
expression of the transporter organic anion-transporting polypeptide 1 (OAT1) re-
sponsible for the uptake of the compounds [56-58]. Alternatively, our IM-PTEC cells, 
like any other proximal tubular cell line cultured in vitro depend on glycolysis com-
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pared to oxidative phosphorylation for PTEC in the in vivo situation. These issues 
require further investigation.
 Despite the fact that the nephrotoxicity of some compounds was not identi-
fied with our assay, the real-time, dynamic measurement of cell death in combination 
with the addition of the immune component TNF-α allowed identification of com-
pounds that were mainly toxic in the presence of TNF-α, such as tacrolimus. This 
observation correlated well with patient data where cyclosporine A induced more 
nephrotoxicity and inflammation after kidney transplantation than tacrolimus [37,59]. 
Furthermore, some of the compounds that failed to induce cytotoxicity in our assays 
were shown to affect the NF-κB pathway in renal cells or other cell lines and organs, 
including acetaminophen [60], gentamycin [61,62] and neomycin [63,64]. Incorporat-
ing NF-κB reporter IM-PTECs in our current fluorescence-based cytotoxicity assay 
may enhance assay sensitivity and identify compounds like gentamycin and neomy-
cin as nephrotoxicants in an in vitro pre-clinical setting. 
 In conclusion, real-time measurements of apoptosis and necrosis in IM-
PTECs in the presence of TNF-α, represents a novel method to detect nephrotox-
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Chapter 6
With an estimated cost of $1.8 billion and 10 -15 years development time for a single 
drug [1-3], drug attrition at late stage development or withdrawal from the market is a 
serious concern for both industry and society. Recent technical advances have rev-
olutionized pharmaceutical research, giving rise to new methodologies and systems 
biology approaches to interpret the mechanistic biological response. Application of 
these technologies in the drug development pipeline is expected to have a major 
positive impact on the discovery of novel drug targets and the development of safe 
medicines.
Drug attrition due to toxicity and efficacy have increased in recent years [4]. Though 
there were several scientific advances that helped in discovering new therapeu-
tic targets, the methods used to test toxicity had little improvements.  A principal 
reason for this is lack of physiologically relevant test systems that can be used for 
pre-clinical screening. We mainly rely on animal models to predict human specific 
responses. Though animal models will give biological responses involving a whole 
organism, often the drug metabolism, pharmacokinetics and pharmacodynamics 
are quite different to humans, for example nifedipine, a calcium channel blocker is 
metabolized by CYP3A4 in humans but not in rats [5]. Also CYP isoforms are dif-
ferent in each species making it difficult and dangerous to extrapolate animal data 
to humans [6]. To overcome this, human cell based in vitro models could be used. 
However, the current gold standards – primary human cells - are difficult to obtain 
and rapidly lose tissue specific functions. Assays using immortalized cell lines have 
also been developed, but these poorly represent human tissue due to loss of tissue 
specific functions in a non-physiological environment. Often, the cells used are of 
cancer origin and host extensive genomic alterations. Though several models have 
been proposed for long-term culture of differentiated cells, a thorough validation 
of these models is required to assess their efficiency and practical applicability in 
high-throughput screening assays. A combination of human cell-based organotypic 
systems with mechanism-based toxicity profiling and high content screening meth-
ods to study dynamic cellular perturbations will be promising future tools in reducing 
drug attrition rates and developing safer drugs. 
 In this thesis we discuss a novel high-throughput screening (HTS) com-
patible organotypic in vitro model that was developed to study drug induced liver 
injury (DILI). This simple static 3D-cell culture model induces morphological and 
functional differentiation of hepatocytes into polarized epithelial spheroids.  An in-
depth analysis of these spheroids was performed to assess the functional similarity 
to in vivo hepatocytes. Microarray gene expression analysis was performed in time 
during hepatocyte differentiation to study various elements involved in the formation 
of polarized spheroids. A comparative transcriptomic study showed similarities in the 
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mechanistic responses between this model and higher in vivo models. In this thesis 
I also describe a high content screening assay that was developed to study dynamic 
cell stress responses to toxicants. 
 Overall, the main focus of this thesis it to address current problems in the 
pre-clinical drug safety assessment in areas related to advancing current in vitro 
models, methodologies used to study toxicity and application of advanced ‘omics 
approaches to predict drug induced toxicity.
3D cell culture systems in pre-clinical drug development
Ever since the invention of 2D cell culture systems there has been little progress in 
developing in vitro models that mimic the tissue-like microenvironment. Cells in our 
body reside in a three-dimensional space surrounded by extracellular matrix. This 
facilitates cell-cell and cell-matrix interactions that regulate gene and protein expres-
sion essential for proper tissue function [7]. Several models have been developed 
to simulate a 3D environment, but to successfully implement them in a drug devel-
opment pipeline, the model should be suitable for high-throughput testing, retain 
a tissue like architecture and polarity for an extended period to allow chronic drug 
exposures and most importantly is sensitive in identifying toxic compounds. In chap-
ter 2 we described a hydrogel-based static 3D cell culture model for inducing and 
maintaining differentiated spheroids from liver hepatoma cell line HepG2. Spher-
oids are also formed from HepG2 cells grown on peptide gels [8] and scaffold-free 
hanging drops [9]. However, due to the presence of native extracellular matrix li-
gands, the morphological complexity and functional similarity to in vivo hepatocytes 
is much more pronounced in our model. HepG2 spheroids in our hydrogel system 
show well-defined apical and baso-lateral domains resembling polarized hepato-
cytes. In chapter 2 transcriptomic changes in time during 3D culture were analysed. 
This gave us an overview of the genes associated with differentiation and regulation 
of functional pathways in HepG2 spheroid culture. A recent study showed formation 
of liver buds with co-cultures of iPSC’s with mesenchymal stem cells and endothelial 
cells (HUVEC’s); when these liver buds are transplanted into mice they vascularized 
and showed functional properties of a liver [10]. 83 genes involved in development 
of liver were analyzed and shown to increase in these liver buds; these 83 genes 
were also serially upregulated in HepG2 spheroids  (Chapter 2) indicating a degree 
of restoration of the complex ontogenic profile of human liver in HepG2 spheroids. 
The metabolism of drugs to toxic intermediates frequently underlies hepatotoxicity 
[11]. The rapid loss of specific CYP450 enzymes in primary human hepatocytes 
[12, 13] or overall low levels in immortalized cell lines including HepG2 cells [14] 
compromise accurate prediction of metabolite induced toxicity. Stable metabolic 
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competence that can enable chronic drug exposures is an ultimate goal for toxicity 
screening assays. Microarray transcript analysis showed serial upregulation of sev-
eral phase I, II, and III drug metabolic enzymes in 3D cultured HepG2 spheroids up 
to 28 days with stable higher expression between day 21 and day 28 (Chapter 3), 
some of these genes were also validated by qPCR analysis which complemented 
the microarray analysis (Chapter 2). HPLC/LC-MS analysis showed higher metabo-
lite levels of phase I, phase II metabolites (glucuronidation, sulphation) in 3D HepG2 
spheroids from midazolam (CYP3A4), diclofenac (CYP2C9 and glucuronidation), 
bufuralol (CYP2D6), testosterone (substrate for multiple CYP’s) and paracetamol 
(sulphation) substrates indicating increased metabolic competence compared to 
monolayer HepG2 cells. With increased metabolic competence and the ability to 
sustain functional stability for longer periods in microplates, HepG2 spheroids may 
be attractive tools in pre-clinical drug safety testing. 
 Current in vitro models used in conventional screening assays are not com-
patible for repeated drug exposure studies. This is mainly due to their continued 
growth in tissue culture plates requiring more space with time. HepG2 spheroids 
overcome this limitation as spheroid differentiation leads to a pronounced reduction 
of proliferation, such that spheroid size remains stable after day 14. Indeed, protein 
and mRNA levels of Ki-67, a marker for cell proliferation were undetectable in dif-
ferentiated HepG2 spheroids (Chapter 2). HepG2 cultured on synthetic hydrogel in 
combination with integrin binding peptide domains did not result in inhibition of cell 
proliferation (in house observations) highlighting the importance of ECM with native 
tissue composition. Microarray analysis also showed strong inhibition of the cell cycle 
pathway in HepG2 spheroids (Chapter 2). Low levels of cell proliferation were also 
observed in differentiated HepaRG spheroids and in hanging drops [15] enabling 
long-term drug exposure studies. The sensitivity to known DILI compounds [16, 17] 
was also significantly higher in HepG2 spheroids with repeated dosing regimens 
(Chapter 2). Previous studies applying high-content imaging approaches to primary 
human hepatocyte cultures measuring mitochondrial function, oxidative stress and 
GSH content could differentiate toxic and non-toxic compounds at a dose range of 
100-fold cMax [17]. Similarly, scoring based on mitochondrial membrane potential, 
DNA content, intracellular calcium levels and plasma membrane permeability on 
HepG2 cells identified DILI compounds with 93% sensitivity at 30-fold cMax concen-
trations [18]. In our study the repeated dosing of HepG2 spheroids showed sensitivi-
ty in identifying all the DILI compounds tested (8).  For example, the withdrawn drug 
trovafloxacin mesylate was toxic at its maximum plasma concentration (cMax) with 
TC50 5.6 μM, whereas the TC50 of trovafloxacin mesylate was around 23.7 μM and 
35.7 μM in a study on micro-patterned primary human hepatocytes from 2 different 
donors [19].  In the same study another withdrawn drug, troglitazone was toxic in 
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one donor and negative in other donor, underscoring the problem of donor variability 
with primary human hepatocytes. Troglitazone was toxic in our study with a TC50 of 
100 μM (Chapter 2). Though we used a small set of compounds to test in this study 
(4 negative and 8 DILI compounds), we emphasized that the repeated dosing is crit-
ical to accurately predict compound toxicity. Repeated (lower concentration) dosing 
might actually represent a more accurate representation of the mechanism of toxicity 
in humans compared to single high dose exposures on 2D in vitro models, which 
have a high incidence of false positives due to parent compound accumulation or 
other off-target effects. Further validation with a large set of compounds is required 
to more comprehensively and accurately assess the sensitivity of HepG2 spheroids 
in identifying DILI. 
Toxicogenomics in drug development 
Toxicogenomics could play a major role in lead discovery and reducing attrition of 
compounds at later stages of drug development. Mechanistic understanding of how 
molecules are involved in toxic injury could lead to identification of biomarkers that 
could serve as a reference to test new chemical entities. Reliable human in vitro 
models would be ideal for predictive toxicogenomic studies, allowing increased 
throughput, reduced animal testing and reduced costs. Though primary human he-
patocytes are considered as ‘gold standards’ in in vitro screening assays [20], large 
inter-individual variability has also been seen in toxicogenomic-transcript profiling 
[21, 22]. Transcriptomic profiling has shown that HepG2 cells are better in discrim-
inating genotoxic and non-genotoxic compounds compared to HepaRG cells [23]. 
With its stable non-proliferating phenotype HepG2 spheroids could be ideal for toxi-
cogenomic studies. We have seen significant upregulation of many pathways asso-
ciated with functional hepatocytes in HepG2 spheroids (Chapter 3). Xenobiotic me-
tabolism pathways such as PXR/RXR, PPARα/RXRα are significantly activated in 
HepG2 spheroids. PXR induces the expression of CYP3A4, which is involved in me-
tabolism of an estimated 60% of xenobiotics [24] other target genes include phase 
I enzymes CYP - 2B6, 2B9, SC8, 2C9, 2C19 and drug transporters MRP2, OATP2 
[25]. PPARα involve in activation CYP4A family and CYP 1A, 2A, 2C, 2E sub fami-
lies.   Thus presence of active xenobiotic metabolism pathways may help in identi-
fying genes associated with mechanistic toxic response in predictive toxicogenomic 
studies. Chapter 4 describes microarray gene expression profiles of HepG2 spher-
oids treated with diclofenac compared with in vivo mouse and rat models, 2D HepG2 
cells, primary human hepatocytes and human liver slices. Molecular pathways asso-
ciated with diclofenac induced hepatocyte injury such as mitochondrial dysfunction 
were activated in HepG2 spheroids, human liver slices and rat liver models, but not 
in other models. Previous studies have shown that the Nrf2 signaling pathway plays 
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an important role in diclofenac injury. Genes such as HO-1 in the Nrf2 pathway are 
important markers for hepatocellular injury. HO-1 gene up regulation was seen in 
in vivo models and HepG2 spheroids but not in HepG2 cells grown in monolayer 
cultures (Chapter 4) indicating enhanced functional activities of HepG2 spheroids 
similar to higher models. Cholestasis is observed in patients taking diclofenac [26]. 
Genes related to cholestatic liver disease were also significantly activated in HepG2 
spheroids. In this study we have investigated transcript profiles from HepG2 spher-
oids exposed to a single dose of diclofenac. A detailed investigation with increasing 
dose and time points would likely provide further insight into the mechanisms leading 
to diclofenac-induced hepatocellular injury. The transcriptomic responses observed 
with a single dose of diclofenac indicate that, in many aspects, HepG2 spheroids 
show similarities in the stress response compared to human liver slices, primary 
human hepatocytes and in vivo models than its 2D counterpart. 
 Identification of key events and stress pathways involved in response to a 
toxic injury will provide information about important genes and proteins that could be 
used as indicators of a cytotoxic cascade. Early screening assays to identify these 
stress reporters would be valuable in drug discovery. Imaging based approaches 
such as High Content Screening  (HCS) assays may complement compound priori-
tization strategies in pre-clinical drug screening. 
High Content Screening (HCS) methods in preclinical drug development
Current in vitro assays measure cell death as an endpoint to assess the safety of 
compounds. Cell death may provide an estimation of a lethal dose, but it cannot 
represent complex molecular perturbations that occur during cell stress and injury. 
High content screening will allow us to visualize dynamic cellular responses upon 
xenobiotic stress and may provide an efficient evaluation of the compound’s safety 
profile. With the advancement in automated imaging systems, HCS is now becoming 
compatible with HTS. Imaging systems are integrated with robotics and automated 
live cell imaging can be performed. In chapter 5, we describe the use of such an 
imaging platform to study the dynamic apoptotic and necrotic responses of mouse 
kidney proximal tubular epithelial cells (PTEC’s) in real time after exposure to toxi-
cants. PTEC’s are susceptible to drug induced injury due to their re-absorption and 
secretory functions. Pro-inflammatory cytokine such as TNFα are induced as a result 
of nephrotoxicant insult to the kidney, which in turn aggravates the toxic injury [27, 
28]. In this study, the dynamic role of TNFα in increasing apoptosis (Annexin-V) 
and necrosis (Propidium iodide) in mouse PTEC’s was studied in real time. Cispla-
tin, cyclosporine A, tacrolimus and azidothymidine showed a synergistic apoptotic 
response to TNFα (Chapter 5). Though we could identify nephrotoxic compounds, 
50% of the tested drugs did not show any signs of toxicity in this study. This may 
133
General  discussion
largely be attributed to the lack of organotypic physiology in monolayer cultures, as 
most nephrotoxic drugs cause kidney injury by complex pathogenic mechanisms 
such as changes in intraglomerular hemodynamics, inflammation and crystalline ne-
phropathy caused by pro-urine concentration [29], which will demand complex or-
ganotypic models for their detection at the very least. Additionally, lack of metabolic 
competence and species differences in these monolayer-cultured mouse PTEC’s 
could also be a reason for decreased sensitivity. Utilization of complex human cell 
based 3D cell culture models, simulating physiological structure and function togeth-
er with immune components are expected to improve the prediction of nephrotox-
icity, but given the complexity of this organ, there is a long way to go before animal 
models can be completely replaced.
 HCS is a new tool that was introduced to toxicology in recent years and 
none of the drugs that are currently on the market have passed through this type 
of screening assay. The pharmaceutical industry is now utilizing these assays at 
pre-clinical screening assays [30] and analyzing its potential to overcome current 
limitations in drug screening. With current improvements in integrating HCS with 
HTS, and feasibility to analyze multiple indicators of cell stress simultaneously, HCS 
would be a valuable tool in prioritizing new chemical entities. 
CONCLUSION AND FUTURE PERSPECTIVES
To address the need for an in vitro model with improved functionality and stability for 
a longer period, we have developed a hydrogel based static 3D in vitro model using 
HepG2 cells. This model induces robust morphological and functional differentia-
tion, with a strong induction of metabolic enzymes and transporters, many of which 
are poorly expressed in monolayer cultures. Functional bile canaliculi are formed in 
3D HepG2 spheroid cultures. Comparative microarray gene expression analysis of 
our 3D HepG2 model with primary human hepatocytes, HepaRG and human liver 
revealed its close resemblance to human liver at the pathway level. The metabolic 
competence of HepG2 spheroids in hydrogels could be retained for up to 4 weeks, 
making repeated drug exposures feasible and repeated dosing on these spheroids 
was sensitive in identifying DILI compounds. Comparative transcriptomic profiling of 
diclofenac induced stress response mechanisms were similar in higher in vivo mod-
els and in vitro HepG2 spheroids. The assay we have developed is implemented in a 
384 well format for low cost and increased throughput. This assay represents a novel 
and more physiologically relevant method for studying drug-induced liver injury.
 In this model we used Matrigel, for re-differentiation of HepG2 cells into 
mature hepatocytes acquiring many specialized functions. Matrigel is a basement 
membrane matrix containing laminin (~60%), type IV collagen (~30%), entactin 
(~8%) and various quantities of decorin, transforming growth factor β1 and other 
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growth factors that help in cell attachment and differentiation [31]. Collagen type 
IV and laminin are present in developing and adult liver and are known to promote 
hepatocyte differentiation [32]. The exact mechanism involved in differentiation of 
HepG2 cells in Matrigel has to be further investigated. Cell surface integrins bind to 
laminins and collagens and induce differentiation [33] and we think this may be the 
first step in the differentiation of HepG2 cells in 3D culture. In this study we have 
seen a strong expression of β1-integrin on the basal surface of the polarized HepG2 
spheroids. β1 integrin plays a crucial role in the early phases of development, [34] 
adhesion of β1 inegrin to Matrigel is evident in our observations. Further investiga-
tion on expression and role of other integrin binding sites on HepG2 spheroids might 
help in designing synthetic gels with tailored integrin binding domains for hepatocyte 
adhesion, growth and differentiation. If successful, this may circumvent the need of 
animal-derived Matrigel that has an undefined composition. Several studies have re-
ported batch-to-batch experimental variation with Matrigel, but in our studies we did 
not see a significant difference in the spheroid morphology, gene expression (qPCR 
validation) or cytotoxic readouts with different batches. 
 With a defined cell density we were able to achieve a spheroid size of ~100 
μm, which is important for proper gaseous exchange as spheroids above >200 μm 
cause hypoxia [35]. H&E staining of HepG2 spheroids (Chapter 2) show a cavity in 
the center of the spheroid. Though we did not investigate the presence of apoptotic 
or necrotic cells, histological examination suggests that the cavity may have some 
debris from extracellular matrix or apoptotic cells. Apoptosis is an intrinsic part of 
tissue remodeling. In 3D cultures of mammary epithelial cells, cavitation was shown 
to occur by apoptosis of cells in the interior of the spheroid [36]. Normally, apoptotic 
cells are cleared by macrophages, which are not present in our in vitro model. Ne-
crosis can be induced by a lack of oxygen or nutrients.  However, we believe that this 
is unlikely in HepG2 spheroids with optimal spheroid size. 
 
The functional unit of the liver, the acinus is divided into 3 zones based on the dis-
tance from the arterial blood supply [37]. Zone 1, which is closest to the portal vein, 
receives the most oxygenated blood and hepatocytes in this region have functions 
that include gluconeogenesis, β-oxidation, amino acid catabolism and cholesterol 
synthesis. CYP450 metabolism, glycolysis, lipogenesis are mainly carried by zone 
3 hepatocytes [37-39]. The increased expression of drug metabolism enzymes and 
genes involved in glycolysis, cholesterol synthesis etc. may indicate the presence 
of zonal gradients and functions in HepG2 spheroids. Oxygen levels in cell culture 
incubators have a significant impact on the functional activity of hepatocytes [40]. 
Normal monolayer cell cultures are exposed to 21% oxygen, whereas hepatocytes 
in vivo have oxygen levels of 8-9% in zone 1 and 3-5% in zone 3 [41]. Though we 
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did not measure the oxygen levels in HepG2 spheroids, the presence of ECM gel 
may have resulted in physiological oxygen concentrations and thereby increased 
functionality. 
 The successful application of an organotypic in vitro model in an industri-
al setup depends on its simplicity and compatibility to HTS assays. This HepG2 
spheroid model stands out with several advantages compared to other spheroid 
models. The advantages include compatibility with regular microplates, use of easily 
available well-characterized HepG2 cells, which differentiate into a non-proliferating 
spheroid with a stable phenotype for longer periods. Spheroids from bioreactors or 
hanging drops need to be transferred to plates before performing an assay and they 
are no longer in an environment that induced the formation of spheroids, whereas in 
our model HepG2 spheroids are stably attached to the hydrogel for any downstream 
applications. 
 With a stable non-proliferating phenotype of HepG2 spheroids may answer 
the need for an in vitro model for sub-chronic toxicity studies. Our repeated dosing 
study for 7-days was sensitive in identifying all the hepatotoxic compounds tested, 
highlighting the importance of repeated dosing in toxicity screening assays. The in-
creased sensitivity could be due to mechanistic toxic injury, for example bosentan, 
which induces cholestatic liver injury, was not toxic in a single exposure study in 
spheroids, but upon repeated dosing the toxicity was observed. Further studies with 
cholestatic endpoints are required to confirm our hypothesis.  We have observed 
that the spheroids are viable with a polarized phenotype at least until 45 days (data 
not shown), which provides an opportunity for further long-term toxicity studies. The 
synthetic fluorescent bile acid uptake assay (chapter 2) that we have developed to 
assess inhibition of OATP1B3 transporter activity may also be used to screen drugs 
that obstruct bile flow leading to cholestatic liver injury. HepG2 spheroids could have 
a multitude of applications, which needs to be further explored. 
 Co-culturing HepG2 spheroids with other liver cell types may further improve 
its physiological relevance and identification of chemical entities where immune me-
diators or other factors secreted by non-parenchymal cells play a key role in aggra-
vating liver injury. Co-culture of iPSC’s (with human MSC’s/HUVEC’s) on Matrigel 
led to formation of liver buds in vitro [10]; it would be interesting to investigate if a 
similar level of differentiation and phenotypic characteristics could be achieved with 
HepG2 cells. iPSC derived hepatocytes were recently tested for safety assessment 
studies. iPSC’s on 3D (nanopillar plate) were shown to perform better than 2D iP-
SC’s and HepG2 cells in identifying hepatotoxic compounds [42], but the metabolic 
competence and sensitivity to hepatotoxic compounds was still significantly lower 
than PHH. iPSC’s cells require special differentiation and selection methods, their 
ease of use and strengths are yet to be evaluated for successful application in the 
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pharmaceutical industry. The use of simple culture methods (10% FBS in DMEM) for 
HepG2 spheroid culture without the need of a proprietary or special media formu-
lations as required for HepaRG and iPSC’s culture will inevitably increase reliability 
and reproducibility and reduce cost of this model. In our experience, complex media 
formulations that included several growth factors to induce differentiation showed 
poor assay reproducibility (Kidney proximal tubule 3D Cell cultures, data not shown). 
DMSO a key factor in differentiation of HepaRG cells was also shown to induce 3-4 
fold higher LDH and AST levels, reduction in proliferation and decreased hepatic 
functions [43]. Though this is a limitation for drug screening assays, previous studies 
and our observations have shown that HepaRG cell gene expression is more similar 
to PHH than HepG2 cells which may increase its predictive power in drug screening 
assays. But, it has to be also noted that HepG2 cells performed better in discriminat-
ing genotoxic compounds than HepaRG cells [21, 23]. 
 Dis-advantages of our HepG2 spheroid model may include the use of animal 
origin ECM product, with undefined growth factors and batch-to-batch variability. The 
levels of CYP450 enzymes though higher are still significantly lower to those of PHH. 
There is an increased susceptibility to contamination during long-term maintenance 
of spheroids, which demands a careful attention in maintaining sterile conditions. 
Contamination during late stages of differentiation would cost significant amount of 
time in a scientific study. Future studies with improved synthetic biomaterials that 
could mediate cellular differentiation and serve as better 3D matrices have to be 
tested. Co-culturing HepG2 cells with other hepatic cells and studying their role in 
improving physiological characteristics would be interesting to analyze. 
 With several advantages and dis-advantages in each model a large valida-
tion screen on these models would help in identifying a better model in pre-clinical 
safety testing assays, which may help to decreasing drug attrition rates. 
 The pressure to develop predictive in vitro models not only comes from the 
pharmaceutical industry to decrease drug attrition but also from legislative pres-
sure to ban animal testing. Recently, in March 2013, animal testing to evaluate hu-
man safety of cosmetic products and their ingredients was banned in the EU [44]. 
HepG2 spheroid model and other organotypic models could be used as an alter-
native to animal models after a thorough validation of their performance in various 
fields. Combination of –omic approaches (protein, miRNA, metabolomic) together 
with transcriptomic study would provide more insights into mode of action of a drug 
and discovering biomarkers. New assays that we have developed for testing ADME 
properties of new chemical entities and high-content screening methods to evaluate 





1 DiMasi, J. a., Hansen, R. W. & Grabowski, H. G. The price of innovation: new estimates of 
drug development costs. Journal of health economics 22, 151-185, doi:10.1016/s0167-
6296(02)00126-1 (2003).
2 Morgan, S., Grootendorst, P., Lexchin, J., Cunningham, C. & Greyson, D. The cost of drug de-
velopment: a systematic review. Health Policy 100, 4-17, doi:10.1016/j.healthpol.2010.12.002 
(2011).
3 Paul, S. M. et al. How to improve R&D productivity: the pharmaceutical industry’s grand chal-
lenge. Nat Rev Drug Discov 9, 203-214, doi:10.1038/nrd3078 (2010).
4 Roberts, R. A. et al. Reducing attrition in drug development: smart loading preclinical safety 
assessment. Drug Discov Today, doi:10.1016/j.drudis.2013.11.014 (2013).
5 Zuber, R., Anzenbacherova, E. & Anzenbacher, P. Cytochromes P450 and experimental mod-
els of drug metabolism. Journal of cellular and molecular medicine 6, 189-198 (2002).
6 Martignoni, M., Groothuis, G. M. & de Kanter, R. Species differences between mouse, rat, dog, 
monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert opinion 
on drug metabolism & toxicology 2, 875-894, doi:10.1517/17425255.2.6.875 (2006).
7 Ben-Ze’ev, A. Animal cell shape changes and gene expression. BioEssays : news and reviews 
in molecular, cellular and developmental biology 13, 207-212, doi:10.1002/bies.950130502 
(1991).
8 Malinen, M. M., Palokangas, H., Yliperttula, M. & Urtti, A. Peptide Nanofiber Hydrogel Induces 
Formation of Bile Canaliculi Structures in Three-Dimensional Hepatic Cell Culture. Tissue Eng 
Part A, doi:10.1089/ten.TEA.2012.0046 (2012).
9 Fozia, N. Organotypic Cultures of Hepg2 Cells for In Vitro Toxicity Studies. Journal of Bioengi-
neering and Biomedical Sciences (2011).
10 Takebe, T. et al. Vascularized and functional human liver from an iPSC-derived organ bud trans-
plant. Nature 499, 481-484, doi:10.1038/nature12271 (2013).
11 Guengerich, F. P. Cytochrome P450s and other enzymes in drug metabolism and toxicity. The 
AAPS journal 8, E101-111, doi:10.1208/aapsj080112 (2006).
12 Westerink, W. M. a. & Schoonen, W. G. E. J. Cytochrome P450 enzyme levels in HepG2 
cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. Tox-
icology in vitro : an international journal published in association with BIBRA 21, 1581-1591, 
doi:10.1016/j.tiv.2007.05.014 (2007).
13 Hart, S. N. et al. A comparison of whole genome gene expression profiles of HepaRG cells and 
HepG2 cells to primary human hepatocytes and human liver tissues. Drug metabolism and 
disposition: the biological fate of chemicals 38, 988-994, doi:10.1124/dmd.109.031831 (2010).
14 Wilkening, S., Stahl, F. & Bader, A. Comparison of primary human hepatocytes and hepatoma 
cell line Hepg2 with regard to their biotransformation properties. Drug metabolism and disposi-
tion: the biological fate of chemicals 31, 1035-1042, doi:10.1124/dmd.31.8.1035 (2003).
15 Gunness, P. et al. 3D organotypic cultures of human HepaRG cells: a tool for in vitro toxicity 
studies. Toxicol Sci 133, 67-78, doi:10.1093/toxsci/kft021 (2013).
16 Chen, M. et al. FDA-approved drug labeling for the study of drug-induced liver injury. Drug 
Discov Today 16, 697-703, doi:10.1016/j.drudis.2011.05.007 (2011).
17 Xu, J. J. et al. Cellular imaging predictions of clinical drug-induced liver injury. Toxicol Sci 105, 
97-105, doi:10.1093/toxsci/kfn109 (2008).
18 O’Brien, P. J. et al. High concordance of drug-induced human hepatotoxicity with in vitro cyto-
toxicity measured in a novel cell-based model using high content screening. Archives of toxicol-
ogy 80, 580-604, doi:10.1007/s00204-006-0091-3 (2006).
19 Khetani, S. R. et al. Use of micropatterned cocultures to detect compounds that cause drug-in-
duced liver injury in humans. Toxicol Sci 132, 107-117, doi:10.1093/toxsci/kfs326 (2013).
20 LeCluyse, E. et al. Expression and regulation of cytochrome P450 enzymes in primary cultures 
of human hepatocytes. Journal of biochemical and molecular toxicology 14, 177-188 (2000).
21 Jetten, M. J., Kleinjans, J. C., Claessen, S. M., Chesne, C. & van Delft, J. H. Baseline and geno-
toxic compound induced gene expression profiles in HepG2 and HepaRG compared to primary 
human hepatocytes. Toxicol In Vitro 27, 2031-2040, doi:10.1016/j.tiv.2013.07.010 (2013).
22 Gerets, H. H. J. et al. Characterization of primary human hepatocytes, HepG2 cells, and Hep-
aRG cells at the mRNA level and CYP activity in response to inducers and their predictivity 
138
Chapter 6
for the detection of human hepatotoxins. Cell biology and toxicology, doi:10.1007/s10565-011-
9208-4 (2012).
23 Jennen, D. G. et al. Comparison of HepG2 and HepaRG by whole-genome gene expression 
analysis for the purpose of chemical hazard identification. Toxicol Sci 115, 66-79, doi:10.1093/
toxsci/kfq026 (2010).
24 Lehmann, J. M. et al. The human orphan nuclear receptor PXR is activated by compounds that 
regulate CYP3A4 gene expression and cause drug interactions. The Journal of clinical investi-
gation 102, 1016-1023, doi:10.1172/JCI3703 (1998).
25 Kliewer, S. A., Goodwin, B. & Willson, T. M. The nuclear pregnane X receptor: a key regulator 
of xenobiotic metabolism. Endocrine reviews 23, 687-702, doi:10.1210/er.2001-0038 (2002).
26 Banks, A. T., Zimmerman, H. J., Ishak, K. G. & Harter, J. G. Diclofenac-associated hepatotox-
icity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. 
Hepatology 22, 820-827 (1995).
27 Benedetti, G. et al. TNF-alpha-mediated NF-kappaB survival signaling impairment by cisplatin 
enhances JNK activation allowing synergistic apoptosis of renal proximal tubular cells. Bio-
chemical pharmacology 85, 274-286, doi:10.1016/j.bcp.2012.10.012 (2013).
28 Ramesh, G. & Reeves, W. B. TNF-alpha mediates chemokine and cytokine expression and 
renal injury in cisplatin nephrotoxicity. The Journal of clinical investigation 110, 835-842, 
doi:10.1172/JCI15606 (2002).
29 Naughton, C. A. Drug-induced nephrotoxicity. American family physician 78, 743-750 (2008).
30 Bickle, M. The beautiful cell: high-content screening in drug discovery. Analytical and bioanalyt-
ical chemistry 398, 219-226, doi:10.1007/s00216-010-3788-3 (2010).
31 Kleinman, H. K. & Martin, G. R. Matrigel: basement membrane matrix with biological activity. 
Seminars in cancer biology 15, 378-386, doi:10.1016/j.semcancer.2005.05.004 (2005).
32 Lora, J. M., Rowader, K. E., Soares, L., Giancotti, F. & Zaret, K. S. Alpha3beta1-integrin as a 
critical mediator of the hepatic differentiation response to the extracellular matrix. Hepatology 
28, 1095-1104, doi:10.1002/hep.510280426 (1998).
33 Streuli, C. H. et al. Laminin mediates tissue-specific gene expression in mammary epithelia. J 
Cell Biol 129, 591-603 (1995).
34 Fassler, R. et al. Lack of beta 1 integrin gene in embryonic stem cells affects morphology, ad-
hesion, and migration but not integration into the inner cell mass of blastocysts. J Cell Biol 128, 
979-988 (1995).
35 Asthana, A. & Kisaalita, W. S. Microtissue size and hypoxia in HTS with 3D cultures. Drug Dis-
cov Today 17, 810-817, doi:10.1016/j.drudis.2012.03.004 (2012).
36 Debnath, J. & Brugge, J. S. Modelling glandular epithelial cancers in three-dimensional cul-
tures. Nature reviews. Cancer 5, 675-688, doi:10.1038/nrc1695 (2005).
37 Jungermann, K. & Katz, N. Functional hepatocellular heterogeneity. Hepatology 2, 385-395 
(1982).
38 Lindros, K. O. Zonation of cytochrome P450 expression, drug metabolism and toxicity in liver. 
General pharmacology 28, 191-196 (1997).
39 Gebhardt, R. Metabolic zonation of the liver: regulation and implications for liver function. Phar-
macology & therapeutics 53, 275-354 (1992).
40 Yan, H. M., Ramachandran, A., Bajt, M. L., Lemasters, J. J. & Jaeschke, H. The oxygen tension 
modulates acetaminophen-induced mitochondrial oxidant stress and cell injury in cultured he-
patocytes. Toxicol Sci 117, 515-523, doi:10.1093/toxsci/kfq208 (2010).
41 Kietzmann, T. & Jungermann, K. Modulation by oxygen of zonal gene expression in liver stud-
ied in primary rat hepatocyte cultures. Cell Biol Toxicol 13, 243-255 (1997).
42 Takayama, K. et al. 3D spheroid culture of hESC/hiPSC-derived hepatocyte-like cells for drug 
toxicity testing. Biomaterials 34, 1781-1789, doi:10.1016/j.biomaterials.2012.11.029 (2013).
43 Hoekstra, R. et al. The HepaRG cell line is suitable for bioartificial liver application. Int J Bio-
chem Cell Biol 43, 1483-1489, doi:10.1016/j.biocel.2011.06.011 (2011).











Medicijn-geïnduceerde orgaantoxiciteit is een groot probleem bij de ontwikkeling 
van medicijnen en voor de veiligheid van patiënten die een behandeling ondergaan. 
Een medicijn bestempelen als veilig is een ingewikkelde uitdaging en de tijd heeft 
bewezen dat huidige methodes niet altijd betrouwbaar zijn. Hierdoor heeft de weten-
schappelijke gemeenschap een  impuls gekregen om het ontwikkelingsproces van 
medicijnen te verbeteren. Het bepalen van toxiciteit wordt vandaag de dag gedaan 
door onderzoek op knaag- of andere zoogdieren. Dit soort onderzoek is op dit mo-
ment de enige manier om toxiciteit op lange termijn te bepalen – ondanks dat de 
voorspellende waarde van dierstudies soms wordt betwijfeld.
 Toxiciteit is vaak idiosyncratisch, wat betekent dat slechts enkele personen 
van de groep die het medicijn neemt toxische reacties vertonen. Deze personen 
reageren anders op de medicijnen vanwege hun specifieke genetische achtergrond 
of een achterliggende ziekte. Hierdoor is het nog moeilijker om het type toxiciteit 
van een geneesmiddel te voorspellen voordat het middel op de markt komt. Het is 
daarom belangrijk om het precieze mechanisme van toxiciteit te onderzoeken en 
mensen op de hoogte te stellen van de mogelijke bijwerkingen van een geneesmid-
del. Dankzij de technologische ontwikkelingen van de afgelopen jaren kunnen we op 
dit moment zelfs kleine veranderingen in de expressie van duizenden genen tegelijk 
associëren met medicijngebruik. Desondanks is kennis over het mechanisme van 
toxiciteit van veel geneesmiddelen slechts minimaal aanwezig of zelfs afwezig. Een 
van de redenen is het gebrek aan juiste modellen om toxiciteit in mensen te voor-
spellen. Cellen, geïsoleerd uit humaan weefsel, vormen een beter modelsysteem 
dan de huidige modellen, maar deze cellen kunnen niet een lange tijd buiten het 
lichaam overleven. Daarentegen kunnen geimmortaliseerde humane cellijnen zoals 
HepG2 levercellen onbeperkt groeien en zijn ze dus een geschikte bron van cellen 
voor in vitro onderzoek. Het nadeel van deze cellen is dat zij hun weefselspecifieke 
functies niet kunnen vasthouden in standaard celkweek, waardoor de voorspellende 
waarde voor toxiciteit-onderzoek sterk afneemt. Het behouden van weefselspec-
ifieke functies gedurende celkweek is essentieel voor de betrouwbaarheid van in 
vitro modellen. Sinds de ontwikkeling van de weefselkweekflessen rond 1920 zijn er 
geen grote veranderingen meer geweest in de standaard kweekmethoden. Op dit 
moment zijn driedimensionale kweekmethoden in ontwikkeling, maar zij hebben nog 
geen plaats in de standaard kweekmethoden gebruikt voor in vitro toxiciteits-testen. 
Dit proefschrift beschrijft de ontwikkeling van een drie dimensioneel (3D) model 
waarin meercellige weefsels gekweekt worden in een hydrogel, waarbij de weef-
selspecifieke functies behouden blijven. Aangezien de lever een grote rol speelt in 
detoxificatie van medicatie en vaak de meeste schade oploopt gedurende medici-
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jn-geïnduceerde toxiciteit, hebben we ons het meest gericht op de ontwikkeling van 
een robuust in vitro model voor levertoxiciteit. Verder beschrijft dit proefschrift ook 
ons onderzoek naar hoe het immuunsysteem niertoxiciteit kan verergeren en in-
troduceren we een geavanceerde screeningsmethode die gebruikt kan worden om 
celtoxiciteit te meten. 
 Lichaamscellen leven in een drie-dimensionele ruimte omgeven door extra-
cellulaire matrix. Deze matrix speelt ook een rol in signaleringsprocessen en regel-
ing van weefselspecifieke functies. De hydrogel Matrigel en de extracellulaire matrix 
hebben vergelijkbare eigenschappen en deze gel is dus geschikt om levercellen 
op te laten groeien. Zoals beschreven in hoofdstuk 2, stoppen HepG2 levercellen 
gekweekt op een 3D hydrogel met delen, differentiëren ze en behouden de weef-
selspecifieke functies van primaire levercellen beter dan dezelfde HepG2 cellen 
gekweekt op standaard plastic 2D kweekschaaltjes. Zo vertonen in 3D gekweekte 
HepG2 cellen bijvoorbeeld een hogere expressie en functie van genen betrokken 
bij het metabolisme van geneesmiddelen. Door dit herstelde metabolisme kan het 
oorspronkelijke medicijn worden gemetaboliseerd tot een toxische tussenvorm, en 
herkend worden als een mogelijke toxische stof. De verhoogde gevoeligheid van 
dit model maakt ook het onderzoek naar het onderliggende mechanisme van tox-
iciteit mogelijk. In hoofdstuk 3 wordt een microarray analyse beschreven waarin 
de genexpressie van in 3D gekweekte HepG2 sferoïden een significante verander-
ing laat zien van moleculaire signaleringsroutes die betrokken zijn bij het metabo-
lisme van geneesmiddelen. Verscheidene andere signaleringsroutes geassocieerd 
met het behoud van lever-specifieke functies waren ook sterker aanwezig in 3D 
HepG2 sferoïden dan in de  2D HepG2 celkweken. Analyse van het hele genoom 
van levercellen, gekweekt in verschillende in vitro modellen, laat grote verschillen 
en overeenkomsten zien vergeleken met primaire levercellen. Expressie van genen 
betrokken bij de celcyclus was sterk onderdrukt in 3D gekweekte HepG2 cellen en 
daardoor vergelijkbaar met cellen uit de menselijke lever. Dit bevestigt onze obser-
vaties in hoofdstuk 2. Continue proliferatie in 2D celkweken beperkt blootstelling 
aan stoffen voor langere periodes, omdat de cellen dan alle beschikbare groeiruimte 
bezetten en uiteindelijk doodgaan door gebrek aan ruimte. Als de cellen georgani-
seerd worden in een gepolariseerde 3D sferoïde stopt de proliferatie. Het fenotype 
wordt behouden voor vele dagen, waardoor het model geschikt is om de effecten 
van geneesmiddelen gedurende langere periodes te onderzoeken. Herhaalde stim-
ulaties maakten cellen gevoeliger voor toxische effecten en verbeterde identificer-
ing van toxische stoffen in ons onderzoek (hoofdstuk 2). In 3D gekweekte HepG2 
sferoïden zijn gemakkelijk in gebruik en ontwikkelen een gedifferentieerd fenotype 
vergelijkbaar met primaire levercellen. Dit maakt deze kweekmethode een veelbe-
lovend model voor het routinematig screenen van nieuwe geneesmiddelen.
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 In hoofdstuk 4 hebben we een systematische vergelijking gemaakt van 
veranderingen in genexpressie in verscheidene in vitro en in vivo modellen na bloot-
stelling aan diclofenac, een bekend hepatotoxisch middel. Dit heeft geleid tot een 
beter begrip van de onderliggende stresssignaleringsroutes in humane- en diermod-
ellen. In 3D gekweekte HepG2 sferoïden reageerden sterker op diclofenac en de 
diclofenac-geïnduceerde stressresponsen waren vergelijkbaar met die in humane 
levercoupes. Moleculaire mechanismen geassocieerd met diclofenac-geïnduceerde 
leverschade zoals de Nrf2 signaalcascade en mitochondriële dysfunctie, waren ver-
hoogd. Dit impliceert dat in 3D gekweekte HepG2 sferoïden een goed model vormen 
voor toekomstig toxicogenomisch onderzoek.
 In hoofdstuk 5 hebben we de rol van TNFα, een pro-inflammatoir cytokine 
in medicijn-geïnduceerde niertoxiciteit onderzocht. Pro-inflammatoire signaalstoffen 
spelen een belangrijke rol in het verergeren van de toxiciteit van sommige medici-
jnen. Voor deze studie gebruikten we een zogeheten ‘high-content assay’ , waarin 
over tijd apoptose en necrose als gevolg van een gecombineerde stimulatie van 
TNFα en niertoxische stoffen werd bepaald. Voor cisplatine, cyclosporine A, tacro-
limus en aiodothymidine werd een synergistich effect waargenomen in combinatie 
met TNFα. Voor de andere niertoxische stoffen konden  we geen synergistisch effect 
waarnemen in dit experiment, alhoewel dit misschien wel het geval is in een ver-
beterd model zoals in een 3D cell culturen en/of het gebruik van andere reporters 
gedurende het experiment. Ondanks deze tekortkomingen kan deze ‘high-content 
assay’ een nieuwe screening-techniek op industriële schaal vormen, speciaal voor 
het screenen van chemische stoffen.
 Kort samengevat hebben onze studies aangetoond dat met 3D celkweek 
een fysiologisch relevante niche ontstaat waarin cellen worden gestimuleerd om 
geïntegreerde weefsels met weefselspecifieke eigenschappen te vormen. Grote 
voordelen van deze 3D kweken zijn de aanwezigheid van een actief metabolisme 
van medicijnen en de stabiliteit van de celeigenschappen over een langere tijd. Dit 
maakt dit type celkweek uitermate geschikt voor het testen van geneesmiddelen op 
grote schaal. Het incorporeren van fluorescente reporter eiwitten uit stress signaler-
ingsroutes zou dit model bijvoorbeeld kunnen uitbreiden en verbeteren en zal leiden 




Drug induced organ toxicity has remained a major challenge in drug development 
and for the safety of patients undergoing treatment. Classifying a drug as safe is a 
complex challenge and history has shown that the current methods are not always 
reliable, driving innovation in the scientific community to improve the drug discovery 
pipeline. Toxicity assessment using rodent and other mammalian species as sur-
rogate models is a common practice as they are the only available alternative for 
studying long-term effects of the drug – although the reliability of other species in 
predicting human toxicity is under question. 
 Toxicity is often idiosyncratic affecting only few individuals due to their genet-
ic background or underlying disease conditions which makes it even more complicat-
ed to predict a type of toxicity before a drug is released into the market. Therefore it 
is important to study the detailed mechanism of toxicity associated with a drug and 
alert people to potential side effects. Though the technology has advanced in recent 
years allowing us to study changes in thousands of genes upon drug exposure us-
ing microarray or sequencing technologies, current knowledge on the mechanisms 
associated with drug-induced toxicity is either minimal or absent for the majority of 
drugs. This is partly due to the absence of test models that would respond in a similar 
way to humans when exposed to a drug. Freshly isolated cells from human tissues 
can serve as better test models but they cannot survive for long periods outside the 
body in a non-physiological environment. With their unlimited growth, immortalized 
human cells obtained either by genetic manipulation or from a cancer tissue repre-
sent a convenient source of cells for in vitro studies, but they are unable to maintain 
tissue specific functions in a culture dish limiting their value in understanding human 
toxicity. Improvements in current culture methods to preserve organ specific func-
tions are essential for reliable in vitro models. Since the development of the tissue 
culture flask in the early 1920’s there haven’t been major advances in standard in 
vitro tissue culture practices. Methods to culture three-dimensional tissues are de-
veloping rapidly, but have not yet entered mainstream use for in vitro testing. This 
thesis describes the development of a hydrogel based three-dimensional (3D) model 
for culturing multicellular tissues that retain their specialized functions. Since liver 
plays a major role in drug detoxification and is a prime target for drug induced liver 
injury, we mainly focused on developing a robust in vitro model for assessing liver 
toxicity as a first step. This thesis also describes our investigation to understand the 
role of immune mediators in aggravating kidney injury and introduces an advanced 
high-content screening approach that we used to measure cytotoxicity. 
 Cells in our body reside in a three-dimensional space surrounded by extra-
cellular matrix, which mediates cellular signaling and regulation of tissue specific 
ENGLISH SUMMARY
146
functions. We used Matrigel, a hydrogel that has similar properties to extracellular 
matrix and supports the growth of hepatocytes. As shown in chapter 2, HepG2 cells 
cultured on a 3D hydrogel stop proliferating, differentiate and maintain specialized 
functions of hepatocytes to a higher degree than cells cultured as monolayer cul-
tures on a two-dimensional (2D) plastic dish. Gene expression and function of sev-
eral important drug metabolising enzymes are significantly increased when HepG2 
cells are placed in 3D culture. This increased functionality can enable drugs to be 
metabolized into their toxic intermediates and manifest their toxic effects.  The re-
sulting increase in sensitivity to toxic compounds also facilitates investigation of the 
underlying mechanisms involved in onset of toxicity. In chapter 3, microarray gene 
expression analysis demonstrated significant upregulation of molecular pathways 
associated with drug metabolism in 3D HepG2 spheroid cultures. Several other mo-
lecular pathways that are associated with physiological maintenance of liver-specific 
functions were also enriched in 3D HepG2 spheroids compared to 2D monolayer 
cultures. Whole genome gene expression comparison of in vitro cellular models to 
human liver gene expression showed the similarities and differences associated with 
cellular models. Cell cycle pathway was strongly suppressed in 3D HepG2 cultures 
and the gene expression was similar to human liver supporting our observations 
in chapter 2. Continuous cell proliferation in 2D cultures is a major limitation for 
long-term drug exposures, as cells occupy the available space and die due to over-
crowding. Once the cells organize into a polarized spheroid in 3D cultures they stop 
proliferating and maintain this stable phenotype for several days presenting opportu-
nities to study long-term effects of drugs in vitro. Repeated exposures were indeed 
more sensitive in identifying toxic compounds in our study (Chapter 2). With its ease 
of use, availability and a differentiated phenotype showing many hallmarks of liver 
tissue 3D HepG2 spheroid cultures are promising for routine drug screening assays. 
In chapter 4, we made a systematic comparison of gene expression changes in vari-
ous in vitro and in vivo models upon exposure to the hepatotoxicant, diclofenac. This 
allowed us to understand the cellular stress responses associated with the toxicant 
and their expression in human and animal model systems. We have seen that 3D 
HepG2 spheroids were more responsive to diclofenac induced stress responses re-
sembling human precision cut liver slices. Molecular mechanisms that are known to 
be associated with diclofenac injury such as Nrf2 signaling pathway and mitochon-
drial dysfunction were enriched indicating that this model may be useful for future 
toxicogenomic studies. 
 In chapter 5, we investigated the role of the pro-inflammatory cytokine, 
TNFα, in drug-induced nephrotoxicity. Inflammatory mediators are known to play 
a major role in aggravating toxicity induced by some drugs. In this study we set up 
a high-content screening approach to measure apoptosis and necrosis in real time 
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upon exposure to nephrotoxicants in the presence of TNFα. The assay was sensi-
tive in identifying a synergistic effect of TNFα in enhancing nephrotoxicity caused by 
cisplatin, cyclosporineA, tacrolimus and aziodothymidine. We were unable to detect 
toxicity induced by other nephrotoxicants, which may be improved by using three-di-
mensional cell cultures and/or including other reporters for live cell imaging. None-
theless, our automated real time imaging represents a novel high-content screening 
approach to screen for chemical entities on an industrial scale. 
 In summary, our studies have shown that 3D cultures provide a physiologi-
cal niche to cells allowing them to form integrated tissues with associated tissue spe-
cific functions. The presence of active drug metabolism pathways and their ability to 
maintain a stable phenotype for long periods in microplates offers a great advantage 
for large scale screening for compound toxicity. Further development of this model, 
for example by incorporating fluorescent reporters of specific cell stress pathways 




2D    Two-dimensional
3D    Three-dimensional
ADME   Absorption, distribution, metabolism and excretion
AhR   Aryl hydrocarbon receptor
ARE   Antioxidant responsive elements
ATP   Adenosine triphosphate
CAR   Constitutive androstane receptor
CLF   Cholyl-lysyl-fluorescein
CYP450   Cytochrome P-450
DEG   Differentially expressed genes
DILI   Drug induced liver injury
DMEM   Dulbecco’s modified eagle’s medium
DMSO   Dimethyl sulfoxide
ECM   Extracellular matrix
FMO5   Flavin Containing Monooxygenase 5
FXR   Farnesoid X receptor  
G6PC   Glucose-6-Phosphatase
GADD45A  Growth arrest and DNA-damage-inducible protein 45 alpha
GAPDH  Glyceraldehyde-3-phosphate dehydrogenase
HNF4A   Hepatocyte Nuclear Factor 4
HO-1   Heme oxygenase 1
HSP40   Heat shock protein 40
iPSC   induced pluripotent stem cells 
LC-MS   Liquid chromatography – mass spectrometry
LPS   Lipopolysaccharide
LXR   Liver X receptor
MDM2   Mouse double minute 2 homolog
NF-κB    Nuclear factor kappa B 
Nrf2   Nuclear factor (erythroid-derived 2)-like 2
PAS   Periodic acid Schiff’s reaction
PBS   Phosphate buffered saline
PCLS   Precision cut liver slices
PTEC   Proximal tubular epithelial cells
PXR   Pregnane X receptor
ROS   Reactive oxygen species
RXR   Retinoid X receptor
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